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ABSTRACT 
Stroke or cerebral vascular accident (CVA) is the 4th leading cause of mortality and the 
principle cause of long-term disability in the United States. Unfortunately, current 
reperfusion-based treatments (e.g. thrombolysis, tPA) cannot be administered to the 
majority of patients presenting with ischemic stroke. Accordingly, new treatments for 
ischemic stroke are desperately needed. 
Reactive astrocytes perform key roles in tissue repair and remodeling following 
stroke such as preservation and repair of the blood-brain barrier, modulation of immune 
cell invasion, glutamate uptake and neuroprotection, and glial scar formation. The 
proliferative subpopulation of reactive astrocytes found immediately adjacent to the 
infarct core after stroke (known as the peri-infarct area) is particularly important for 
protecting the brain parenchyma from ischemic damage and inflammation. Defining the 
signaling network that controls reactive astrocyte formation and function has potential to 
provide new treatment strategies for patients ineligible for reperfusion therapy. 
Notch1 signaling is required for the proliferation of peri-infarct reactive astrocytes 
after stroke. To identify downstream targets and potential functional effectors of Notch1 
signaling in reactive astrocytes, we developed an ex vivo forward signaling screen. To 
generate large quantities of adult reactive astrocytes, we employed adult Reactive 
astrocyte-derived Neural Stem Cells (Rad-NSCs) isolated from the peri-infarct area of 
mice after stroke. Astrocytes re-differentiated from Rad-NSCs (AstroRad-NSC) were then 
exposed to immobilized Jagged-1, a Notch1 ligand. In response to Jagged-1, many genes 
involved in reactive astrocyte-mediated tissue protection, metabolic regulation, 
angiogenesis and glial scar formation were up-regulated. Of special interest, several 
genes for proteins that regulate with glutamate uptake and metabolism were increased by 
Jagged-1/Notch signaling, including the glial-specific GLutamate-ASpartate Transporter 
(GLAST). With loss-of-function experiments, we determined that deletion of Notch1 
decreased GLAST transcript and protein levels in cultured AstroRad-NSC. Furthermore, we 
isolated reactive astrocytes directly from cerebral cortex after stroke and confirmed the 
effects of Notch1 on GLAST in vivo. Our results suggest that treatments designed to 
stimulate Notch1 signaling after stroke may promote glutamate uptake, thereby 
decreasing excitotoxicity and neuronal cell death. 
Binding of Endothelin peptides to the type B Endothelin receptor (ETBR) has 
been shown to alter cell proliferation. Investigating a possible relationship between 
Jagged-1/Notch1 and Endothelin signaling in reactive astrocytes, we determined that 
Notch1 signaling regulated ETBR indirectly, by activating STAT3, an unidentified 
transcriptional activator of ETBR. Using inducible transgenic astrocyte-specific 
conditional knockout (cKO) mice (GFAP-ETBR-cKO), we found that specific deletion of 
ETBR in reactive astrocytes phenocopied the defect in reactive astrocyte proliferation 
observed in our previous work with GFAP-Notch1-cKO mice. Notably, the Notch1-
STAT3-ETBR axis we identified is likely to control reactive astrocyte proliferation in 
most, if not all, forms of CNS injury. 
The experimental results presented in this doctoral dissertation provide novel 
insight into signaling mechanisms that may someday be exploited to improve care for 
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CHAPTER 1. COMPREHESIVE LITERATURE REVIEW. 
1.1 Background and Impetus for the Study of Stroke 
Stroke or “cerebrovascular accident” (CVA) is clinically defined as the acute onset of a 
neurological deficit caused by inadequate blood flow to the central nervous system. 
Based on 2009 statistics from the Centers of Disease Control (CDC), every year since 
1998 an average of ~795,000 people in the United States has experienced a stroke. Stroke 
is the fourth leading cause of death in the United States, accounting for approximately 1 
in 18 deaths, and is only superseded in morality by heart disease, malignant neoplasms 
and chronic lower respiratory diseases (Towfighi and Saver, 2011; Heron, 2013).  
Recent efforts of researchers and clinicians have lowered stroke mortality in the 
United States. The age-adjusted mortality rate due to stroke was lowered 37% in 10 
years: from 61.6 per 100,000 deaths in 1999 to ~34 per 100,000 in 2010 (Kissela et al., 
2012). However, the trend for decreased stroke mortality is now threatened by an upward 
swing in the prevalence of stroke risk factors like obesity and type 2 diabetes (Mitka, 
2012). 
Secondary to mortality, the majority of the disease burden of stroke is attributed 
reduced neurologic function. As of 2012, the number of Americans suffering from 
disability after stroke is approximately 7,000,000 and it remains the leading cause of 
serious long-term disability in the United States (Roger et al., 2012). Approximately, 
45% of stroke patients have moderate to severe disabilities. In the 2004 National Nursing 
Home Survey, 11.7% of nursing home residents had a primary diagnosis upon entry of 





The quality of life is decreased amongst stroke survivors due to their disabilities 
and the economic impact of cardiovascular disease and stroke is substantial. In 2008, the 
healthcare system spent 18.8 billion dollars in direct costs due to stroke and 15.5 billion 
in estimated indirect costs due to morality and loss of productivity. Notably, home health 
care costs for stroke surpassed 5.5 billion (Roger et al., 2012). By comparison, hospital 
expenditures for acute myocardial infarction (MI) amounted to 51.1 billion dollars and 
post-MI patient home care expenditures were 7.9 billion dollars (Roger et al., 2012). 
1.2. Challenges to the Treatment of Stroke 
Stroke has a broad etiology. The most common cause is infarction, or blockage, of a 
cerebral blood vessel by a fibrin clot. Known as an ischemic stroke, this type of stroke 
accounts for 80% of stroke cases. Symptoms and signs can vary widely from minor 
neurological deficit to major physical disability and death. The location of the infarct 
dictates the area of the brain that becomes ischemic and thus, the forms of neurological 
deficits that occur. Of the major vessels in the cerebral vascular system, the middle 
cerebral artery (MCA) is the largest, supplying a vast area of the cerebral cortex. Within 
the vascular territory of the MCA on the dominant hemisphere are areas involved in 
motor control, sensation and speech. Notably, the MCA is the vessel most often occluded 
in stroke (Goldstein et al., 2011). 
 3 
Current treatments for stroke are based on reestablishing blood flow with 1) 
Enzymes that accelerate disruption of the offending blood clot (a.k.a. thrombolytic 
therapy), or 2) Devices inserted into the arterial lumen to physically remove the clot, (e.g. 
MERCI devices). Recombinant tissue Plasminogen Activator (tPA, Alteplase) was the 
first thrombolytic therapy for stroke. Although clinical trials have demonstrated benefit 
from tPA treatment, it does not decrease the overall morality of stroke (Lees et al., 2010). 
As a stroke treatment, tPA has specific and stringent administration criteria. It is 
estimated that only 2% to 3% of patients with acute ischemic stroke receive IV tPA 
(Kleindorfer et al., 2008). The low treatment rate for tPA is attributable to its narrow time 
window for administration after the onset of neurological deficits due to stroke. Patients 
who receive tPA at 90 minutes or earlier after the onset of symptoms experience 
significant neurological recovery. However, few patients who receive tPA beyond 4 
hours from the onset of symptoms will have significant neurological recovery (Lees et 
al., 2010; Gursoy-Ozdemir et al., 2012). Notably, the administration of tPA is not without 
risk: 6% of patients experience edema and hemorrhage after thrombolysis (Donnan et al., 
2011).  
1.3. The Need for Safe and Effective Therapies for Ischemic Stroke  
Despite decades basic science research in the area of CNS injury, medical science has not 
been able to provide a clinically relevant therapy for ischemic stroke. To date, numerous 
compounds and biologics aimed at providing neuroprotection, vasoprotection, anti-
inflammation, or enhanced elimination of free radicals have not helped patients recover 
from stroke. A recent search of the National Institute for Health’s (NIH) clinical trials 
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database (http://clinicaltrials.gov) produced over 292 records for ongoing or completed 
clinical trials investigating treatments for acute ischemic stroke in adults. These 
treatments included surgical interventions, cellular therapies, small-molecule drugs, 
thrombolytics and cerebral cooling interventions, amongst many others. The following is 
a representative list of therapies that have been investigated in large, double-blind, 
placebo-controlled clinical trials that failed to confer benefits to patients: the neuro-
protectant and antithrombotic Piracetam (Ricci et al., 2012), fibrinogen depleting agents 
(Hao et al., 2012), the antioxidant NXY-059 (Savitz and Fisher, 2007; Diener et al., 
2008) and corticosteroids (Qizilbash et al., 2002; Sandercock and Soane, 2011). 
Thrombolytic therapies continue to improve, but are still far from ideal (Sandercock et 
al., 2012). Trials examining surgical decompression for cerebral edema by 
hemicraniectomy following large cerebral infarcts have yielded favorable outcomes  
(Cruz-Flores et al., 2012). However, this intervention requires removal of part of the 
skull, allowing the brain to expand out of the cranial vault and is only indicated for very 
large cortical infarcts that would otherwise lead to brain herniation and death. Surgical 
decompression also requires a facility capable of performing the surgery and providing 
post-operative care. 
1.4. The Pathophysiology of Stroke 
Understanding the evolution of CNS injury is essential for creating new therapies for 
stroke. The stepwise response to injury of the mammalian central nervous system (CNS) 
has a similar pattern across many modes of injury that include stroke, trauma, and tumor 
invasion (Pekny and Nilsson, 2005). For focal cerebral ischemia, the pathological 
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progression begins with an infarct that either decreases blood flow or stops it entirely. In 
patients, imaging that employs time-of-flight contrast computed tomography (CT) has 
been useful for identifying the infarct core, an area directly downstream of the infarct 
where cerebral blood flow (CBF) can drop from ~50 ml per 100 grams of brain tissue per 
minute to 15–18 ml/100g/minute (Bramlett and Dietrich, 2004); this flow is insufficient 
to maintain the metabolic demands of the tissue. Collateral flow creates an area around 
the infarct core, known as the ischemic penumbra or peri-infarct area. For this reason, the 
rescue of peri-infarct tissue at risk of damage from ischemia is the goal of many stroke 
treatments (Back, 1998; Fisher and Bastan, 2012). 
 Cell death in the infarct core is mediated by both apoptosis and necrosis (Back, 
1998). During stroke, glutamate-dependent excitotoxicity occurs as glutamate remains in 
synaptic clefts. This causes prolonged calcium influx into neurons through N-
nitrosodimethylamine (NMDA) channels/receptors, which then trigger pro-apoptotic 
events (Mark et al., 2001). Production of oxidative and nitrate radicals by multiple cell 
types also cause damage to the brain parenchyma (Gursoy-Ozdemir et al., 2012). 
Furthermore, as platelets in the thrombus activate and release vasoactive and 
inflammatory mediators (e.g. ADP, thromboxane, Nitric Oxide) the endothelium 
becomes increasingly pro-thrombotic and the downstream microcirculation begins to clog 
with secondary thrombi (Gursoy-Ozdemir et al., 2012).  
 At this point, a few hours may have elapsed since the initial thrombotic event 
(Bramlett and Dietrich, 2004). The tight junctions of endothelial cells that maintain the 
blood brain barrier become disrupted, in part due to proteolytic cleavage of these proteins 
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in the cell membrane as well as the extracellular matrix. Plasma proteins are then free to 
leak into the parenchyma of the brain. The plasma proteins are followed by molecules of 
water, resulting in cerebral edema (Gursoy-Ozdemir et al., 2012). After stroke, local 
inflammation in the brain is mediated by cytokine and chemokine release by endothelial 
cells, astrocytes, pericytes and microglia (resident CNS macrophages) (Back, 1998). 
Acute immune invasion, primarily by neutrophils and macrophages, marks the secondary 
phase of damage to the brain parenchyma and additional immune-mediated neuronal 
apoptosis (Bramlett and Dietrich, 2004; Jaerve and Muller, 2012).  
1.5. Reactive Astrogliosis 
1.5.1 Introduction 
Reactive astrogliosis occurs in most central nervous system injuries including: 
penetrative injuries, contusions, hemorrhages, infections of all etiologies and tumors 
(Graham, 1996). In the case of cerebral ischemia, within 6 hours after occlusion, 
astrocytes residing near the ischemic infarct core begin a series of stereotyped molecular 
and morphological changes in response to tissue injury. These changes are collectively 
known as reactive astrogliosis. The ubiquity and stereotypy of reactive astrogliosis in 
CNS injury suggests a critical role for this process in protecting the CNS from immune-
mediated damage, spreading of cytotoxic substances from areas of tissue damage and 
secondary neuronal death.  
Reactive astrogliosis resolves in to a glial scar: a persistent collection of 
extracellular matrix and cells that impedes axonal re-growth from injured neurons 
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(Eddleston and Mucke, 1993; Pekny and Nilsson, 2005; Sofroniew, 2009). Since the time 
of Ramon y Cajal, the glial scar was considered maladaptive and an impediment to CNS 
regeneration after injury. Based on research performed in the last two and a half decades, 
the glial scar is now considered the resolution of an important protective acute response 
by proliferating astroglial. 
 Reactive astrogliosis occurs in tissue surrounding a CNS injury when astrocytes 
become hypertrophic and increase their expression of various intermediate filament (IF) 
proteins such Glial Fibrillary Acid Protein (GFAP), vimentin and nestin (Eddleston and 
Mucke, 1993). The intensity of the reactive astroglial response is directly related to the 
severity of CNS damage (Sofroniew, 2009). However, at either end of the injury 
continuum, the resolution of astrogliosis can be vastly different, ranging from fully 
healed CNS parenchyma with no evidence of glial scarring to the formation of a large 
and persistent glial scar that contains new-born astrocytes and fibro-meningeal cells 
(Sofroniew, 2009; Burda and Sofroniew, 2014). Strokes large enough to cause 
neurological symptoms in humans elicit reactive astrogliosis that leads to glial scarring.   
 To date, only a few studies have been published that successfully determined cell 
signaling mechanisms or other molecular mediators of reactive astrogliosis in vivo. The 
role of reactive astrocytes in tissue preservation, repair and remodeling after CNS injury 
has largely been achieved through experiments with various strains of transgenic 
knockout mice designed to 1) delete intermediate filaments proteins such as GFAP, 
thereby inhibiting reactive astrocyte (RA) formation, 2) deplete proliferating reactive 
 8 
astrocytes, or 3) delete important transcription factors in astrocytes such as STAT3 and 
SOCS3 (Okada et al., 2006; Herrmann et al., 2008).  
1.5.2. Inhibition of Neuronal Plasticity by Reactive Astrogliosis  
Evidence for the deleterious effects of reactive astrogliosis has been well-documented 
(reviewed in Silver and Miller, 2004; Pekny and Nilsson, 2005). Many of the deleterious 
effects of reactive astrocytes are attributed to the inhibition of axon sprouting and 
guidance and, general suppression of neuronal plasticity by the glial scar. Histological 
evidence for the inhibitory effects of glial scarring on axon regeneration and outgrowth 
can be found in the work of Ramon y Cajal (Silver and Miller, 2004). He described and 
named the so-called “dystrophic endbulbs”, newly sprouted axons that appeared to stall at 
the edge of the glial scar. The chondroitin and keratan sulfate proteoglycans produced by 
reactive astrocytes within the glial scar are now known as the inhibitors of axonal 
regeneration (Silver and Miller, 2004).  
Menet et al. (2003) reported improved functional recovery after spinal cord 
lesions in double knockout GFAP-/- vimentin-/- mice compared with recovery in control 
animals (Menet et al., 2003). Citing many studies that obtained histological and 
functional data for weeks and months after injury, Pekny and Nilsson (2005) suggest a 
biphasic model for reactive astrogliosis: “The effect of reactive astrocytes after CNS 
trauma has two stages: reactive astrocytes play a beneficial role in the acute stage after 
CNS injury, but later act as inhibitors of CNS regeneration”. 
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1.5.3. Protective roles of Reactive Astrogliosis 
Astrocytes are necessary for tissue protection and repair during the acute phase of CNS 
injuries like spinal cord injury and stroke. Pekney and others (1999) performed some of 
the first experiments to elucidate the protective and reparative role of reactive astrocytes 
in the acute phase of CNS injury. They found that knockout of the GFAP and vimentin 
genes in mice increased immune cell infiltration and the persistence of acute 
inflammation cells in the injury area; this correlated with a reduced rate and degree of 
astroglial scar formation (Pekny et al., 1999). Targeted ablation of proliferating reactive 
astrocytes in vivo produced phenotypic results similar to IF deletion, and disrupted repair 
of the BBB (Bush et al., 1999). Notably, ablation of reactive astrocytes increased 
neuronal apoptosis (Faulkner et al., 2004; Myer et al., 2006) and worsened functional 
outcomes relative to control animals (Faulkner et al., 2004).  
Reactive astrocytes protect neurons from excitotoxicity by uptake of glutamate 
(Rothstein et al., 1996) and from reactive oxygen species after injury through a 
glutathione-dependent mechanism (Pekny and Nilsson, 2005). They also mitigate post-
infarct edema by up-regulating the expression of aquaporin proteins that provide 
transmembrane water channels (Hirt et al., 2009). Reactive astrocytes also support 
neurovascular remodeling after injury, which is important for tissue repair/remodeling 
and recovery of motor function after focal ischemia (Hayakawa et al., 2010).   
The inflammatory response following stroke is necessary for clearance of necrotic 
and dying cells, but also causes the disruption of the BBB and secondary CNS injury 
mediated by cells of the innate immune system (reviewed in Iadecola and Anrather, 
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2011).  Reactive astrocytes secrete both pro- and anti-inflammatory cytokines to 
modulate the immune response to injury (Iadecola and Anrather, 2011). Most 
importantly, proliferating reactive astrocytes create physical barrier the injury area and 
close off infiltrating innate immune cells from the parenchyma (Voskuhl et al., 2009; 
Wanner et al., 2013).   
In all, these studies show that the astroglial response to CNS injury is necessary 
for tissue protection and repair during the acute phase of injury, and greatly out-weights 
any long-term inhibitory effects on neural plasticity.   
1.5.4. Comparative Astrogliosis: Restricted Regeneration of CNS tissue in Mammals 
CNS tissue damage and regeneration have been well researched in cold-blooded animals. 
Amphibians (Xenopus laevis) and Teleost fish such as zebrafish (Danio rerio) have an 
amazing ability to regenerate the CNS after injury (Del Rio-Tsonis and Tsonis, 2003). 
Sean Carroll’s recent book “Endless Forms Most Beautiful: The New Science of Evo 
Devo” illustrates the stark differences between mammals and fish in response to retinal 
damage. In brief, Müller glia (retinal astrocytes) in fish respond to retinal injury by 
proliferating, forming a scar and then generating neuroblasts that repopulate the damaged 
retina. Remarkably, healing of the CNS in these animals is both structurally and 
functionally complete. In mice, the response to retinal damage is arrested at glia scar 
formation, leaving the mice blind (Carroll, 2005) (see Del Rio-Tsonis and Tsonis [2003] 
for a peer-reviewed article on this subject). 
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1.6. Neural Stem Cells  
1.6.1. Adult Neural Stem Cells 
A neural stem cell is a specific type of stem cell that can divide symmetrically to make   
two identical daughter cells, or asymmetrically to create a daughter cell and a neural 
progenitor cell. Neural progenitor cells give rise to precursor cells with restricted 
potential to differentiate into one of the three cell types in the neural lineage: neurons, 
oligodendrocytes or astrocytes. Therefore, neural stem cells are said to possess the 
property of self-renewal, i.e. they create identical daughter cells that maintain their 
capacity for multipotent differentiation through multiple cell divisions and over time. 
Adult neural stem cells (NSC) were first isolated from mice and cultured in the 
early 1990’s (Reynolds and Weiss, 1992). Up to that point, NSCs could only be obtained 
from embryonic neuroepithelium. To date, specialized “niches” that contain NSCs have 
been identified in the adult CNS of many different mammalian species including rats, 
mice, and man (Yao et al., 2012).  
1.6.2. Adult Neurogenic Niches 
Adult NSCs reside in two niches in the brain, the sub granular zone (SGZ) of the 
hippocampal dentate gyrus and the subventricular zone (SVZ) of the lateral ventricle. 
Both niches support a population of self-renewing stem/progenitor cells that give rise to 
neuroblasts and nascent neurons, as well as glial precursors. The SGZ generates neurons 
that integrate within the network of the dentate gyrus/CA3 region of the hippocampus to 
facilitate learning and memory (Bonaguidi et al., 2012). The SVZ creates migratory 
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neuroblasts that travel to the olfactory bulb where they differentiate into GABAergic 
interneurons (inhibitory neurons) that integrate into the mitral layer and the granular layer 
to refine odorant discrimination (Breton-Provencher and Saghatelyan, 2012).  
The SVZ provides an environment that supports self-renewing adult NSCs in the 
mammalian forebrain (Morshead et al., 1994). The SVZ NSC niche consists of several 
different cell types that facilitate adult neuro- and gliogenesis. Doetsch and colleagues 
(2002) proposed a model that ascribes the labels “A”, “B” and “C” to different cell types 
in the neurogenic niche. Type B cells are the putative stem cell and have astrocyte-like 
morphology and have processes that contact microvessels and the cerebral spinal fluid in 
the lumen of the lateral ventricle. They express multiple proteins characteristic of NSCs: 
Sex determining region Y-box 2 (Sox2), GFAP, nestin, and CD15/SSEA-1 (Ihrie and 
Alvarez-Buylla, 2011). Transit amplifying progenitor cells, or Type C cells, arise from 
asymmetrical divisions of Type B cells. Type C cells express the EGF receptor and the 
transcription factor MASH1 (Doetsch et al., 2002); these cells divide rapidly to produce 
Type A cells (neuroblasts). The Type A cells are destine to become neurons and express 
markers of early neural lineage cells (neuroblasts): polysialylated neural adhesion 
molecule (PSA-NCAM), doublecortin (DCX), and β-tubulin III (Tuj1). When removed 
from the SVZ and cultured in basic fibroblast growth factor (bFGF) and EGF, Type C 
cells create self-renewing, multipotent neurospheres (Doetsch et al., 2002). The self-
renewal capacity of NSCs declines with passaging in some species (e.g. rats), but remains 
intact for hundreds of passages in mice (Steffenhagen et al., 2011).  The ability of murine 
SVZ NSCs to self-renew and to maintain multi-lineage potential has allowed researchers 
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to study them in great detail. In addition, cultured SVZ NSCs can be grafted into the 
lateral ventricle of a host and some behave normally, producing neuroblasts capable of 
migrating down the rostral migratory stream and generating interneurons in the OB 
(Aguirre and Gallo, 2004; Lledo et al., 2008; Shimada et al., 2012).   
1.6.3. Cortical Development and the Adult Sub-Ventricular Zone (SVZ) 
During formation of the cortical layers, radial glial cells that reside in the ventricular zone 
extend single, radial processes out towards the embryonic pia mater. Radial glial cells 
divide asymmetrically, forming neuroblasts that migrate along the radial processes and 
that differentiate into neurons that compose the layers of the cerebral cortex. The layering 
of cortical neurons proceeds in a coordinated manner that is timed and dictated by 
mechanisms intrinsic and extrinsic to radial glial cells (Kazanis et al., 2008).  
Gliogenesis, the formation of oligodendrocytes and astrocytes, begins around 
E18.5 and continues into the post-natal period. A few days after birth, radial glial cells 
give rise to glioblasts that populate the newly-formed cortex (Qian et al., 2000).  
Subsequently, the apical processes of a few remaining radial glial cells retract; these cells 
will reside in the SVZ as self-renewing, multipotent adult NSC (Merkle et al., 2004).  
1.6.4. Endogenous Stem Cell Therapy for Ischemic injury from the SVZ 
Since the discovery of the SVZ niche, researchers have attempted to harness it as a source 
of stem cells for repair after brain injury (Temple and Alvarez-Buylla, 1999). For 
cortical/striatal injury, including strokes, the SVZ has been the subject of intense study 
because of its anatomical proximity to stroke injury. Migration of neuroblasts from the 
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SVZ was reported for both adult rats and mice after they were subjected to ischemic 
insult (Arvidsson et al., 2002; Gotts and Chesselet, 2005b, a; Yamashita et al., 2006). 
Migration is a key aspect of injury repair by neuroblasts. Neuroblasts utilize the 
architecture of the cerebral vasculature to migrate to sites of injury (Shen et al., 2008; 
Kojima et al., 2010). New neurons derived from doublecortin (DCX+)-positive 
neuroblasts tagged with thymidine-analogue 5-bromo-2'-deoxyuridine (BrdU) from the 
time of injury have been observed in the murine striatum after transient intra-luminal 
middle cerebral artery occlusion (tiMCAO) (Arvidsson et al., 2002; Yamashita et al., 
2006). It remains controversial whether or not functional recovery is enhanced by newly 
born SVZ-derived neurons. 
Using a focal injury model that damaged the cortex, corpus callosum and distal 
striatum, Gotts and Chesselet (2005b) observed the migration of SVZ DCX+ neuroblasts 
to the area of injury, but did not observe new neurons that derived from these cells. With 
the use of a permanent distal Middle Cerebral Artery Occlusion (dMCAO) model our 
group induced focal cortical ischemic injury that did not damage the striatum. Notably, 
we observed that no DCX+ cells migrated from the SVZ to areas near the cortical infarct 
or peri-infarct area (Shimada et al., 2010). From these studies, it appears that the SVZ is 
stimulated by ischemic injury, but the severity and/or proximity of injury dictates the 
number of neuroblasts that migrate from the niche to area of tissue damage. 
1.6.5. Reactive Astrocyte-derived Neural Stem Cells 
Lang et al. (2004) identified a population of nestin-expressing reactive astrocytes that 
formed after hemi-transection of the rat spinal cord. In culture, these cells could form 
 15 
neurospheres under the same conditions as SVZ-derived NSCs. They also showed that 
these cells were multipotent in culture (Lang et al., 2004). Lineage-tracing studies that 
utilized inducible reporters under the control of astrocyte-specific promoters have 
identified astrocytes as the source of NSCs derived from injured cortical tissue. Reactive 
astrocyte-derived NSCs (Rad-NSCs) have been identified in brain stab injury (Buffo et 
al., 2008), neonatal hypoxia injury (Bi et al., 2011) and stroke (Shimada et al., 2012).  
Interestingly, not all brain injuries generate reactive astrocytes that are capable of 
conversion to NSCs in culture. Sirko et al. (2013) examined the sphere-forming capacity 
of reactive astrocytes in several mouse models of cortical injury. Certain injuries such as 
cortical needle stab injury and ischemic stroke, respectively, affect reactive astrocytes in 
a way that makes them competent for conversion to NSCs, in vivo. Insults and 
pathologies such as murine models for Alzheimer’s (specifically the Swedish mutation: 
AppS1) and neurotoxicity do activate astrocytes, but do not achieve the temporally brisk 
activation or the reactive astrocyte proliferation that stroke and needle stab elicit.  
1.6.6. Reactive Astrocyte Reprogramming, In Vivo 
Reactive astrocytes share several characteristics with adult NSCs (i.e. Type B cells in the 
SVZ). For example, both cell types express stem cell-associated transcription factors (e.g. 
SOX2) and intermediate filaments (e.g. GFAP, nestin). The astrocyte-like stem cells in 
the SVZ neurogenic niche divide undergo division, but are quiescent most of the time. 
Similarly, cortical astrocytes are mitotically quiescent for long periods of time, then 
undergo a period of rapid division during the response to injury after their conversion to 
reactive astrocytes, and they become quiescent again. The new cells form during reactive 
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astrocyte proliferation generate mature astrocytes and contribute to the glial scar (Wanner 
et al., 2013). In contrast to adult NSC, adult reactive astrocytes are lineage-restricted in 
vivo. This lineage restriction is controlled by both cell-extrinsic and intrinsic factors.  
Futhermore, despite their multipotency in culture, Rad-NSCs grafted back to the 
SVZ were not able to create neurons in the olfactory bulb (Shimada et al., 2012). Post-
natal day 7 cortical NG2+ neural progenitor cells were unable to create neurons in the OB 
after engraftment into the SVZ (Aguirre et al., 2005).  
The addition of exogenous bFGF and EGF to injured CNS tissue is not sufficient 
to spur neurogenesis from reactive astrocytes (Ohori et al., 2006). However, neurogenesis 
in the peri-infarct area can be achieved to a limited degree by transfecting reactive 
astrocytes with neurogenic transcription factors such as Nkx2.2 (Ohori et al., 2006) or 
Pax6 (Heins et al., 2002). Niu et al. (2013) demonstrated that lentivirus-induced 
expression of Sox2 under the control of the human GFAP promoter both necessary and 
sufficient to induce astrocytes to become neuroblasts in the striatum of adult mice. Of 
interest, they found that astrocytes first passed through a proliferative state—a feature of 
reactive astrocytes—before becoming neuroblasts. Niu et al. (2013) were able to 
terminally differentiate astrocyte-derived neuroblasts with Brain Derived Neurotrophic 
Factor (BDNF) and Noggin treatment or Valproic Acid alone to produce mature, 
functionally-integrated neurons. Thus, dividing reactive astrocytes that respond to injury 
somewhat resemble NSCs and are amenable to viral induction by transcription factors 
that break the multipotency barrier, allowing neurogenesis to occur. However, it remains 
to be seen whether neurogenesis can be influenced in an orchestrated manner after injury 
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in order to beneficially alter CNS tissue remodeling and restore function to damaged 
neural tissue. 
1.7. The Regulation of Reactive Astrocytes 
1.7.1. Introduction 
Understanding the signaling pathways that regulate proliferation and protective functions 
of reactive astrocytes is essential for exploiting them therapeutically. Moreover, 
manipulating reactive astrocytes to provide maximal therapeutic effect will require 
knowledge of how they respond differently to particular types of CNS injury. For 
example, Zamanian et al. (2012) found that reactive astrocytes formed during a model of 
neuro-inflammation in the cortex expressed a markedly different set of genes compared 
to reactive astrocytes responding to ischemic stroke.  
1.7.2 Notch Signaling: a Brief Introduction 
Notch signaling is a highly conserved cell-cell signaling system that is found in 
multicellular animals (Hori et al., 2013). The gene and its significance in Metazoan 
development were first described by Thomas Hunt Morgan in Drosophila melanogaster a 
century ago (Imayoshi and Kageyama, 2014).  
Components of the pathway  
Mammalian express 4 genes with homology to the Notch gene in Drosophila: named 
Notch 1 through 4. In terms of nomenclature, mammalian Notch ligands are separated 
into two groups: the Delta-like or Delta group  (DLL1-4) with homology to the 
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Drosophila Delta receptor and the Jagged group (Jagged1 and 2) with homology to the 
Drosophila Serrate receptor. Notch receptors undergo extensive post-translational 
modifications including O-linked glucosylation and fucosylation; these are important for 
proper protein folding and intracellular trafficking of the receptors. Notch receptors 
undergo a proteolytic cleavage before presentation to the cell surface (S1 cleavage) and 
upon binding to its ligands (S2 and S3 cleavage) (Hori et al., 2013).  
S3 cleavage is necessary for Notch signaling (Rozmahel et al., 2002) and 
ismediated by a proteolytic intramembrane protein complex known as γ-secretase. In 
mammalian systems γ-secretase is composed of four proteins: Nicastrin, Presenilin 
Enhancer 2 (PEN2), Anterior PHarynx-defective 1 (APH1) and an aspartyl proteases 
Presenilin1 or 2 (Kopan and Ilagan, 2004). Presenilins1 or 2 provides the catalytic site for 
proteolysis, but do not have normal activity outside of the γ-secretase complex. Both 
require Nicastrin for proteolytic activity (Chung and Struhl, 2001).  
The γ-secretase complex has been proposed as the “proteasome of the membrane” 
due to the wide array of membrane-bound receptors and proteins it cleaves and its 
apparent role in receptor shedding (Kopan and Ilagan, 2004). It cleaves several other 
type-1 transmembrane proteins, notably a protein linked to Alzheimer’s dementia called 
Amyloid Precursor Protein. Several pharmacological inhibitors of γ-secretase activity 
have been developed and are useful to inhibit the cleavage of Notch receptors and Notch 
signaling. Most inhibit proteolysis by inhibiting the catalytic site of Presenilin1 and 2 
(Wolfe and Haass, 2001).  
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Signaling Mechanism 
Canonical Notch signaling proceeds as follows: the Notch receptor binds to a Notch 
ligand presented on the surface of an adjacent cell. The Notch-ligand interaction causes a 
conformational change in the transmembrane domain of Notch that exposes a sequence of 
peptides that is recognized and cleaved by γ-secretase. Cleavage releases the intracellular 
domain of Notch (NICD) from the membrane. It then translocates to the nucleus and 
interacts with the transcriptional repressor protein CSL (RBPJκ in mice). Upon 
association, NICD/CSL recruits mastermind-like protein (MAML) and other co-
activators to form a transcriptional activator complex that initiates gene expression of 
downstream effector proteins such as transcription factors (Ables et al., 2011). Several of 
the transcription factors that are activated by Notch, such as the Hairy/Enhancer of Split 
(HES) family, are highly conserved across species and promote cell division and lineage 
specification (Louvi and Artavanis-Tsakonas, 2006).  
General Function in Animal Development 
Notch signaling is necessary for the specification and differentiation of many cell and 
tissue types during animal development, and is a large player in tissue patterning (Lai, 
2004). In addition, Notch signaling can also induce proliferation or apoptosis (Hori et al., 
2013). During CNS development in vertebrates, Notch signaling is essential for 
determining the number of neurons generated by regulating the size of the neural 
progenitor pool and therefore affects brain morphogenesis (reviewed in Louvi and 
Artavanis-Tsakonas, 2006). 
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1.7.3. Jagged: a Ligand of Notch 
The cDNA encoding Jagged, the mammalian homologue of the Serrate receptor in D. 
melanogaster, was first cloned and described in rats (Lindsell et al., 1995). In this 
seminal study, Jagged mRNA was shown to pattern the developing rat neural tube in a 
distribution similar to that of Notch1, 2 and 3. Furthermore, Lindsell et al. (1995) 
demonstrated that cloned Jagged cDNA expressed by L-cells could induce Notch1 
signaling on adjacent myoblasts in culture. These observations suggested its activity as a 
Notch1 ligand.  
 There are two mammalian Jagged genes: Jag1 and Jag2. The Jag1 gene encodes a 
single-pass transmembrane domain receptor with a molecular weight of ~135 kDa 
(Lindsell et al., 1995). Compared with Jagged proteins, members of the Delta family of 
Notch ligands are smaller in molecular weight. Like the Notch receptors, Delta and 
Jagged are processed by γ-secretase to release their respective intracellular domains, 
although no signaling has been attributed to these fragments (LaVoie and Selkoe, 2003). 
Both families of receptors contain a Delta-Serrate-LAG-2 (DSL) domain, which is highly 
conserved across species and required for Notch receptor trans-activation and cis-
inhibition (Cordle et al., 2008). Notch receptors discriminate between Delta and Jagged 
ligands depending on the context and conditions of the interaction (Yamamoto et al., 
2012).  
The existence of two separate ligands of Notch in both D. melanogaster (Delta 
and Serrate) and mammals (Delta 1-4 and Jagged 1,2) suggests functional importance in 
metazoan biology. Differential expression of mRNA for Notch, Delta and Jagged 
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isoforms in regions of the developing mammalian embryo, and particularly in the 
developing brain, suggest specific roles for these receptors (Lindsell et al., 1996). 
However, there does not appear to be a consensus of Notch signaling effects attributable 
to Delta binding verses Jagged binding in mammalian systems. In early human 
hematopoiesis, Jagged-2 signaling through Notch has an effect similar to that of Delta 1-
4. It signals through Notch1 and induces T-cell lineage differentiation while inhibiting B-
cell and myeloid cell development. In contrast, Jagged-1 prevents T-cell differentiation 
and promotes the B-cell fate (Van de Walle et al., 2011). Elyaman et al. (2007) 
demonstrated favorable outcomes after infusion of Jagged-1-FC in an experimental 
model of autoimmune encephalomyelitis, whereas treatment with a Delta-1-FC or with a 
neutralizing antibody to Jagged-1 was found to exacerbate the injury. These studies 
provide evidence that Notch ligand isoforms differentially modulate Notch signaling to 
influence development, cell fate determination, and response to injury.  
Jagged in Neurodevelopment and Disease.  
Little is known about how the Jagged family of Notch ligands participate in 
neurodevelopment. Jagged-1 is essential for mammalian development as Jag1 null mice 
do not survive embryogenesis and die in utero due to malformation of the cardiovascular 
system and subsequent hemorrhaging (Xue et al., 1999). Jag1 mRNA is expressed in 
different regions and at different times in the developing CNS and is independent of 
Delta ligand patterning (Lindsell et al., 1996). In the developing optic nerve, Jagged-1 is 
transiently-expressed on retina ganglion cells that interact with Notch1-expressing 
oligodendrocyte precursors (OPC). Notch1 signaling in OPCs inhibits their maturation to 
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oligodendrocytes. Though these cell-cell interactions, Jagged-1/Notch signaling controls 
myelination of the optic nerve (Wang et al., 1998). Jagged-2 maintains multipotency and 
proliferation of neural progenitors while inhibiting neuronal differentiation in the ventral 
spinal cord of developing zebra fish (Yeo and Chitnis, 2007).  
Mutations in the human gene encoding Jagged-1 causes Alagille syndrome, an 
inherited developmental disorder that affects formation of the bile ducts in the liver and 
the development of craniofacial bones. Alagille syndrome is also associated with 
developmental delay and reduced cognitive function (Oda et al., 1997). 
1.7.4 Notch Signaling in Astrogliogenesis 
 Development of the vertebrate cerebral cortex is a highly orchestrated event during 
which neurogenesis is followed by gliogenesis. This process is discussed further in 
section 1.6.3. Cortical Development and the Adult Sub-Ventricular Zone (SVZ).  
Just before birth, radial glial cells in the developing cortex first populate the 
cortical layers with neurons. At birth, radial glial cells switch to producing astrocytes in 
an event known as the neurogenic-gliogenic switch (Okano and Temple, 2009). During 
the early stages of neurogenesis, Notch signaling sustains symmetric divisions of radial 
glial cells in order to maintain the pool of progenitors and to generate neurons (Yoon et 
al., 2008; Dong et al., 2012). Notch1 overexpression in the neuroepithelium during early 
forebrain development promotes the radial glial phenotype prematurely (Gaiano et al., 
2000).  
At the neurogenic-gliogenic switch, glioblasts are the predominant cell type 
created from the asymmetric divisions of radial glia (Temple and Alvarez-Buylla, 1999). 
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Notch signaling drives this process through collaboration with BMP/SMAD signaling 
and GP130/STAT3 signaling to promote the transcription of glial-specific genes like 
GFAP. Notch1 signaling also promotes the expression of astroglial fate-specification 
genes such as Nuclear Factor 1 (NF1a) and GLAST in spinal cord development (Deneen 
et al., 2006; Miller and Gauthier, 2007). Notch suppresses the neurogenic program by 
action of HES5. Direct protein-protein interactions with pro-neural basic helix-loop-helix 
factors and HES5 prevent premature neurogenesis and maintain undifferentiated radial 
glia during development (Imayoshi and Kageyama, 2014). In sum, Notch signaling 
provides an important extrinsic signal that maintains the radial glial phenotype and self-
renewal in prenatal cortical development, and later drives astrogliogenesis at the 
neurogenic-gliogenic switch.  
1.7.5. Regulation of adult NSCs in the SVZ by Notch signaling 
The SVZ of the adult mouse contains a germinal zone where NSCs give rise to 
neuroblasts, oligodentrocyte precursors and astrocytes (Aguirre and Gallo, 2004). 
Astrocyte-like type B cells (adult NSCs) depend on Notch1 signaling to maintain 
properties of self-renewal (Aguirre et al., 2010a; Basak et al., 2012). Using a transgenic 
mouse model to conditionally delete Notch1 in nestin-expressing NSCs, Basak et al. 
(2012) saw a reduction of neurogenesis and depletion of the progenitor pool in the SVZ. 
Using the anti-mitotic AraC to ablate proliferating Type C transit-amplifying cells in the 
SVZ and then allowing for a period of recovery, they demonstrated a defect in the 
symmetrical division of NSCs (Basak et al., 2012). In another study, upon recovery from 
AraC treatment, the levels of NICD and RBPJκ (CSL) were increased in the SVZ. This 
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was accompanied by a decrease in Numb, a protein that antagonizes Notch signaling 
(Aguirre et al., 2010b).  
Jagged-1 is expressed in the adult murine SVZ and SGZ (Stump et al., 2002). In 
the SVZ, Jagged-1 expression was localized to GFAP-expressing astrocytes, whereas 
Notch1 was expressed on DCX+ neuroblasts. Infusion of Jagged-1-FC into the lateral 
ventricle increased the amount of DCX+ cells migrating out from the SVZ (Wang et al., 
2009).   
1.7.6. Notch Signaling and Stroke: Helpful or Hurtful? 
Following stroke, the outcome of Notch signaling is controversial. It has been reported to 
be either detrimental or beneficial to tissue repair and neurological outcomes. Arumugam 
et al. (2006) employed an occlusion/reperfusion model and found that, following stroke, 
inhibition of Notch signaling with a γ-secretase inhibitor (GSI) or a Notch antisense RNA 
decreased infarct volume and improved neurological function compared with control 
levels. Conversely, Benner et al. (2013), using a photothrombosis-mediated MCA 
permanent occlusion model, found that disruption of Notch signaling in nestin-expressing 
reactive astrocytes worsen injury outcome. Arboleda-Velasquez et al. (2008) found that 
deletion of Notch3 in vascular smooth muscle cells resulted in worse outcomes in a 
transient cerebral ischemia model. Unfortunately, variations in stroke model, strategy for 
disrupting Notch signaling, cell-type specificity for gene conditional knockouts and the 
age differences make it difficult to compare the results from these three papers.  
 Jagged-1 mediated Notch signaling in reactive astrocytes has been also studied in 
the context of demyelinating injury. In this case, recovery requires OPC migration, 
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differentiation and remyelination of axons. Reactive astrocytes are also present in these 
lesions. OPCs in the lesion area express Notch1 and contact reactive astrocytes that 
express Jagged-1. Subsequent induction of Notch signaling in OPCs inhibits their 
terminal differentiation into oligodendrocytes (Hammond et al., 2014; Wang et al., 1998). 
In contrast, other groups have found no evidence of Jagged-1/Notch signaling causing 
deficiencies of myelination of the CNS during development (Zhang et al., 2009) or after 
demyelinating injury (Stidworthy et al., 2004).  
1.7.7. Jagged-1/Notch Signaling in Reactive Astrocytes 
Notch signaling in reactive astrogliosis has not received the kind of intense investigation 
it has received for its roles in developmental processes. This is surprising considering the 
clear importance of Notch1 in astrogliogenesis and in light of evidence suggesting that 
Notch signaling supports gene and protein expression that promotes astrocyte identity 
(Imayoshi and Kageyama, 2014). Our group has shown that Notch1 is required for 
normal proliferation of reactive astrocytes after stoke (Shimada et al., 2011). The role of 
Jagged-1/Notch signaling in reactive astrocyte functions remains undefined.  
1.7.8. A Brief Introduction to Endothelin Signaling 
The Endothelin signaling axis consists of three soluble peptides, Endothelin-1, -2, and 3, 
that require proteolytic cleavage with Endothelin Converting Enzyme (ECE) in order to 
be biologically active. Their cognate receptors, ETAR and ETBR, are G-protein coupled 
receptors that increase intracellular Ca2+ through the action of phospholipases to effect 
transcription early response genes. These receptors also crosstalk with many intracellular 
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signaling pathways: MAPK, PI3K–AKT, NF‑κB, β‑catenin, HIF1α, RHO, PKA and PKC 
(Rosano et al., 2013). ETAR has higher affinity for ET-1 and ET-2 than ET-3, whereas 
ETBR has equal affinity for all three Endothelins. Endothelins, ECEs and ET receptors 
are found in many organs systems and tissues. The Endothelin system is integral to the 
vascular system, the kidneys, and the pulmonary tree, where it regulates blood pressure, 
blood ion and acid-base balance, and bronchial tone, respectively (Masaki, 2004; Ge et 
al., 2008; Uchida et al., 1988).  
The Endothelin-1 was first discovered in the conditioned medium of endothelial 
cells and was determined to be a potent vasoconstrictor (Yanagisawa et al., 1988). Under 
normal physiological conditions, Endothelin 1 (ET-1) is secreted from endothelial cells 
and controls tonic vasoconstriction by stimulating smooth muscle cell contraction. 
Binding of ET-1 to ETAR on vascular smooth muscle cells causes signaling through the 
phospholipase system that then increases intracellular calcium. This activates the 
myosin/actin system and causes contraction of the smooth muscle cell. Endothelial cells 
express ETBR, but not ETAR. Signaling through endothelial ETBR drives the production 
of nitric oxide (NO), which causes relaxation of smooth muscle and vasodilatation. In 
this way, ET-1 signaling maintains vascular tone. Perturbations of ET-1 signaling have 
been implicated in the pathophysiology of many cardiovascular diseases including 
hypertension-induced renal failure, arteriosclerosis, pulmonary fibrosis and hypertrophic 
remodeling of the heart (reviewed in Kedzierski and Yanagisawa, 2001; Masaki, 2004).    
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Special Focus: Endothelin Receptor B and Hischprung’s disease 
ETBR regulates the development and migration of the neural crest, a specialized group of 
multipotent cells that arise from the dorsal end of the neural tube during vertebrate 
embryogenesis. Neural crest cells proliferate extensively and migrate to distal sites and 
colonize the skin as melanocytes and the gut as enteric neurons. Mice with a spontaneous 
deletion in the Ednrb gene, known as piebald-lethal (Ednrbs-l ) mice, have altered 
melanocyte distribution, which gives them a patchy coat color, and die of toxic 
megacolon, due to a lack of enteric neurons that mediate gastric motility in the colon 
(Hosoda et al., 1994). By inducible transgenic Ednrb-rescue of Ednrbs-1 mice, Shin et al. 
(1999) showed that ETBR was required for the proper migration of melanocyte precursor 
and enteric neuron precursor cells.  
Hischprung’s syndrome, an inherited human disease, is the result of a missense 
mutation in the EDRNB gene, which encodes for human ETBR. Hischprung’s syndrome 
is characterized by severely decreased gastric motility in the distal colon that can 
progress to toxic megacolon—a fatal complication. Similar to Ednrbs-1 mice, patients with 
Hischprung’s are missing enteric ganglia in the distal colon; this leads to reduced gastric 
motility (Puffenberger et al., 1994).   
1.7.9. Endothelin and Cerebral Ischemia  
The Endothelin signaling axis plays a critical role in cerebral ischemia (reviewed in 
Kaundal et al., 2012). Extracellular ET-1 levels increase in the brain acutely after focal 
and global ischemia at 24 hours (Barone et al., 1995) and plasma levels increase in 
humans following stroke (Ziv et al., 1992). ET-1 is produced at the site of injury and acts 
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as an acute phase signaling peptide, producing a multitude of different effects on the 
injury environment and acts on vascular smooth muscle cells, reactive astrocytes and 
other cell types (discussed in detail later).  
Researchers and drug developers have focused their efforts on understanding the 
vascular effects of the Endothelin signaling axis after cerebral ischemia largely through 
pharmacological manipulation of ETAR and ETBR using selective antagonists and 
agonists, as well as pan-receptor antagonists. Antagonism of ETAR in reperfusion models 
of stroke is associated with increased cerebral blood flow after ischemic insult, decreased 
infarct volume, and improved neurological outcomes. A meta-analysis of animal studies 
that treated transient cerebral ischemia with ETAR antagonists suggested that this 
pharmacological strategy could be used to mitigate cerebral ischemia following 
reperfusion in patients (Kaundal et al., 2012). Notably, most ischemic injuries in humans 
are caused by permanent occlusions of large and/or small vessels. 
Following focal cerebral ischemic injury, global ischemia from hypoperfusion and 
subarachnoid hemorrhage (SAH), smooth muscle cells up-regulate ETBR and this causes 
vasoconstriction, an effect opposed to its role in vasodilation in endothelial cells 
(Stenman et al., 2002, Johansson et al., 2012). ETBR antagonists attenuate cerebral 
vasospasm and subsequent ischemic damage of SAH in animal models (Zuccarello et al., 
1998).  Mixed ET receptor antagonists have been used with the same effect in patients 
with SAH (Macdonald et al., 2008). However, ETBR antagonists failed to increase 
cerebral blood flow and improve outcomes in global ischemia (Patel and McCulloch, 
1996). ETBR antagonists used in treatment studies in animal models of both transient and 
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permanent focal ischemia decreased infarct volume when combined with ETAR 
antagonists (Barone et al., 1995; Table 1-1). A study using both ETA and ETB receptor 
antagonists had similar outcomes (Moldes et al., 2012; Table 1-1). Importantly, selective-
antagonism of ETBR exacerbates focal ischemia (Chuquet et al., 2002; Table 1-1). 
Moreover, stimulation of ETBR signaling improves outcomes after focal ischemic injury 
(Leonard et. al., 2011; Table 1-1). In summary, ETBA or pan ET receptor antagonism 
seems to be beneficial for treating SAH-induced vasospasm and for increasing cerebral 
blood flow following transient cerebral ischemia, but neither therapy improves focal 
cerebral ischemia without reperfusion. Conversely, ETBR antagonists exacerbate cerebral 
ischemia, while agonists of ETBR are beneficial in cerebral ischemia without reperfusion.     
Pharmacologic 
agent Injury Model Study Endpoints Reference 
Pre-treatment with 
SB 217242 (ETR 
pan-antagonist) 
Permanent MCAO in 
spontaneously hypertensive 
rats. 
30% reduction in infarct volume. No 





Permanent middle cerebral 
artery occlusion in rats 
85% reduction in infarct volume. 





Rats were subjected to 
transient (60 minutes) focal 
cerebral ischemia (MCAO) or 
cortical injection of NMDA. 
178% increase in infarction volume 
(MCAO). 26% decrease in CBF. No 





& BQ-788 (ETBR 
antagonist) 
Ischemia by transient 
intraluminal MCAO (90 min) 
in rats. 
Clazosentan reduced edema. 
Combination therapy further reduced 





Table 1-1. Animal studies treating permanent or transient cerebral ischemia with 
ETBR antagonists and agonists. 
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1.7.10. Endothelin and Reactive Astrocytes 
One of the first and most comprehensive studies of the expression and distribution of 
Endothelin receptor subtypes in the brain showed that ETBR was expressed by many 
different cell types, including cortical astrocytes (Hori et al., 1992). Reactive astrocytes 
up-regulate ET-1 in response to focal ischemia (Jiang et al., 1993), transient cerebral 
ischemia (Yamashita et al., 1994), white matter lesions (Hammond et al., 2014), and 
Alzheimer’s disease-related lesions (Jiang et al., 1993; Zhang et al., 1994). Cultured 
primary astrocytes secrete ET-1 in response to thrombin, a component the clotting 
cascade present in the CNS after injury (Ehrenreich et al., 1993). Similarly ETBR is 
highly expressed in reactive astrocytes after many different CNS injuries (Baba, 1998; 
Peters et al., 2003, Rogers et al., 2003).  
ET-1 signaling through ETBR is capable of “activating” cultured astrocytes: 
causing hypertrophy and proliferation (Baba, 1998). ET-1 produced by reactive 
astrocytes signals through ETBR in an autocrine fashion (Ehrenreich et al., 1991; 
Hasselblatt et al., 2001).  Infusion of recombinant ET-1 increases proliferation of reactive 
astrocytes in vivo (Koyama and Michinaga, 2012). Antagonism of ETBR, but not ETAR, 
was shown to decrease the number of proliferating reactive astrocytes following chemical 
demyelination of white matter through a JNK/ERK/c-Jun-dependent mechanism (Gadea 
et al., 2008). In cultured astrocytes, exposure to ET-1 induced the expression of cyclin D1 
and proliferation. ET-1 signaling through ETBR/JNK/ERK caused phosphorylation of the 
transcription factor Sp1 and enhanced its binding to consensus sequences in the cyclin D1 
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promoter (Michinaga et al., 2013). This body of research establishes that Endothelin 
signaling through ETBR controls reactive astrocyte proliferation.   
Koyama and Michinaga (2012) summarize an extensive body of literature 
pertaining to ETBR signaling its affect(s) in reactive astrocytes. Beyond proliferation, 
ETBR signaling induces gene expression for proteins that are important for the function of 
reactive astrocytes (Table 1-2). To summarize, ETBR signaling promotes the expression 
of neurotrophic factors, which provide trophic support for ischemic neurons and protect 
against apoptosis. ETBR signaling increases the production and secretion of Tissue 
Inhibitors of Matrix metalloproteinases (TIMPs); these proteins inhibit the disruption of 
the blood brain barrier (BBB) by counteracting proteases such as MMP2 and MMP9 that 
contribute to degradation of the BBB after injury. Yet, ETBR signaling has been shown 
affect the increase of MMP2, and 9, and VEGF-A (Table 1-2). VEGF-A causes BBB leak 
following injury. The disruption of the BBB can increase free water in brain tissue, 
causing it to expand and leading to further damage. However, MMP2, and 9, and VEGF-
A are necessary for angiogenesis and the neovascularization of the injury area during 
tissue repair (Zhang et al., 2000; Sood et al., 2008).  
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Table 1-2. ETs regulate the production of various signaling molecules in cultured 
astrocytes and the brain.  
Adapted from Koyama and Michinaga (2012). IL: interleukin, TNF: tumor necrosis 
factor, TIMP: tissue inhibitor of matrixmetalloproteinase, COX2: cyclooxygenase-2, 
iNOS: inducible NO synthase. 
1.7.11. Transcriptional Control of ETBR 
The transcriptional regulation of ETBR in smooth muscle cells and reactive astrocytes of 
the brain after ischemic injury is not well understood. However, transcriptional regulation 
of the human EDNRB gene has been described in melanocytes, derivatives of the 
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multipotent neural-crest lineage. Yokoyama and colleagues (2006) showed that Sry-box 
10 (SOX10) transcription factor, in combination with the transcription factor Sp1, binds 
to cis-acting elements in the EDNRB promoter thereby increasing ETBR expression. 
Thus, similar transcriptional control of ETBR may occur in reactive astrocytes and 
vascular smooth muscle cells. 
Section 1.8. Summary and Introduction to the Dissertation 
Reactive astrocytes are essential for the protection and repair of CNS tissue following 
injury. Proliferating reactive astrocytes that border the infarct area are especially 
important for containing the necrotic tissue and inflammatory cells and protect 
surrounding neurons from secondary damage by creating a scar. The first step in 
exploiting the protective features of reactive astrocytes to acquire a deep knowledge of 
the cellular signaling pathways that regulate genes/proteins that physically interact with 
the injury environment.  
Given the importance of Notch signaling in astrogliogenesis during CNS 
development and its role in maintaining the self-renewal of astrocyte-like adult NSCs in 
the SVZ, it is likely that this conserved and ancient signaling pathway regulates the 
identity, function and behavior of reactive astrocytes. For example, our group has shown 
that Notch1 is required for normal proliferation of cortical reactive astrocytes following 
stroke (Shimada et al., 2011).  
Recent work has connected Jagged-1/Notch signaling to Endothelin signaling in 
reactive astrocytes through ET-1-dependent up-regulation of Jagged-1 (Hammond et al., 
2014). But, it is not known if Notch modulates reactive astrocyte function directly or if it 
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acts indirectly by supporting other cell signaling pathways that affect reactive astrocyte 
function and proliferation. The experiments in this dissertation were designed to identify 
new targets of Notch signaling in reactive astrocytes. The data from these experiments 
provides evidence that Notch signaling has both direct and indirect transcriptional control 
over the expression of proteins that perform protective functions in response to injury. 
To investigate downstream effectors of Notch signaling, we developed an ex vivo 
forward signaling screen with adult reactive astrocytes. By exposing cultured adult 
astrocytes to immobilized Jagged-1, and comparing the transcriptome of these cells to 
that of control cells, we were able to determine changes in gene expression mediated by 
Jagged-1/Notch signaling. Genes for many proteins relevant to reactive astrocyte function 
up-regulated. We used transgenic mouse models to conditionally delete Notch1 from 
adult reactive astrocytes ex vivo and in vivo to explore the regulation of two target genes 
identified in the screen: 1) Glutamate Aspartate Transporter (GLAST) and 2) Endothelin 
Receptor B (ETBR). The data herein suggests Notch signaling acts directly on GLAST to 
control its expression and indirectly on ETBR expression by enhancing the activity of a 
direct effector of ETBR transcription: Signal Transducer and Activator of Transcription 3 
(STAT3).   
Reactive astrocytes protect healthy tissue and promote repair in the acute phase of 
many types of injuries by taking up extracellular glutamate, secreting neurotrophic 
factors, protecting the BBB and modulating the inflammatory response. The proliferation 
of reactive astrocytes is essential for reactive astrocyte-mediated protection after severe 
CNS injuries, like stroke. Therefore, enhancing reactive astrocyte proliferation after 
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stroke may provide greater protection and improve functional outcomes. The results of 
experiments performed in this dissertation suggest that Notch signaling may directly 
promote glutamate uptake and processing by reactive astrocytes. Additionally and 
importantly, Notch signaling participates in a feed-forward loop with Endothelin 
signaling to drive proliferation. Therefore, pharmacological stimulation of the Notch 
signaling pathway may help mitigate CNS damage caused by ischemic stroke by 
augmenting the protective function and number of reactive astrocytes. 
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Reactive astrocytes have much promise as therapeutic targets in CNS injury. Promoting 
their protective and reparative functions could improve outcomes after ischemic stroke, in 
particular; this would require a broad knowledge of their regulation. 
Notch1 signaling increases after injury in reactive astrocytes and is required for 
the proliferation of peri-infarct reactive astrocytes after stroke. It may also enhance the 
functions of reactive astrocytes such as extracellular ion homeostasis and glutamate 
uptake and metabolism. Molecular effectors involved in astrocyte function and controlled 
by Notch1 signaling were investigated by developing an ex vivo screen employing adult 
reactive astrocyte-derived neural stem cells (Rad-NSCs) isolated from the peri-infarct 
area of mice after stroke (permanent ligation model). Astrocytes re-differentiated from 
Rad-NSCs (AstroRad-NSC) were then exposed to immobilized Jagged-1, a ligand of Notch. 
Notch signaling supported the transcriptional effectors that promote astrocyte identity 
while suppressing those of neural or oligodendrocyte lineages. Furthermore, in response 
to Jagged1 signaling, many genes known to be involved in reactive astrocyte function and 
tissue protection were up-regulated. We focused on genes involved in glutamate uptake 
and metabolism that were increased by Jagged-1/Notch signaling. For one of these, glial-
specific Glutamate-Aspartate Transporter (GLAST), we confirmed that loss of Notch1 
decreased its transcript and protein levels in AstroRad-NSC. AstroRad-NSC take up glutamate 
from the extracellular space and inhibition of Notch signaling decreased this function. 
Furthermore, in vivo, after stroke, reactive astrocytes in which Notch1 was conditionally 
deleted demonstrated decreased the level of GLAST protein. Our results suggest that, in 
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addition to regulating reactive astrocyte proliferation, Jagged1/Notch1 signaling controls 
critical aspects of reactive astrocyte function such as glutamate uptake. During or after 
ischemic stroke, promotion of Notch signaling in reactive astrocytes may enhance 




Within hours of cerebral ischemia, an infarct core forms that is composed predominantly 
of necrotic tissue and immune cells. Coincident with these events, astrocytes proximal to 
the site of infarction undergo hypertrophy and proliferate in response to signals from the 
injury environment (Burda and Sofroniew, 2014). These “reactive astrocytes” provide 
numerous critical functions after stroke and many other forms of CNS injury that include 
neuroprotection, preservation and remodeling/repair of the blood brain barrier (BBB), 
regulation of immune cell invasion and formation of a glial scar. 
The Notch1 receptor is well known to control glial cell fate in CNS tissue. In 
development, Notch signaling specifies radial glial cell identity (Gaiano et al, 2000) and 
neural crest cell fate (Morrison et al., 2000). In adults, Notch regulates the self-renewal of 
neural stem cells (Hitoshi et al., 2002). After CNS injury, the biology of other glial cell 
types such as reactive astrocytes is also affected by Notch signaling. For example, 
reactive astrocytes from the stroke peri-infarct area require Notch1 signaling to 
proliferate (Shimada et al., 2011). The fundamental roles of Notch in glial cell identity, 
self-renewal, and cell division raise the question of whether it controls also adult glial cell 
function(s) in the healthy CNS and after injury. 
Astrocytes are known to support neuronal activity in the brain, in part, by closely 
regulating extracellular levels of L-glutamate (Glu), the main excitatory neurotransmitter. 
Glu is removed from synapses and the surrounding extracellular space by astroglial 
uptake and is converted into L-glutamine by a series of enzymatic reactions. Upon 
conversion, the glutamine becomes “re-available” as a precursor molecule for amino acid 
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neurotransmitters (e.g. Glu and GABA) (Bak et al., 2006). During cerebral ischemia, 
traumatic brain injury, or CNS disease, glutamate and ammonia levels can rise 
dramatically, resulting in excitotoxicity and death of neurons, in part, by overstimulation 
of neural receptors for N-ethyl-D-aspartic acid (NMDA) and kainic acid (KA) (Hazell et 
al., 2003, 2010). Identification of molecular mechanisms or cell-cell signaling that 
determines the level and/or activity of cellular glutamate transporters may lead to new 
neuro-protective therapies for patients with stroke or other CNS injuries.  
To control extracellular glutamate levels, astrocytes and endothelial cells use two 
membrane-bound excitatory amino acid transporters: Glutamate transporter 1 (GLT-1, 
EAAT-2, SLC1A2) (Rothstein et al., 1994) and the Glial High Affinity 
Glutamate/Aspartate Transporter (GLAST, EAAT-1, SLC1A3). The importance of 
glutamate transport in brain injury was demonstrated by increased infarct volumes after 
stroke in animals that received glutamate uptake inhibitor (Yan et al., 1998) and by 
increased brain edema and reduced motor function in GLAST-knockout mice following 
cerebellar injury compared with controls (Watase et al., 1998). Of special interest, 
GLAST is thought to perform the bulk of astroglial Glu transport in the cortical peri-
infarct area after stroke (Beschorner et al., 2007; Ketheeswaranathan et al., 2011). 
Previously, we reported the multipotent differentiation capacity of Reactive 
astrocyte-derived Neural Stem Cells (Rad-NSCs) isolated from the peri-infarct area after 
stroke (Shimada et al., 2011; 2012). Adult astrocytes survive poorly in culture, however 
Rad-NSCs can be maintained in culture for many passages and are useful to re-
differentiate into large numbers of reactive astrocytes (AstroRad-NSC) for screening 
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purposes. Here we use a Jagged1 forward signaling screen with AstroRad-NSC to identify 
multiple genes that are putative targets of Jagged-1/Notch1 signaling and control 
astroglial Glu. We demonstrate that Jagged1/Notch1 signaling induces GLAST levels 
early after stroke. Our results indicate that Notch1 itself or downstream effectors of 
Jagged1/Notch1 signaling may provide targets to modify Glu levels in patients with CNS 
disease or brain injury. 
Results 
Jagged-1 forward signaling screen for Notch-induced gene expression in adult 
astrocytes 
Previous studies by our group show that Notch1 signaling is required for reactive 
astrocyte proliferation after stroke (Shimada et al., 2011). In addition to controlling 
proliferation, Notch1 may also regulate gene expression for proteins that contribute to the 
protective functions of reactive astrocytes after CNS injury. To explore this hypothesis ex 
vivo, developed a stem cell-based method for generating large amounts of cultured adult 
reactive astrocytes. Reactive astrocyte-derived Neural Stem Cells (Rad-NSCs) were 
isolated from the cortical peri-infarct area 3 d after distal middle cerebral artery occlusion 
(dMCAO) (Shimada et al., 2012). Rad-NSC neurospheres (passage 2 to 4) were 
dissociated and re-differentiated in medium containing 10% fetal bovine serum (see 
Methods) to generate a population enriched for adult reactive astrocytes, called AstroRad-
NSC (Figure 2-1).  
 63 
To induce Notch signaling, we exposed AstroRad-NSC to cell culture surfaces that 
were previously coated with immobilized Jagged-1-FC/Protein-G/laminin or laminin only 
(control). After 2 d of exposure, we isolated total RNA from experimental and control 
AstroRad-NSC cultures for microarray assays of gene expression (Figure 2-1B). Two 
independently-derived AstroRad-NSC cell lines isolated from separate experimental animals 
responded to immobilized Jagged-1 by decreasing their expression of the basic helix-
loop-helix (bHLH) factors oligodendrocyte transcription factor (Olig2) and Achaete-scute 
homolog 1 (Ascl1, a.k.a Mash1) transcription factors that direct neural stem cell fate 
toward oligodendrocyte or neuron, respectively (Table 2-1). The expression and activity 
of these bHLH factors are antagonized by Notch signaling effectors. In contrast, mRNA 
for Hairy/enhancer-of-split related with YRPW motif protein 2 (HEY2) and 
Hairy/enhancer-of-split 5 (HES5) were up-regulated by immobilized Jagged-1. 
Expression of HEY2 and HES5 is induced by Notch intracellular domain (NICD), a 
cleavage product after canonical Notch signaling (Table 2-1). During postnatal 
astrogliogenesis, HES factors, along with Id factors, promote the differentiation of 
astrocytes from neural precursor cells (Imayoshi and Kageyama, 2014). 
The Glial Fibrillary Acidic Protein (GFAP) promoter is a direct target for NICD-
mediated transcriptional activation (Table 2-1) (Ge et al., 2002). In agreement with 
canonical Jagged-1/Notch signaling, we observed that GFAP mRNA was increased in 
cells of both clonal AstroRad-NSC lines after exposure to Jagged-1. Therefore, successful 
stimulation of Jagged-1/Notch signaling in AstroRad-NSC was achieved based on the 
pattern of gene expression of several well-known targets of Notch signaling. 
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Jagged-1/Notch signaling reduced gene expression for DNA-binding proteins and 
cell differentiation 
We filtered our microarray data for genes that were either increased or decreased at least 
1.2-fold in AstroRad-NSC after exposure to immobilized Jagged-1. Only genes that changed 
in expression by this amount for both AstroRad-NSC clonal lines were further explored. By 
this criteria, the expression of 278 genes decreased, whereas that of 449 genes increased 
(Table 2-3 and Table 2-4, respectively). The two gene lists were submitted to the 
Database for Annotation, Visualization and Integrated Discovery (DAVID). The DAVID 
tool assesses enrichment of annotation terms in an experimental gene list, deriving a 
statistical likelihood of such enrichment to occur in the background genome by chance. 
DAVID also identifies functional clusters by grouping functionally-related annotation 
terms (see Methods) (Huang da et al., 2009). Genes down-regulated by Jagged-1 were 
most enriched for a cluster of annotations that related to bHLH DNA-binding motifs and 
neurogenesis (Table 2-7). Of the specific annotations (Figure 2-1A), 28 of 278 genes had 
the annotation for “DNA binding” (p = 1.70E-02. Table 2-7), whereas 45 had the 
annotation “regulation of transcription” (p = 4.70E-04. Table 2-6), and 8 of 278 were 
annotated “Helix-loop-helix dimerization region bHLH” (p = 5.40E-4, Table 2-8). 
Amongst these genes were those for bHLH factors involved in neurogenesis: Ascl1 and 
Single-minded homolog 1 (Sim1), and those involved in oligodendrogenesis: Olig1 and 2 
(Table 2-8). 
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Jagged-1/Notch signal induced gene expression for receptors with known functions 
in reactive astrocytes 
DAVID functional clustering analysis of the 449 genes up-regulated by Jagged-1 
revealed significant enrichment for annotations related to proteins with extracellular 
domains, particularly for those that have N-linked glycosylation (Table 2-9, annotation 
group 1). A large fraction of the up-regulated genes (144 of 449 genes) were annotated 
“transmembrane” (p = 3.10E-04), whereas 115 genes were annotated “glycosylation site: 
N-linked” (p = 2.5E-07. Table 2-9), and 96 genes had the annotation “Signal peptide” (p 
= 1.60E-05, Figure 2-2B). In addition to the enrichment of genes encoding for cell 
surface receptors and membrane channels, genes for secreted factors were also enriched, 
but to a lesser extent (44 of 449 genes, p = 0.013, Table 2-10, annotation group 1). In 
addition, Jagged-1/Notch signaling up-regulated the expression of genes that enriched the 
following functional clusters (Table 2-10): “Cellular and chemical homeostasis“ 
(annotation group 2, Figure 2-2C), “Vascular development and angiogenesis” (annotation 
group 3), and “Inflammatory response to injury” (Figure 2-2C, annotation group 8).  
Reactive astrocytes and meningeal fibroblasts commonly form a “scar” during the 
resolution of CNS injury, e.g. after stroke or traumatic brain injury (Pekny and Nilsson, 
2005). We found two functional groups associated with glial scar formation: “Cell and 
biological adhesion” (Table 2-10, annotation group 5) and  “Plexin/Semaphorin”-specific 
group (Table 2-10, annotation group 6). Amongst gene members of the cell adhesion 
group, the screen identified Neurocan and chondroitin sulfate proteoglycan 5 
(Neuroglycan C). These proteins are both chondroitin sulfate proteoglycans and are 
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extracellular components of the CNS scar (Sofroniew, 2009). Plexins and Semaphorins 
constitute a transmembrane receptor/ligand system and Plexin signaling in neurons 
causes axonal growth cone collapse and repulsion of the neurite. Semaphorin expression 
has been localized to meningeal fibroblasts and Plexins to neurons (Sandvig et al., 2004). 
Loss of Notch1 in AstroRad-NSC decreases GLAST mRNA and protein  
We chose to focus on and verify expression of several genes up-regulated by Jagged-
1/Notch with functional significance to glutamate uptake and metabolism in astrocytes 
(Hertz and Zielke, 2004). Although DAVID contained no specific functional clustering 
related to glutamate metabolism and/or transport, our screen identified genes for 4 
proteins known to function in astroglial handling of glutamate: Glutamate Dehydrogenase 
1, Glutamate Ammonia Ligase (a.k.a. Glutamine Synthetase, Glul), glutamate receptor 
metabotropic 5, and Solute Carrier Family 1 Member 3 (Slc1a3) (a.k.a. GLAST, Table 2-
2). 
By mapping the Glast promoter sequence, we identified a CBP-1/Suppressor of 
Hairless/Lag-1 (CSL) DNA-binding sequence approximately 2.67 kb upstream of the 
transcription start site (Figure 2-3A’); this sequence indicated direct regulation of Glast 
transcription by Notch. To determine if Notch signaling regulated GLAST expression, we 
treated AstroRad-NSC with Dibenzazepine (DBZ), a γ-secretase inhibitor (GSI). GSIs 
inhibit proteolytic cleavage of Notch and its subsequent signaling by inhibiting the active 
site of Presenilin, the proteolytic component of γ-secretase. We then assessed gene 
expression by quantitative reverse transcriptase PCR (qRT-PCR). Glast and Notch1 
expression was significantly reduced in DBZ-treated cells compared with vehicle 
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(DMSO)-treated control cells (Glast: -1.54-fold ± 0.07, p ≤ 0.01. Notch1: -1.35-fold ± 
0.09, p ≤ 0.01. Mean ± SEM, DMSO vs DBZ, n=3; Figure 2-3B).  
GSIs can inhibit signaling through all four Notch receptors and any other 
transmembrane receptor that requires γ-secretase cleavage for activity. To determine 
whether Notch1 alone regulated GLAST mRNA and protein levels, we isolated Rad-
NSCs from hGFAP-CreERTM;Notch1loxp/loxp animals (n=2 clonal cell lines, each from 
different mice) and re-differentiated them into AstroRad-NSC (GNastroRad-NSC). To delete 
Notch1, GNastroRad-NSC cells were incubated in 4-hydroxy-tamoxifen (OHTM), the 
water-soluble form of tamoxifen (Figure 2-3C). Targeted deletion of Notch1 in 
GNastroRad-NSC decreased Notch1, Gfap and Glast gene expression (Glast: -1.34-fold ± 
0.06, p ≤ 0.01; Notch1: -1.52-fold ± 0.02, p ≤ 0.01; Gfap: -1.7-fold ± 0.16, p ≤ 0.01. 
Mean ± SEM, DMSO vs DBZ, n=3; Figure 2-3B’) and also reduced the amount of 
GLAST protein expressed by both clonal lines of GNastroRad-NSC (Figure 2-3D, 3F).  
Glutamate Transporter 1 (GLT-1) is expressed by adult cortical astrocytes 
(Rothstein et al., 1994) and together with GLAST controls astroglial glutamate uptake. In 
cell lysates from GNastroRad-NSC, we observed that GLT-1 was expressed and was not 
reduced by the loss of Notch1 (Figure 2-3E). Instead, GLT-1 levels appeared to increase 
slightly after Notch1 knockdown, consistent with reports that tamoxifen induces GLT-1 
gene expression (Karki et al., 2013). These data demonstrated that Notch1 controls Glast 
expression in adult reactive astrocytes (AstroRad-NSC). 
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Inhibition of Notch signaling decreases extracellular glutamate uptake by adult 
astrocytes 
Several groups have studied glutamate uptake in cultured astrocytes isolated from 
postnatal rat or mouse cortex (Dallas et al., 2007; Boycott et al., 2008; Lehmann et al., 
2009; Raymond et al., 2011). However, postnatal astrocytes may differ from adult 
astrocytes in glutamate uptake or metabolism. To examine the effects of Notch signaling 
on GLAST-mediated glutamate uptake in adult astrocytes, we added a fix amount of 
glutamate to AstroRad-NSC cultures and then measured the residual glutamate in the 
medium after 15 minutes. To determine if AstroRad-NSC could take up glutamate through 
both GLT-1 and Notch signaling-control GLAST, we blocked GLT-1 activity in with 
dihydrokainic acid (DHK), a specific GLT-1 antagonist (Garlin et al., 1995) and treated 
cells with a GSI. AstroRad-NSC that had been incubated for 2 days with a GSI (DAPT) 
prior to addition of DHK significantly increased the level of residual glutamate relative to 
levels in the medium of vehicle controls (Normalized residual glutamate, DHK+DAPT 
vs. vehicle: 1.629 ± 0.163 vs. 1 ± 0.008, Mean ± SEM, n=3, p ≤ 0.01; Figure 2-4A).  
We noted the decrease in GLAST protein and mRNA after Notch1 knockout in 
two separate clonal lines of GNastroRad-NSC were highly consistent (Figure 2-3F vs. 3D). 
However, AstroRad-NSC are differentiated from clonally-isolated neurospheres and could 
therefore be subject to clonal variation of glutamate uptake capacity. To address this 
possibility, we assayed AstroRad-NSC from three clonal lines of Rad-NSCs, each derived 
from a separate animal. We found that incubation in DAPT for 2 d was sufficient to 
increase residual extracellular glutamate for all three clones (Normalized residual 
 69 
glutamate, combined DAPT vs. combined Vehicle: 1.442 ± 0.045 VS 1 ± 0.053, mean ± 
SEM, n=3 clones, p = 0.0014; Figure 2-4B). In addition to glutamate, GLAST takes up 
extracellular aspartate. Of interest, our results agreed with attenuated aspartate uptake by 
C6 glioma cells after treatment with DAPT reported by Angulo-Rojo et al. (2013). 
Conditional Notch1 knockout decreases reactive astroglial GLAST levels after focal 
ischemic injury in vivo 
To determine if Notch1 regulated GLAST levels in reactive astrocytes in vivo, we 
evaluated cortical tissue from injured and normal hGFAP-CreERTM;Notch1loxp/loxp mice 
after injections of tamoxifen to delete Notch1 from reactive astrocytes. We used 
magnetic-activated cell sorting (MACS) with antibodies to GLT-1 to directly isolate and 
evaluate adult astrocytes or reactive astrocytes from disassociated cortex. We first 
isolated astrocytes from the left and right cortices of normal (healthy) hGFAP-
CreERTM;Notch1loxp/loxp mice that received tamoxifen or vehicle control (corn oil) 30 d 
prior. We found that GLAST was weakly-expressed by normal cortical astrocytes (Figure 
2-5A), in agreement with GLAST levels previously reported by others (Rothstein et al., 
1994; Regan et al., 2007). In contrast, GFAP levels were significantly decreased by 
deletion of Notch1 in astrocytes that had been acutely isolated by GLT-1 MACS from 
normal cortex (Figure 2-5A). We hypothesized that CNS injury, such as cerebral 
ischemia, GLAST levels increase in astrocytes that respond to injury through a Notch1-
dependent mechanism. To test this concept, we used hGFAP-CreERTM; Notch1loxp/loxp 
mice and followed the same tamoxifen treatment regime as with normal (uninjured) mice. 
At 30 d post-treatment, 3 mice per treatment group were subjected to dMCAO. After 3 d 
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of recovery, we isolated the ipsilateral cortex from each mouse and disassociated it. To 
obtain enough GLT-1-positive cells for immunoblotting, we pooled the cell suspensions 
by treatment group prior to GLT-1 MACS. By immunoblot, pooled GLT-1-positive 
MACS fractions were highly-enriched for both GLAST and GFAP (Figure 2-5B). GLT-
1-positive MACS cell fractions from pooled ipsilateral cortical tissues of vehicle control 
animals had more GLAST and GFAP protein compared with isolates from tamoxifen-
treated animals (Figure 2-5). These data indicated that Notch1 signaling controls the level 
of GLAST in reactive astrocytes in vivo after stroke.   
Discussion 
Here we report and validate a new model based on AstroRad-NSC for the study of signaling 
in adult reactive astrocytes. In a Jagged1 forward signaling screen that used AstroRad-NSC 
as a source of adult astrocytes, we generated a set of putative Jagged1/Notch-induced 
gene targets. Among the gene targets we found multiple genes implicating Notch1 as 
“master” regulator of glutamate uptake. We report that Notch1 controls the level of 
GLAST both in cultured AstroRad-NSC and for reactive astrocytes in vivo, early after 
stroke.  
To date, the effects of Jagged1/Notch1-mediated signaling on reactive astrocyte 
function(s) are poorly understood. Notch1 signaling is required for reactive astrocyte 
proliferation after focal cortical ischemia (Shimada et al., 2011), and has been implicated 
in the astrocyte-mediated inhibition of neurogenesis in the hippocampus (Wilhelmsson et 
al., 2012) and oligodendrogenesis after white matter lesions (Hammond et al., 2014). By 
increasing gene expression for a wide variety of astrocyte-associated receptors and 
 71 
transporters, and decreasing expression of transcription factors involved non-astroglial 
cell specification, Jagged1/Notch signaling in AstroRad-NSC appeared to promote astrocyte 
identity, in part by increasing expression of Hey2, HES5 and GFAP. From many gene 
candidates identified by our screen, we elected to focus on Notch1-mediated control of 
GLAST in reactive astrocytes. GLAST is expressed highly by neural progenitor cells and 
radial glial cells during CNS development and by adult neural stem/progenitor cells in the 
subventricular zone (Regan et al., 2007). In the cerebrum of adult mice, GLAST 
expression is limited and thus unlikely to contribute measurably to uptake of glutamate in 
normal cerebral cortex (i.e. uninjured and without pathology).  
GLAST and GLT-1 have been extensively studied in the context of hypoxia and 
ischemia ex vivo and in vivo (Rao et al., 2001; Dallas et al., 2007; Ketheeswaranathan et 
al., 2011; Raymond et al., 2011). We found that GLAST was expressed weakly by GLT-
1-positive astrocytes in normal, healthy adult cortex, but its level increased markedly in 
GLT-1-positive astrocytes from ipsilateral cortex 3 days following focal ischemia. 
Furthermore, we showed that GLAST, along with the NICD1/CSL target GFAP, was 
decreased in GLT-1-positive cells sorted from injured cortex in which Notch1 has been 
conditionally deleted. Thus, Notch1 signaling may be critical for the rapid increase in 
GLAST that occurs after CNS injury, whereas GLAST levels in astrocytes from normal 
cortex may be less dependent on Notch1.  
Current knowledge of signaling mechanisms that control the level and/or activity 
of astroglial glutamate transporters in vivo is limited. In culture, the hormone estrogen 
was shown to increase astroglial mRNA and protein for GLT-1 and GLAST (Pawlak et 
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al., 2005). Similarly, Raloxifene (Rx), an estrogen receptor modulator, was reported to 
increase astroglial levels of both GLT-1 and GLAST (Karki et al., 2014). Other 
factors/receptor ligands shown to induce GLAST gene expression include EGF, TGF-α, 
and PACAP (Unger et al., 2012). The extracellular matrix component Tenascin-R, was 
also recently shown to increase GLAST expression (Okuda et al., 2014).  
GLT-1 levels have been consistently shown to decrease in several models of cerebral 
hypoxia/ischemia: transient focal ischemia (Rao et al., 2001; Ketheeswaranathan et al., 
2011), transient forebrain ischemia (Fujita et al., 1999; Gottlieb et al., 2000) and perinatal 
hypoxia (Raymond et al., 2011). Deficits in the expression of GLAST have been less-
convincingly shown, as some studies report an increase after injury (Rao et al., 2001; Tao 
et al., 2001). Raymond et al (2011) showed a decrease in GLAST and GLT-1 expression 
commensurate with decreased GFAP expression in white matter astrocytes of mice 
subjected to perinatal hypoxia. Unlike GLT-1 expression, GLAST expression was 
sensitive to perturbations in JAK/STAT3 signaling in this model. JAK/STAT3 is known 
to be critical for reactive astrocyte formation and function (Okada et al., 2006; Herrmann 
et al., 2008; Nobuta et al., 2012; Wanner et al., 2013).  
As a new model, re-differentiating cultured Rad-NSC into AstroRad-NSC provides 
an efficient way to obtain large numbers of adult astrocytes for screening or other 
purposes. But, how closely do the derived cells resemble bona fide cortical astrocytes or 
reactive astrocytes in vivo? Lovett et al. (2008) evaluated the transcriptome of acutely 
isolated protoplasmic astrocytes from adult mouse cortex using Fluorescent-Activated 
Cell Sorting (FACS) for GLT-1 and GFAP-GFP. Notably, our list for genes up-regulated 
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by Jagged1 exposure contained 8 of the 20 targets that Lovett et al. (2008) identified as 
“enriched” (Supplemental table 9, see also Lovatt et al., 2007). Also relevant to our work, 
gene expression profiling by Cahoy et al. (2008) demonstrated that gene-members of the 
Notch signaling pathway were enriched in acutely-isolated astrocytes relative to those for 
signaling by JAK/STAT, WNT/β-catenin, or TGF-β (Cahoy et al., 2008). Zamanian and 
colleagues of the Barres group (2012) provided gene expression data for reactive 
astrocytes 1 day after MCA occlusion. We found five genes up-regulated by Jagged1 in 
AstroRad-NSC that were also included on Zamanian et al.’s list for “top 50 most-changed 
genes” in reactive astrocytes (Supplement Table 10) (Zamanian et al., 2012). 
Interestingly, a group of genes involved in p53 signaling and apoptosis that were 
increased in reactive astrocytes in their study were decreased in Astrorad-NSC at 48 hours 
after Jagged1 exposure (Supplemental Table 11). 
Our work identified Jagged1/Notch1 signaling as a regulator of GLAST and 
glutamate uptake in adult reactive astrocytes. Accordingly, modulation of the Notch 
signaling pathway or it downstream effectors by pharmacologics or biologics during 
and/or after ischemic stroke may provide a means to enhance glutamate uptake, promote 
neuroprotection and improve patient outcomes.    
Experimental procedures 
Mice 
All animal work was approved by the University of Vermont College of Medicine’s 
Office of Animal Care in accordance with the American Association for Accreditation of 
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Laboratory Animal Care and National Institutes of Health guidelines. Adult male 
C57BL/6J mice (6–8 wks of age) were obtained from Taconic Farms. We obtained 
GFAP-CreERTM mice from Dr. Suzanne Baker (St. Jude Children’s Research Hospital, 
Memphis, TN) (Chow et al., 2008). Notch1tm2Rko/GridJ mice (Notch1-flox mice, 
Cat#006951) from JAX.  Genotyping was performed with the REDExtract-N-Amp 
Tissue PCR Kit (XNAT-1KT; Sigma). We used the following primers: Notch1, forward-
5’-TGCCCTTTCCTTAAAAGTGG-3’, reverse-5’-GCCTACTCCGACACCCAA TA-3’; 
GFAP-CreERTM, forward-5’-AGCGATCGCTGCCAGGAT-3’, reverse-5’-
ACCAGCGTTTTCG TTCTGCC-3’.  
dMCAO surgery  
Mice were anesthetized with isoflurane (1–5%; Webster Veterinary) and body 
temperature was maintained with a heated pad. Focal cerebral ischemia was produced by 
permanently occluding the middle cerebral artery (MCA) (Shimada et al., 2010; Bakondi 
et al., 2011; Shimada et al., 2012). Under low-power magnification, the left temporo-
parietal region of the head was shaved, and an incision was made between the left orbit 
and the left ear in the shape of a “U.” An incision was made superiorly on the upper 
margin of the temporal muscle forward. The MCA was observed through the semi-
translucent skull. A small burr hole (1–2 mm) was drilled into the outer surface of the 
skull just over the MCA. The inner layer of skull was removed with fine forceps. The 
MCA was then encircled with 10–0 monofilament nylon suture (7V33; S & T), ligated, 
and transected superior to the ligation point. The small flap of temporo-parietal skin 
covering the skull was closed with Vetbond (3M Animal Care). For conditional knockout 
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mouse studies, animals received 0.1 mg/g of tamoxifen (TM; T5648; Sigma) dissolved in 
9:1 corn oil:absolute ethanol (vehicle) or vehicle alone by intraperitoneal injection for 3 
consecutive days from d 0 to 3, followed by a 7 d or 20 d washout period, then subjected 
to dMCAO. Mice were euthanized at various time points after dMCAO. Brain tissue was 
then either processed for immunohistochemistry or cell isolation (see below).   
Isolation and culture of Rad-NSCs 
For isolation of Rad-NSCs, brains were removed 3 d after dMCAO, placed into a 
polyacrylic brain block (Acrylic Matrices, RBMA-200C; World Precision Instruments), 
and cut coronally into 1 mm sections. The sections were transferred into alpha-MEM 
(Invitrogen) in 6-well plates. The cortical peri-infarct area was dissected under a light 
microscope. Tissues from the anterior lateral ventricle, posterior lateral ventricle, 
hippocampal arch, dentate gyrus, white matter, and third ventricle were carefully 
excluded. The tissues containing the peri-infarct area were harvested, diced into ~1 mm3 
pieces, and digested in enzyme digestion solution containing 200 U papain 
(Worthington), 20 ug/ml DNase (Worthington), 1.5 mM EDTA (Fisher Scientific), 1.5 
mM CaCl2 (Sigma), 2 mg L-cysteine (Sigma), and DMEM/F12 media (Lonza), at 37°C 
for 20 min. Following enzymatic digestion, the tissues were triturated two times in 
trituration solution: 5 ml DMEM/F12 medium containing 15 mg trypsin inhibitor 
(Invitrogen) and 15 mg bovine serum albumin (BSA; Fisher Scientific). Cells were 
resuspended in DMEM/F12 medium containing 0.9 M sucrose and centrifuged to remove 
myelin (300 × g for 10 min). Cells were grown at a low density (10,000 cells/ml) in NSC 
growth medium containing 10 ng/ml Epidermal Growth Factor (EGF; BD Biosciences), 
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20 ng/ml basic Fibroblast Growth Factor (bFGF; recombinant human bFGF produced in 
our laboratory), 1× B27 supplement (Invitrogen), 2 mM L-glutamine (Mediatech), and 
100 U/ml penicillin/100 ug/ml streptomycin, in NeurobasalA (Invitrogen) in 12-well 
plates (Nunc Thermo Fisher Scientific).  To generate clonal spheres, individual small 
spheres (10–100 cells) were pipetted under microscopy into separate 24-well plates 1 wk 
after plating. Clonally-isolated neurospheres were expanded and passaged in NSC growth 
medium for further studies.  
Ex Vivo differentiation of astrocytes from Rad-NSCs 
 Rad-NSCs were expanded in NSC medium as neurospheres and dissociated with trypsin-
EDTA. Dissociated cells were plated in 10% CCM at a density of 5.5 × 105 cells/cm2 into 
100 mm2 dishes (NUNC) previously coated with laminin/poly-D-lysine (5ug/ml each, 
BD Biosciences). Under the above conditions, the plated cells differentiated for 7 d with 
medium changes every 2 d.  
Immobilized Jagged-1 treatment of AstroRad-NSC 
To prepare culture surfaces with immobilized Jagged-1 we coated 100×20mm cell culture 
plates (Nunc) with 50 µg/mL protein G (Sigma) + 5 µg/mL mouse laminin (BD sciences) 
in PBS for 4 hours at normal culture conditions. We then rinsed plates with PBS ×2 with 
minimal agitation before adding 5 µg/mL Recombinant Rat Jagged 1 Fc Chimera 
(Cat#599-JG-100, R&D Systems) in PBS and incubated in normal culture conditions for 
approximately 18 hours. The control surface was prepared by coating plates with 5 
µg/mL mouse laminin for 18 hours under the same conditions. Both conditions were 
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rinsed with PBS ×2 before AstroRad-NSC were plated in 10% CCM at a density of 3 × 105 
cells per plate. Cells were allowed to incubate for 2 days before RNA extraction.  
RNA purification, amplification, labeling, and hybridization 
PureLink RNA Mini Kit (Cat#12183018A, Life Technologies) and protocol were used to 
lyse and extract total RNA from cultured AstroRad-NSCs. The integrity and concentration of 
the isolated total RNA was confirmed by an Agilent 2100 bioanalyzer (Agilent 
Technologies). Twenty ng of total RNA from each sample was amplified and biotin 
labeled using the Two-cycle Target Labeling kit (Affymetrix) then hybridized to a 
GeneChip Mouse Gene 1.0 ST Array (Affymetrix). Samples were hybridized using a 
GeneChip Hybridization Oven 640 (Affymetrix), processed using a GeneChip 
FluidicsStation 450 (Affymetrix), and scanned using a 7G Genechip Scanner 
(Affymetrix). All sample-handling aside from the RNA extraction and all Genechip 
processing was preformed by the Microarray Core Facility at the University of Vermont.  
Calculation of probe set statistics and normalization of array signals 
The raw image data from each chip was summarized by Affymetrix GCOS software 
using one probe intensity (in CEL files, one per chip). Probe-level intensities were 
calculated using the Robust Multichip Average (RMA) algorithm, including background-
correction, normalization (quantile), and summarization (median polish), for each probe 
set and sample, as is implemented in Partek Genomic Suites®, version 6.6 (Copyright © 
2009, Partek Inc., St. Louis, MO, USA). Sample quality is assessed based on the 3’:5’ 
ratio (3’ arrays only), relative log expression (RLE), and normalized un-scaled standard 
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error (NUSE). Principal Component Analysis (PCA) is also used to look for outlier 
samples that would potentially introduce latent variation into the analysis of differential 
expression across sample groups.  
Compilation of gene lists and Functional Cluster Analysis 
RLE for each gene from the control set was subtracted from the experimental set then 
converted to fold-change for each clone. These list were filtered to include genes that 
were ≥ 1.2 (up-regulated in experimental group) or ≤ -1.2 (down-regulated in 
experimental group). Gene lists were analyzed for statistically enriched pathways and 
functional groups using the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) http://david.abcc.ncifcrf.gov/tools.jsp (Huang da et al., 2009). Using 
the official gene symbols, each list was submitted to the tool. Mus musculus was select as 
the background genome. Functional clustering was preformed with the default variable 
for classification stringency (medium), Kappa similarity (similarity term overlap: 3, 
similarity threshold: 0.50), classification (initial group membership: 3, final group 
membership: 3, multiple linkage threshold: 0.50). Functional groups with an EASE score 
of > 1.3 were included in the analysis.  
Experiments with AstroRad-NSC 
For conditional knockout of Notch1 in reactive astrocytes that were re-differentiated from 
Rad-NSCs of GFAP-CreERTM-Notch1-cKO mice, 10% CCM was removed and replaced 
with 10% CCM containing 1 uM 4-OH-TM (Sigma) or ethanol (vehicle control). This 
treatment was refreshed every 2 d for 5-8 days. For experiments with Gamma-secretase 
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inhibitors (GSI), cells were treated with 10 µM N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-
S-phenylglycine t-butyl ester (DAPT, D5942; Sigma), od dimethylsulfoxide (DMSO; 
vehicle) for 2 d.  
Glutamate uptake experiments 
AstroRad-NSCs were differentiated in situ on 24-well plates (Nunc) at a density of 1×105 
cells/well using the methods previously described. For GLT-1 transporter-blocking 
experiments we added 200 µM Dihydrokainic acid (Sigma) diluted in growth medium 20 
minutes prior to the glutamate uptake assay (Dallas et al., 2007). AstroRad-NSCs treated 
with the GSI DAPT or DMSO control for 2 d prior to addition of DHK or glutamate 
uptake assay. To assess the glutamate uptake capacity of AstroRad-NSCs, growth medium 
was removed from the wells and these were rinsed ×2 with PBS. Phenol-free DMEM 
containing 20 µM of glutamic acid was added to the wells. Experimental or control 
groups were represented in triplicate wells. The cells were then cultured under normal 
conditions for 10 to 15 minutes, depending on the experiment performed. The medium 
contain residual glutamate was removed at that time and glutamate concentration was 
assessed with the Amplex Red Glutamic Acid/Glutamate Oxidase Assay Kit (Cat#A-
12221, Life technologies) per protocol. The fluorescence of the product of the reaction 
(dependent on the starting concentration of residue glutamate) was read at an excitation 
of 530 nm and emission of 590 nm with an appropriately configured Synergy HT 
Multimode Microplate reader (BioTek Instruments, Inc.; Winooski, VT).  
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Immunobloting 
Total protein was extracted from cells with a RIPA cell lysis buffer containing: 1.0% 
Triton-X 100, 0.1% SDS, 0.5% Deoxycholate, 50 mM Tris HCL, 150 mM NaCl, 5 mM 
EDTA, 1× Protease inhibitor Cocktail (Roche), and 1× phosphatase inhibitor Cocktail 
(Sigma) when required. Protein concentrations were determined with a Bio-Rad DC 
Protein Assay (Bio Rad). Protein preparations were separated by SDS-PAGE and 
transferred to immobilon-P membrane (PVDF; Millipore). The membrane was blocked 
with 5% w/v dry milk/0.1% Tween-20/1× PBS and then incubated with primary antibody 
diluted in blocking buffer overnight at 4°C or at room temperature for anti-GAPDH. 
Primary incubation with anti-GLAST was done in a blocking buffer of 5% w/v 
BSA/0.1% Tween-20/1× PBS. After washes, the membrane was incubated with a 
horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The 
blot was visualized with Western Lightning Plus-ECL (NEL103001EA; Pierce), and 
exposed to Kodak x-ray film. Equivalence of protein loading was verified by probing for 
GAPDH. We used the following primary antibodies: GFAP (1:2000, Z0334; DAKO), 
GFAP (1:1000, G3893; Sigma), GLAST (1:500,130-095-826, Miltenyi Biotech), cleaved 
NICD1 (1:1000; AB8925; Abcam), GAPDH (1:2500, MAB374; Millipore), and GAPDH 
(1:2500, G9545; Sigma). Films were scanned at 600 dpi for densitometry (ImageJ 
software).   
Real-time Quantitative Reverse-transcriptase Polymerase Chain Reaction 
 RNA was extracted from cells using a HighPure RNA Isolation kit (Roche, Cat: 
11828665001). After first-strand cDNA synthesis with the SuperScript® III RT-PCR 
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System (Life Technologies), relative quantification real-time PCR was performed as 
described by Tharp et al., (2012) with minor modifications. Several TaqMan (Life 
Technologies) gene expression kits and assays for mouse were employed: Notch1-FAM, 
Mm00435249_m1; GFAP-FAM, Mm01253033_m1; Glast-FAM, Mm00600697_m1; 
GAPDH-VIC, Mm99999915_g1). The cDNA input template was diluted 1:12 and 
GAPDH-VIC probe was added to each well as an internal control. All samples were run 
in triplicate. Real-time qRT-PCR was performed on an Applied Biosystems 7300 Real-
Time PCR System with standard settings (Applied Biosystems Inc, Foster City, CA). 
Gene expression was normalized to internal GAPDH controls and fold change was 
calculated using the 2(-Delta Delta C[T]) method (Livak and Schmittgen, 2001).  
Statistical analysis  
Statistical analyses were performed with GraphPad Prism software (version 6.0e). 
Individual groups were compared by Student’s t-test (unpaired). Multiple comparisons 
were made by analysis of variance (ANOVA) with Bonferroni post-hoc testing. P values 
of less than 0.05 were considered significant.  
 
Author contributions 
M.D.L., H.D., and J.S. designed the experiments. M.D.L., H.D., and J.S. performed 
assays and data analysis. M.D.L. and J.S. wrote the paper. 
 82 
Acknowledgments 
Chapter 2 References 
Angulo-Rojo C, Manning-Cela R, Aguirre A, Ortega A, Lopez-Bayghen E (2013) 
Involvement of the Notch pathway in terminal astrocytic differentiation: role of 
PKA. ASN neuro 5:e00130. 
Bak LK, Schousboe A, Waagepetersen HS (2006) The glutamate/GABA-glutamine 
cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J 
Neurochem 98:641-653. 
Beschorner R, Simon P, Schauer N, Mittelbronn M, Schluesener HJ, Trautmann K, Dietz 
K, Meyermann R (2007) Reactive astrocytes and activated microglial cells 
express EAAT1, but not EAAT2, reflecting a neuroprotective potential following 
ischaemia. Histopathology 50:897-910. 
Boycott HE, Wilkinson JA, Boyle JP, Pearson HA, Peers C (2008) Differential 
involvement of TNF alpha in hypoxic suppression of astrocyte glutamate 
transporters. Glia 56:998-1004. 
Burda JE, Sofroniew MV (2014) Reactive gliosis and the multicellular response to CNS 
damage and disease. Neuron 81:229-248. 
Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, Xing Y, 
Lubischer JL, Krieg PA, Krupenko SA, Thompson WJ, Barres BA (2008) A 
transcriptome database for astrocytes, neurons, and oligodendrocytes: a new 
resource for understanding brain development and function. J Neurosci 28:264-
278. 
 83 
Dallas M, Boycott HE, Atkinson L, Miller A, Boyle JP, Pearson HA, Peers C (2007) 
Hypoxia suppresses glutamate transport in astrocytes. J Neurosci 27:3946-3955. 
Fujita H, Sato K, Wen TC, Peng Y, Sakanaka M (1999) Differential expressions of 
glycine transporter 1 and three glutamate transporter mRNA in the hippocampus 
of gerbils with transient forebrain ischemia. Journal of cerebral blood flow and 
metabolism : official journal of the International Society of Cerebral Blood Flow 
and Metabolism 19:604-615. 
Gaiano N, Nye JS, Fishell G (2000) Radial glial identity is promoted by Notch1 signaling 
in the murine forebrain. Neuron 26:395-404. 
Garlin AB, Sinor AD, Sinor JD, Jee SH, Grinspan JB, Robinson MB (1995) 
Pharmacology of sodium-dependent high-affinity L-[3H]glutamate transport in 
glial cultures. J Neurochem 64:2572-2580. 
Ge W, Martinowich K, Wu X, He F, Miyamoto A, Fan G, Weinmaster G, Sun YE (2002) 
Notch signaling promotes astrogliogenesis via direct CSL-mediated glial gene 
activation. Journal of neuroscience research 69:848-860. 
Gottlieb M, Domercq M, Matute C (2000) Altered expression of the glutamate 
transporter EAAC1 in neurons and immature oligodendrocytes after transient 
forebrain ischemia. Journal of cerebral blood flow and metabolism : official 
journal of the International Society of Cerebral Blood Flow and Metabolism 
20:678-687. 
 84 
Hammond TR, Gadea A, Dupree J, Kerninon C, Nait-Oumesmar B, Aguirre A, Gallo V 
(2014) Astrocyte-Derived Endothelin-1 Inhibits Remyelination through Notch 
Activation. Neuron 81:588-602. 
Hazell AS, Pannunzio P, Rama Rao KV, Pow DV, Rambaldi A (2003) Thiamine 
deficiency results in downregulation of the GLAST glutamate transporter in 
cultured astrocytes. Glia 43:175-184. 
Hazell AS, Sheedy D, Oanea R, Aghourian M, Sun S, Jung JY, Wang D, Wang C (2010) 
Loss of astrocytic glutamate transporters in Wernicke encephalopathy. Glia 
58:148-156. 
Herrmann JE, Imura T, Song B, Qi J, Ao Y, Nguyen TK, Korsak RA, Takeda K, Akira S, 
Sofroniew MV (2008) STAT3 is a critical regulator of astrogliosis and scar 
formation after spinal cord injury. J Neurosci 28:7231-7243. 
Hertz L, Zielke HR (2004) Astrocytic control of glutamatergic activity: astrocytes as stars 
of the show. Trends in neurosciences 27:735-743. 
Hitoshi S, Alexson T, Tropepe V, Donoviel D, Elia AJ, Nye JS, Conlon RA, Mak TW, 
Bernstein A, van der Kooy D (2002) Notch pathway molecules are essential for 
the maintenance, but not the generation, of mammalian neural stem cells. Genes 
& development 16:846-858. 
Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of 
large gene lists using DAVID bioinformatics resources. Nature protocols 4:44-57. 
Imayoshi I, Kageyama R (2014) bHLH factors in self-renewal, multipotency, and fate 
choice of neural progenitor cells. Neuron 82:9-23. 
 85 
Karki P, Webb A, Zerguine A, Choi J, Son DS, Lee E (2014) Mechanism of raloxifene-
induced upregulation of glutamate transporters in rat primary astrocytes. Glia 
62:1270-1283. 
Karki P, Webb A, Smith K, Lee K, Son DS, Aschner M, Lee E (2013) CREB and NF-
kappaB Mediate the Tamoxifen-induced Upregulation of GLT-1 in Rat 
Astrocytes. J Biol Chem. 
Ketheeswaranathan P, Turner NA, Spary EJ, Batten TF, McColl BW, Saha S (2011) 
Changes in glutamate transporter expression in mouse forebrain areas following 
focal ischemia. Brain Res 1418:93-103. 
Lehmann C, Bette S, Engele J (2009) High extracellular glutamate modulates expression 
of glutamate transporters and glutamine synthetase in cultured astrocytes. Brain 
Res 1297:1-8. 
Lovatt D, Sonnewald U, Waagepetersen HS, Schousboe A, He W, Lin JH, Han X, 
Takano T, Wang S, Sim FJ, Goldman SA, Nedergaard M (2007) The 
transcriptome and metabolic gene signature of protoplasmic astrocytes in the adult 
murine cortex. J Neurosci 27:12255-12266. 
Morrison SJ, Perez SE, Qiao Z, Verdi JM, Hicks C, Weinmaster G, Anderson DJ (2000) 
Transient Notch activation initiates an irreversible switch from neurogenesis to 
gliogenesis by neural crest stem cells. Cell 101:499-510. 
Nobuta H, Ghiani CA, Paez PM, Spreuer V, Dong H, Korsak RA, Manukyan A, Li J, 
Vinters HV, Huang EJ, Rowitch DH, Sofroniew MV, Campagnoni AT, de Vellis 
 86 
J, Waschek JA (2012) STAT3-mediated astrogliosis protects myelin development 
in neonatal brain injury. Annals of neurology 72:750-765. 
Okada S, Nakamura M, Katoh H, Miyao T, Shimazaki T, Ishii K, Yamane J, Yoshimura 
A, Iwamoto Y, Toyama Y, Okano H (2006) Conditional ablation of Stat3 or 
Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nature 
medicine 12:829-834. 
Okuda H, Tatsumi K, Morita S, Shibukawa Y, Korekane H, Horii-Hayashi N, Wada Y, 
Taniguchi N, Wanaka A (2014) Chondroitin sulfate proteoglycan tenascin-R 
regulates glutamate uptake by adult brain astrocytes. J Biol Chem 289:2620-2631. 
Pawlak J, Karolczak M, Krust A, Chambon P, Beyer C (2005) Estrogen receptor-alpha is 
associated with the plasma membrane of astrocytes and coupled to the MAP/Src-
kinase pathway. Glia 50:270-275. 
Pekny M, Nilsson M (2005) Astrocyte activation and reactive gliosis. Glia 50:427-434. 
Rao VL, Bowen KK, Dempsey RJ (2001) Transient focal cerebral ischemia down-
regulates glutamate transporters GLT-1 and EAAC1 expression in rat brain. 
Neurochemical research 26:497-502. 
Raymond M, Li P, Mangin JM, Huntsman M, Gallo V (2011) Chronic perinatal hypoxia 
reduces glutamate-aspartate transporter function in astrocytes through the Janus 
kinase/signal transducer and activator of transcription pathway. J Neurosci 
31:17864-17871. 
Regan MR, Huang YH, Kim YS, Dykes-Hoberg MI, Jin L, Watkins AM, Bergles DE, 
Rothstein JD (2007) Variations in promoter activity reveal a differential 
 87 
expression and physiology of glutamate transporters by glia in the developing and 
mature CNS. J Neurosci 27:6607-6619. 
Rothstein JD, Martin L, Levey AI, Dykes-Hoberg M, Jin L, Wu D, Nash N, Kuncl RW 
(1994) Localization of neuronal and glial glutamate transporters. Neuron 13:713-
725. 
Sandvig A, Berry M, Barrett LB, Butt A, Logan A (2004) Myelin-, reactive glia-, and 
scar-derived CNS axon growth inhibitors: expression, receptor signaling, and 
correlation with axon regeneration. Glia 46:225-251. 
Shimada IS, Borders A, Aronshtam A, Spees JL (2011) Proliferating reactive astrocytes 
are regulated by Notch-1 in the peri-infarct area after stroke. Stroke; a journal of 
cerebral circulation 42:3231-3237. 
Shimada IS, LeComte MD, Granger JC, Quinlan NJ, Spees JL (2012) Self-renewal and 
differentiation of reactive astrocyte-derived neural stem/progenitor cells isolated 
from the cortical peri-infarct area after stroke. J Neurosci 32:7926-7940. 
Sofroniew MV (2009) Molecular dissection of reactive astrogliosis and glial scar 
formation. Trends in neurosciences 32:638-647. 
Tao F, Lu SD, Zhang LM, Huang YL, Sun FY (2001) Role of excitatory amino acid 
transporter 1 in neonatal rat neuronal damage induced by hypoxia-ischemia. 
Neuroscience 102:503-513. 
Wanner IB, Anderson MA, Song B, Levine J, Fernandez A, Gray-Thompson Z, Ao Y, 
Sofroniew MV (2013) Glial Scar Borders Are Formed by Newly Proliferated, 
Elongated Astrocytes That Interact to Corral Inflammatory and Fibrotic Cells via 
 88 
STAT3-Dependent Mechanisms after Spinal Cord Injury. J Neurosci 33:12870-
12886. 
Watase K, Hashimoto K, Kano M, Yamada K, Watanabe M, Inoue Y, Okuyama S, 
Sakagawa T, Ogawa S, Kawashima N, Hori S, Takimoto M, Wada K, Tanaka K 
(1998) Motor discoordination and increased susceptibility to cerebellar injury in 
GLAST mutant mice. The European journal of neuroscience 10:976-988. 
Wilhelmsson U, Faiz M, de Pablo Y, Sjoqvist M, Andersson D, Widestrand A, Potokar 
M, Stenovec M, Smith PL, Shinjyo N, Pekny T, Zorec R, Stahlberg A, Pekna M, 
Sahlgren C, Pekny M (2012) Astrocytes negatively regulate neurogenesis through 
the Jagged1-mediated Notch pathway. Stem cells 30:2320-2329. 
Yan YP, Yin KJ, Sun FY (1998) Effect of glutamate transporter on neuronal damage 
induced by photochemical thrombotic brain ischemia. Neuroreport 9:441-446. 
Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA (2012) Genomic 
analysis of reactive astrogliosis. J Neurosci 32:6391-6410. 
 89 
Figures and Tables 
 
Figure 2-1. Reactive astrocyte derived-neural stem cells (Rad-NSCs) differentiated 
into astrocytes respond to immobilized Jagged-1.  
A) Diagram of the distal middle cerebral artery occlusion (dMCAO) model and cell 
isolation schema. Three days following ligation, reactive astrocytes surround an infarct 
core composed of necrotic tissue and other cell types. Reactive astrocytes isolated from 
the peri-infarct area (pink oval) form neural spheres after 14 days in neural stem cell 
culture, so-called reactive astrocyte derived-stem cells (Rad-NSC). These spheres can 
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(astrocyte culture) to create a proponderance of astrocytes refered to as AstroRad-NSC. B) 
Strategy for screening the transcriptome of AstroRad-NSC in response to immobilized 
Jagged-1. AstroRad-NSC were plated on Jagged-1 or control surface and cultured for two 
days. RNA was extracted and gene expression was then assayed with Affymetrix Gene 
Chips. Expression data was normalized and converted to relative log expression (RLE). 
R: rostral, C: caudal, D: dorsal, V: ventral, MCA: middle cerebral artery, GFAP: glial 
fibilary acidic protein, d: days.  
 
Gene Symbol Gene Description 
Δ Jagged-1 vs Laminin  
(fold change) 
Clone 1 Clone 2 
Olig2 Oligodendrocyte fate specification, negatively regulated by Notch 
-2.3  -1.3 
Ascl1 Neuronal fate specification, negatively regulated by Notch 
-3.1  -2.1 
Hey2 Transcriptional effector of Notch Signaling 2.3  1.6 
Hes5 Transcriptional effector of Notch Signaling 1.2  1.5 
Gfap Astrocyte intermediate filament. Transcriptionally regulated by Notch signaling 
1.4 1.8 
Table 2-1. Notch-related Genes and Fold Change in Response to Immobilized 
Jagged-1. 
Shown are genes known to be affected by Notch signaling and their relative change in 
AstroRad-NSC in response to Jagged-1 versus control. Two clonal AstroRad-NSC lines isolated 
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p = 2.5E-07 p = 3.10E-04 p = 1.60E-05 
p = 4.70E-04 p = 1.70E-02 p = 5.40E-4 
Annotation Cluster 8 Enrichment Score: 1.96 Count P_Value 
GOTERM_BP_FAT response to wounding 19 8.00E-04 
GOTERM_BP_FAT inflammatory response 12 1.20E-02 
Annotation Cluster 2 Enrichment Score: 3.88 Count P_Value 
GOTERM_BP_FAT ion homeostasis 21 9.40E-06 
GOTERM_BP_FAT chemical homeostasis 23 2.40E-05 
GOTERM_BP_FAT homeostatic process 26 1.40E-03 
D C 
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Figure 2-2. Jagged-1 up-regulates membrane-bound and secreted proteins and 
down-regulates transcription factors and cell fate effectors. 
A) Genes decreased more than or equal to 1.20-fold by Jagged-1 were enriched for 
functional annotations for transcription and transcription factors. Pie charts show 
percentage of genes in the down-regulated set that have a given annotation term (in 
group). P values represent the probability that the experimenal list enriched for a given 
annotation by chance compared with the background genome (see methods). B) Genes 
with expression that was increased more than or equal to 1.2-fold by Jagged-1 enriched 
for proteins with annotations related to membrane-bound proteins and proteins 
glycosolated for secretion or presentation at the cell surface. C) DAVID output tabulating 
for two functional clusters that were enriched in the Jagged-1 up-regulated list. (Top) 
Cluster 2: Homeostasis cluster (partial table. See Table 2-10). (Bottom) Inflammatory 
response cluster. D) DAVID-generated 2D plot of annotation terms (columns) vs gene 
symbol (rows). A green square indicates gene membership in an annotation group. The 
black arrow highlights Sla1A3 aka GLAST.  
Gene Symbol Gene Description and Title 
Δ Jagged-1 vs Laminin  
(fold change) 
Clone 1 Clone 2 
Glast Glutamate uptake transporter. No known transcriptional regulation by Notch. 1.4 1.5 
Glul Glutamine Synthetase. No known transcriptional regulation by Notch. 2.4 1.6 




Figure 2-3. GLAST gene and protein expression is decreased by GSI and specific 
Notch1 deletion. 
A’) A CSL sequence found ~2.67 KB upstream of the GLAST transcriptional start point 
in Mus musculus. This suggests that it could be directly transcriptionally-activated by 
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d of incubation in DBZ. B’) 4-OH Tamoxifen (OHTM)-induced conditional deletion of 
Notch1 from a clonal line of GNAstroRad-NSC significantly decreased GLAST gene 
expression along with Gfap and Notch1 expression. See main text for statistics. Protein 
levels of cleaved Notch1 (NICD1) (C) and GLAST (D), but not GLT-1 (E) were reduced 
in GNAstroRad-NSC treated with OHTM. F) Another clonal GNAstroRad-NSC line 
independent of that used for immunoblot (D) showed a time-dependent decrease in 
GLAST protein: 5 > 8 days in OHTM.  CSL: CBP-1/suppressor of hairless/LAG-1, GSI: 
Gamma Secretase Inhibitor, EtOH: Ethanol. 
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Figure 2-4. GSI DAPT inhibits AstroRad-NSC ability to take up extracellular 
glutamate. 
A) At 15 minutes following addition of glutamate to AstroRad-NSC culture medium, 
residual extracellular glutamate was significantly higher in cultures treated with a GSI 
(DAPT) and specific GLT-1 antagonizist (DHK) (*p < 0.01, Unpaired Student’s T-test, 
n=3). All residual glutamate levels were normalized to vehicle (DMSO + water) control 
culture levels. B) 2 d incubation in DAPT significantly decreased glutamate uptake 



















































































































































variations between clones. “Combined” indicates the mean representation of the invidual 
clonal uptake data displayed in the graph (*p < 0.01, unpaired Student’s t-test, n=3 
clones).  
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A) GFAP was decreased in GLT-1-positive astrocytes sorted from uninjured cortex in 
animals treated with tamoxifen (tm) compared with vehicle control (oil) (*p < 0.05, n=3 
per group). GLAST protein levels were low or undetectable and not dependent on 
treatment group. B) 3 days after dMCAO, GLT-1-positive astrocytes were isolated from 
ispalateral cortex and pooled by treatment group. GLAST and GFAP protein levels 
decreased in the pooled tm group compared with oil-treated control. GLT-1-negative 
fraction contains no detectable GLAST or GFAP protein.  
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96 NM_170778 // Dpyd // dihydropyrimidine dehydrogenase // 3 G1|3 // 99586 /// ENSMUST0000 
1.36 1.27 
97 NM_001081235 // Mn1 // meningioma 1 // 5 F|5 59.0 cM // 433938 /// ENSMUST00000094463 / 
1.36 1.28 
98 NM_010330 // Emb // embigin // 13 D2.3|13 // 13723 /// ENSMUST00000022242 // Emb // emb 
1.36 1.22 
99 NM_020044 // Lat2 // linker for activation of T cells family, member 2 // 5 G2|5 // 567 
1.35 1.28 
100 NM_008536 // Tm4sf1 // transmembrane 4 superfamily member 1 // 3 D|3 // 17112 /// ENSMU 
1.35 1.35 
101 NM_001081417 // Chd7 // chromodomain helicase DNA binding protein 7 // 4 A1|4 1.0 cM // 
1.35 1.21 
102 NM_145482 // Setd4 // SET domain containing 4 // 16 C4|16 // 224440 /// ENSMUST00000023 
1.35 1.27 
103 NM_021352 // Crybb3 // crystallin, beta B3 // 5 F|5 60.0 cM // 12962 /// ENSMUST0000007 
1.35 1.35 
104 NR_045766 // Gm10509 // zinc finger protein 51 pseudogene // 17 A3.2 // 100310809 /// N 
1.35 1.61 
105 NM_009944 // Cox7a1 // cytochrome c oxidase, subunit VIIa 1 // 7 B1|7 8.0 cM // 12865 / 
1.35 1.40 
106 NM_001083927 // Tle3 // transducin-like enhancer of split 3, homolog of Drosophila E(sp 
1.35 1.28 
107 NM_029863 // 9230110F15Rik // RIKEN cDNA 9230110F15 gene // 9 A4|9 // 77080 /// ENSMUST 
1.35 1.57 
108 NM_146664 // Olfr734 // olfactory receptor 734 // 14 C3-D1|14 // 258658 /// ENSMUST0000 
1.34 1.36 
109 NM_011397 // Slc23a1 // solute carrier family 23 (nucleobase transporters), member 1 // 
1.34 1.33 
110 NM_008928 // Map2k3 // mitogen-activated protein kinase kinase 3 // 11 B2|11 // 26397 / 
1.34 1.32 
111 NM_025403 // Nop10 // NOP10 ribonucleoprotein homolog (yeast) // 2|2 E4 // 66181 /// EN 
1.34 1.23 
112 NM_134195 // Vmn1r227 // vomeronasal 1 receptor 227 // 17 A3.2|17 // 171229 
1.34 1.66 
113 NM_011808 // Ets1 // E26 avian leukemia oncogene 1, 5' domain // 9 A4|9 15.0 cM // 2387 
1.34 1.21 
114 NM_025863 // Trim59 // tripartite motif-containing 59 // 3|3 E2 // 66949 /// ENSMUST000 
1.34 1.25 
115 NM_172125 // Adam1b // a disintegrin and metallopeptidase domain 1b // 5 F|5 // 280667 
1.34 1.29 
116 NM_009731 // Akr1b7 // aldo-keto reductase family 1, member B7 // 6 B1|6 14.0 cM // 119 
1.33 1.29 
117 NM_145852 // Ropn1l // ropporin 1-like // 15 B2|15 // 252967 /// ENSMUST00000110408 // 
1.33 1.23 
118 NM_001114385 // Chrdl1 // chordin-like 1 // X F3|X // 83453 /// ENSMUST00000112878 // C 
1.33 1.36 
119 NM_008327 // Ifi202b // interferon activated gene 202B // 1 H3|1 // 26388 /// NM_011940 
1.33 2.54 
120 NM_146786 // Olfr914 // olfactory receptor 914 // 9 A5|9 // 258782 /// ENSMUST000000577 
1.33 1.27 
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121 NM_027261 // Taf1d // TATA box binding protein (Tbp)-associated factor, RNA polymerase 
1.33 1.46 
122 NM_011560 // Tcte3 // t-complex-associated testis expressed 3 // 17 A2|17 8.16 cM // 21 
1.33 1.24 
123 NM_009214 // Sms // spermine synthase // X F4|X 65.45 cM // 20603 /// AF031486 // Sms / 
1.33 1.40 
124 ENSMUST00000129632 // Tcp1 // t-complex protein 1 // 17 A3-B|17 7.5 cM // 21454 
1.32 1.22 
125 NM_001085549 // Gm12824 // predicted gene 12824 // 4 D1|4 // 666048 /// ENSMUST00000094 
1.32 1.29 
126 AK033210 // 8030451A03Rik // RIKEN cDNA 8030451A03 gene // 4 C1|4 // 100504061 /// XR_1 
1.32 1.23 
127 NM_019643 // Fam60a // family with sequence similarity 60, member A // 6 G3|6 // 56306 
1.32 1.22 
128 NM_172482 // Zfp719 // zinc finger protein 719 // 7 B4|7 // 210105 /// ENSMUST000001638 
1.31 1.26 
129 NM_138757 // 4933424B01Rik // RIKEN cDNA 4933424B01 gene // 6 G3|6 // 71177 /// ENSMUST 
1.31 1.23 
130 NM_008274 // Hoxd12 // homeobox D12 // 2 C3|2 45.0 cM // 15432 /// ENSMUST00000001878 / 
1.31 1.21 
131 NM_146666 // Olfr736 // olfactory receptor 736 // 14 C3-D1|14 // 258660 /// ENSMUST0000 
1.31 1.56 
132 NM_011560 // Tcte3 // t-complex-associated testis expressed 3 // 17 A2|17 8.16 cM // 21 
1.31 1.26 
133 NM_010053 // Dlx1 // distal-less homeobox 1 // 2 C2|2 44.0 cM // 13390 /// ENSMUST00000 
1.31 1.63 
134 NM_177175 // Tmem215 // transmembrane protein 215 // 4 A5|4 // 320500 /// ENSMUST000000 
1.31 1.55 
135 NM_148413 // Myo3a // myosin IIIA // 2 A3|2 // 667663 /// ENSMUST00000044749 // Myo3a / 
1.31 1.27 
136 ENSMUST00000025764 // Cst6 // cystatin E/M // 19 A|19 4.0 cM // 73720 /// BC061036 // C 
1.30 1.29 
137 NM_013598 // Kitl // kit ligand // 10 D1|10 57.0 cM // 17311 /// ENSMUST00000105283 // 
1.30 1.36 
138 NM_009967 // Crygs // crystallin, gamma S // 16 B1|16 16.1 cM // 12970 /// ENSMUST00000 
1.30 1.55 
139 NM_021362 // Pappa // pregnancy-associated plasma protein A // 4 C1|4 32.2 cM // 18491 
1.30 1.29 
140 NR_030764 // 2700097O09Rik // RIKEN cDNA 2700097O09 gene // 12 C1|12 // 72658 /// NM_02 
1.30 1.36 
141 NM_146319 // Olfr727 // olfactory receptor 727 // 14 C1|14 // 258316 /// ENSMUST0000007 
1.30 1.29 
142 NM_019643 // Fam60a // family with sequence similarity 60, member A // 6 G3|6 // 56306 
1.30 1.23 
143 NR_033613 // 1700001J11Rik // ring finger protein 19A pseudogene // 9 A5.1|9 // 72224 
1.30 1.33 
144 NM_172514 // Tmem71 // transmembrane protein 71 // 15 D2|15 // 213068 /// ENSMUST000000 
1.30 1.27 
145 NM_026150 // 4921536K21Rik // RIKEN cDNA 4921536K21 gene // 11 A1|11 // 67430 /// ENSMU 
1.30 1.33 
146 NM_007986 // Fap // fibroblast activation protein // 2 C1.3|2 36.0 cM // 14089 /// ENSM 
1.30 1.22 
 103 
147 NM_009464 // Ucp3 // uncoupling protein 3 (mitochondrial, proton carrier) // 7 E3|7 50. 
1.30 1.26 
148 ENSMUST00000027422 // Slc16a14 // solute carrier family 16 (monocarboxylic acid transpo 
1.30 1.33 
149 ENSMUST00000137376 // Gm11362 // predicted gene 11362 // 13 A3.1|13 // 626683 /// ENSMU 
1.29 1.31 
150 NM_025414 // Myo19 // myosin XIX // 11|11 B5 // 66196 /// ENSMUST00000093969 // Myo19 / 
1.29 1.26 
151 AK164247 // Nfxl1 // nuclear transcription factor, X-box binding-like 1 // 5|5 D // 100 
1.29 1.24 
152 NM_029271 // Mrpl32 // mitochondrial ribosomal protein L32 // 13|13 A2 // 75398 /// ENS 
1.29 1.28 
153 NM_023816 // Ankrd36 // ankyrin repeat domain 36 // 11 A1|11 // 76389 /// ENSMUST000001 
1.29 1.42 
154 NM_008066 // Gabra2 // gamma-aminobutyric acid (GABA) A receptor, subunit alpha 2 // 5 
1.29 1.27 
155 NM_008933 // Prm2 // protamine 2 // 16 A1|16 3.4 cM // 19119 /// ENSMUST00000037996 // 
1.29 1.23 
156 AK038227 // Gm9734 // predicted gene 9734 // 11 E2|11 // 76377 /// XR_035387 // Gm9734 
1.29 1.30 
157 NM_023794 // Etv5 // ets variant gene 5 // 16 B1|16 // 104156 /// ENSMUST00000079601 // 
1.29 1.46 
158 NM_172308 // Mthfd1l // methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-lik 
1.29 1.30 
159 NM_001013816 // Gm5622 // predicted gene 5622 // 14 C2|14 // 434459 /// ENSMUST00000096 
1.29 1.29 
160 NM_201411 // Flrt1 // fibronectin leucine rich transmembrane protein 1 // 19 A|19 // 39 
1.29 1.21 
161 NM_001081417 // Chd7 // chromodomain helicase DNA binding protein 7 // 4 A1|4 1.0 cM // 
1.29 1.37 
162 NM_025844 // Chordc1 // cysteine and histidine-rich domain (CHORD)-containing, zinc-bin 
1.28 1.41 
163 NM_054058 // Psg20 // pregnancy-specific glycoprotein 20 // 7 A3|7 // 434540 /// ENSMUS 
1.28 1.29 
164 NM_177367 // Gemin4 // gem (nuclear organelle) associated protein 4 // 11 B5|11 // 2769 
1.28 1.23 
165 NM_207153 // Olfr325 // olfactory receptor 325 // 11 B1.3|11 // 258261 /// ENSMUST00000 
1.28 1.28 
166 NM_023653 // Wnt2 // wingless-related MMTV integration site 2 // 6 A2-A3.1|6 4.2 cM // 
1.28 1.25 
167 NM_198011 // E430018J23Rik // RIKEN cDNA E430018J23 gene // 7 F3|7 // 101604 /// ENSMUS 
1.28 1.21 
168 NM_146875 // Olfr895 // olfactory receptor 895 // 9 A5|9 // 258875 /// ENSMUST000000938 
1.28 1.29 
169 NM_001167983 // Sipa1l1 // signal-induced proliferation-associated 1 like 1 // 12 D1|12 
1.28 1.44 
170 XM_001002269 // Gm8290 // predicted gene 8290 // 10 C1|10 // 666790 /// ENSMUST00000079 
1.28 1.21 
171 BC117944 // Slco5a1 // solute carrier organic anion transporter family, member 5A1 // 1 
1.28 1.20 
172 NM_177092 // Msrb3 // methionine sulfoxide reductase B3 // 10 D2|10 // 320183 /// ENSMU 
1.28 1.31 
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173 ENSMUST00000020849 // Tom1l1 // target of myb1-like 1 (chicken) // 11 D|11 53.0 cM // 7 
1.28 1.36 
174 AK048707 // C230012O17Rik // RIKEN cDNA C230012O17 gene // 4 A3|4 // 319564 
1.28 1.39 
175 NM_181406 // Rars2 // arginyl-tRNA synthetase 2, mitochondrial // 4 A5|4 // 109093 /// 
1.28 1.25 
176 NM_008961 // Pter // phosphotriesterase related // 2 A1|2 // 19212 /// ENSMUST000001347 
1.27 1.40 
177 NM_001146180 // Mtss1 // metastasis suppressor 1 // 15 D1|15 // 211401 /// ENSMUST00000 
1.27 1.81 
178 NM_010244 // Fv1 // Friend virus susceptibility 1 // 4 E2|4 76.5 cM // 14349 /// ENSMUS 
1.27 1.22 
179 NM_024187 // U2af1 // U2 small nuclear ribonucleoprotein auxiliary factor (U2AF) 1 // 1 
1.27 1.26 
180 AK145303 // Gm10747 // predicted gene 10747 // --- // 100038610 /// XR_105386 // Gm1074 
1.27 1.31 
181 NM_001166024 // Arfgap2 // ADP-ribosylation factor GTPase activating protein 2 // 2 E1| 
1.27 1.20 
182 NM_025520 // Lsm5 // LSM5 homolog, U6 small nuclear RNA associated (S. cerevisiae) // 6 
1.27 1.32 
183 AK155938 // Gm10388 // predicted gene 10388 // --- // 100038707 /// XR_140411 // Gm1038 
1.27 1.42 
184 NM_146451 // Olfr164 // olfactory receptor 164 // 16 B1|16 // 258443 /// ENSMUST0000005 
1.27 1.48 
185 NR_033261 // Gm14492 // predicted gene 14492 // 7 F5|7 // 677289 
1.27 1.24 
186 NM_198026 // Iqcc // IQ motif containing C // 4 D2.2|4 // 230767 /// ENSMUST00000046675 
1.27 1.35 
187 NM_001013813 // Maml2 // mastermind like 2 (Drosophila) // 9 A1|9 // 270118 /// ENSMUST 
1.27 1.27 
188 NM_013496 // Crabp1 // cellular retinoic acid binding protein I // 9 A5.3|9 31.0 cM // 
1.27 1.43 
189 NM_029755 // Calcoco2 // calcium binding and coiled-coil domain 2 // 11 C|11 55.8 cM // 
1.26 1.22 
190 NM_011505 // Stxbp4 // syntaxin binding protein 4 // 11|11 C // 20913 /// ENSMUST000001 
1.26 1.20 
191 NM_024187 // U2af1 // U2 small nuclear ribonucleoprotein auxiliary factor (U2AF) 1 // 1 
1.26 1.30 
192 NM_026348 // Itgb3bp // integrin beta 3 binding protein (beta3-endonexin) // 4 C6|4 // 
1.26 1.41 
193 NM_153459 // Dusp7 // dual specificity phosphatase 7 // 9 F1|9 // 235584 /// ENSMUST000 
1.26 1.24 
194 NM_001161845 // Sgk1 // serum/glucocorticoid regulated kinase 1 // 10 A3|10 // 20393 // 
1.26 1.48 
195 NM_011382 // Six4 // sine oculis-related homeobox 4 homolog (Drosophila) // 12 C3|12 // 
1.26 1.35 
196 NM_026257 // Ubxn11 // UBX domain protein 11 // 4 D3|4 65.7 cM // 67586 /// ENSMUST0000 
1.26 1.23 
197 NM_001099688 // Fbxo39 // F-box protein 39 // 11 B4|11 // 628100 /// ENSMUST00000108504 
1.26 1.22 
198 ENSMUST00000126435 // Mri1 // methylthioribose-1-phosphate isomerase homolog (S. cerevi 
1.26 1.23 
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199 NM_023142 // Arpc1b // actin related protein 2/3 complex, subunit 1B // 5 G2|5 // 11867 
1.26 1.35 
200 NM_001134461 // Prickle2 // prickle homolog 2 (Drosophila) // 6 D1|6 // 243548 /// ENSM 
1.25 1.29 
201 NR_028359 // 5830417I10Rik // gon-4-like pseudogene // 3 F1|3 // 100302730 
1.25 1.34 
202 NM_010584 // Itln1 // intelectin 1 (galactofuranose binding) // 1|1 H2 // 16429 /// AY1 
1.25 1.27 
203 NM_001146007 // Trim12c // tripartite motif-containing 12C // 7 E3|7 // 319236 /// NM_1 
1.25 1.65 
204 NM_001029876 // Urb2 // URB2 ribosome biogenesis 2 homolog (S. cerevisiae) // 8 E2|8 // 
1.25 1.51 
205 NM_011463 // Spink4 // serine peptidase inhibitor, Kazal type 4 // 4|4 A // 20731 /// E 
1.25 1.40 
206 NM_001033348 // Ralgapa2 // Ral GTPase activating protein, alpha subunit 2 (catalytic) 
1.25 1.24 
207 NR_027619 // Mug-ps1 // murinoglobulin, pseudogene 1 // 6 F1|6 // 17835 /// NM_008646 / 
1.25 1.23 
208 BC030179 // Fam173b // family with sequence similarity 173, member B // 15 B2|15 // 680 
1.25 1.22 
209 NM_015759 // Fgd3 // FYVE, RhoGEF and PH domain containing 3 // 13 A5|13 31.0 cM // 309 
1.25 1.28 
210 NM_017399 // Fabp1 // fatty acid binding protein 1, liver // 6 C1|6 30.0 cM // 14080 // 
1.25 1.36 
211 NM_001161548 // Tmem184a // transmembrane protein 184a // 5 G2|5 // 231832 /// ENSMUST0 
1.25 1.23 
212 NM_001042592 // Arrdc4 // arrestin domain containing 4 // 7 D1|7 // 66412 /// ENSMUST00 
1.25 1.30 
213 NM_011946 // Map3k2 // mitogen-activated protein kinase kinase kinase 2 // 18 B3|18 // 
1.25 1.23 
214 NR_015491 // A630089N07Rik // RIKEN cDNA A630089N07 gene // 16 C4|16 // 320586 
1.25 1.34 
215 ENSMUST00000032192 // Itpr1 // inositol 1,4,5-trisphosphate receptor 1 // 6 E1-E2|6 48. 
1.25 1.21 
216 NM_025356 // Ube2d3 // ubiquitin-conjugating enzyme E2D 3 // 3 G3|3 // 66105 /// ENSMUS 
1.25 1.25 
217 ENSMUST00000100403 // Tmem106a // transmembrane protein 106A // 11 D|11 // 217203 /// N 
1.25 1.27 
218 NM_026656 // Mcoln2 // mucolipin 2 // 3 H2|3 // 68279 /// NM_001005846 // Mcoln2 // muc 
1.24 1.39 
219 ENSMUST00000078508 // Sp7 // Sp7 transcription factor 7 // 15 F3|15 // 170574 /// AF184 
1.24 1.23 
220 NM_007981 // Acsl1 // acyl-CoA synthetase long-chain family member 1 // 8|8 B2 // 14081 
1.24 1.21 
221 NM_029427 // Pnpla5 // patatin-like phospholipase domain containing 5 // 15|15 E3 // 75 
1.24 1.27 
222 NM_009707 // Arhgap6 // Rho GTPase activating protein 6 // X F5|X // 11856 /// ENSMUST0 
1.24 1.48 
223 NM_134067 // AW209491 // expressed sequence AW209491 // 13 A1|13 // 105351 /// ENSMUST0 
1.24 1.36 
224 NM_009238 // Sox4 // SRY-box containing gene 4 // 13 A3-A5|13 20.0 cM // 20677 /// ENSM 
1.24 1.31 
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225 NM_009979 // Cst9 // cystatin 9 // 2|2 H1 // 13013 /// ENSMUST00000028935 // Cst9 // cy 
1.24 1.31 
226 NM_145434 // Nr1d1 // nuclear receptor subfamily 1, group D, member 1 // 11 D|11 // 217 
1.24 1.24 
227 NM_029733 // 2010005H15Rik // RIKEN cDNA 2010005H15 gene // 16 B3|16 // 76770 /// BC125 
1.24 1.41 
228 NM_009214 // Sms // spermine synthase // X F4|X 65.45 cM // 20603 /// BC058688 // Sms / 
1.24 1.35 
229 NM_001048168 // Nfyc // nuclear transcription factor-Y gamma // 4 D2.2|4 55.0 cM // 180 
1.24 1.30 
230 NM_009601 // Chrnb1 // cholinergic receptor, nicotinic, beta polypeptide 1 (muscle) // 
1.23 1.24 
231 NM_011376 // Sim1 // single-minded homolog 1 (Drosophila) // 10 B3|10 26.5 cM // 20464 
1.23 1.25 
232 NM_026866 // Disp1 // dispatched homolog 1 (Drosophila) // 1|1 101.2 cM // 68897 /// EN 
1.23 1.30 
233 NM_009189 // Six1 // sine oculis-related homeobox 1 homolog (Drosophila) // 12 C3|12 31 
1.23 1.37 
234 NM_025430 // Mrpl35 // mitochondrial ribosomal protein L35 // 6|6 C3 // 66223 /// ENSMU 
1.23 1.38 
235 NM_009687 // Apex1 // apurinic/apyrimidinic endonuclease 1 // 14 C3|14 18.5 cM // 11792 
1.23 1.23 
236 NM_176933 // Dusp4 // dual specificity phosphatase 4 // 8 A4|8 // 319520 /// ENSMUST000 
1.23 1.31 
237 NM_001034902 // Gm5878 // predicted gene 5878 // 6 C3|6 // 545861 /// ENSMUST0000011380 
1.23 1.42 
238 NM_001146002 // Txndc2 // thioredoxin domain containing 2 (spermatozoa) // 17|17 E1.2-E 
1.23 1.21 
239 NM_026352 // Ppid // peptidylprolyl isomerase D (cyclophilin D) // 3|3 F1 // 67738 /// 
1.23 1.21 
240 NM_013813 // Epb4.1l3 // erythrocyte protein band 4.1-like 3 // 17 E1.3|17 42.5 cM // 1 
1.23 1.31 
241 NM_146005 // Ank3 // ankyrin 3, epithelial // 10 B5.3|10 38.0 cM // 11735 /// NM_170688 
1.23 1.39 
242 NR_027885 // Vaultrc5 // vault RNA component 5 // --- // 378472 
1.23 1.37 
243 NM_030743 // Rnf114 // ring finger protein 114 // 2 H3|2 // 81018 /// ENSMUST0000010921 
1.23 1.22 
244 NM_013722 // Syn3 // synapsin III // 10|10 C2 // 27204 /// ENSMUST00000120638 // Syn3 / 
1.23 1.23 
245 NM_025274 // Dppa5a // developmental pluripotency associated 5A // 9 E1|9 // 434423 /// 
1.23 1.45 
246 NM_001025561 // Pus1 // pseudouridine synthase 1 // 5 F|5 // 56361 /// ENSMUST000000866 
1.23 1.26 
247 NM_001113180 // Gria4 // glutamate receptor, ionotropic, AMPA4 (alpha 4) // 9 A1|9 8.0 
1.23 1.21 
248 NM_001024385 // Crls1 // cardiolipin synthase 1 // 2|2 F3 // 66586 /// NM_025646 // Crl 
1.23 1.30 
249 NM_001081417 // Chd7 // chromodomain helicase DNA binding protein 7 // 4 A1|4 1.0 cM // 
1.23 1.22 
250 NM_009384 // Tiam1 // T cell lymphoma invasion and metastasis 1 // 16 C3-4|16 61.8 cM / 
1.23 1.35 
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251 ENSMUST00000078623 // Cryba1 // crystallin, beta A1 // 11 B-C1|11 44.71 cM // 12957 /// 
1.23 1.21 
252 NM_001002927 // Penk // preproenkephalin // 4 A1|4 0.8 cM // 18619 /// ENSMUST000000703 
1.22 1.20 
253 NM_026371 // Loh12cr1 // loss of heterozygosity, 12, chromosomal region 1 homolog (huma 
1.22 1.50 
254 NM_007710 // Ckm // creatine kinase, muscle // 7 A3|7 4.5 cM // 12715 /// ENSMUST000000 
1.22 1.23 
255 NM_001011822 // Olfr787 // olfactory receptor 787 // 10 D3|10 // 258069 /// ENSMUST0000 
1.22 1.33 
256 ENSMUST00000002708 // Shh // sonic hedgehog // 5 B1|5 16.0 cM // 20423 /// NM_009170 // 
1.22 1.24 
257 NM_010504 // Ifna4 // interferon alpha 4 // 4 C4|4 42.6 cM // 15967 /// ENSMUST00000094 
1.22 1.28 
258 NM_029370 // Spata25 // spermatogenesis associated 25 // 2 H3|2 // 75642 /// ENSMUST000 
1.22 1.21 
259 NM_172818 // Ttll8 // tubulin tyrosine ligase-like family, member 8 // 15 E3|15 // 2395 
1.22 1.26 
260 NM_001033306 // Shb // src homology 2 domain-containing transforming protein B // 4 B1| 
1.22 1.37 
261 ENSMUST00000087521 // Nif3l1 // Ngg1 interacting factor 3-like 1 (S. pombe) // 1|1 C // 
1.22 1.27 
262 NM_008888 // Phox2b // paired-like homeobox 2b // 5 C3.1|5 40.0 cM // 18935 /// ENSMUST 
1.22 1.35 
263 NM_027926 // Cpa4 // carboxypeptidase A4 // 6 A3.3|6 // 71791 /// ENSMUST00000049251 // 
1.22 1.21 
264 ENSMUST00000022656 // 6720463M24Rik // RIKEN cDNA 6720463M24 gene // 14 E2.2|14 // 7774 
1.22 1.24 
265 NR_037995 // 0610009B14Rik // RIKEN cDNA 0610009B14 gene // 12 C3|12 // 68354 
1.22 1.21 
266 NM_146323 // Olfr1232 // olfactory receptor 1232 // 2 E1|2 // 258320 /// ENSMUST0000009 
1.22 1.27 
267 NM_001042653 // Oip5 // Opa interacting protein 5 // 2 E5|2 // 70645 /// ENSMUST0000012 
1.22 1.54 
268 NM_026878 // Rasl11b // RAS-like, family 11, member B // 5|5 D // 68939 /// ENSMUST0000 
1.22 1.41 
269 NM_025738 // Cypt1 // cysteine-rich perinuclear theca 1 // X A1.2|X // 66742 /// BC0610 
1.22 1.30 
270 NM_001004194 // Nlrp4e // NLR family, pyrin domain containing 4E // 7 A3|7 // 446099 // 
1.21 1.54 
271 NM_010664 // Krt18 // keratin 18 // 15 F3|15 58.86 cM // 16668 /// ENSMUST00000023803 / 
1.21 1.27 
272 ENSMUST00000120432 // Mlkl // mixed lineage kinase domain-like // 8|8 D3 // 74568 /// N 
1.21 1.31 
273 NM_025481 // Smurf2 // SMAD specific E3 ubiquitin protein ligase 2 // 11 E1|11 // 66313 
1.21 1.28 
274 NM_019764 // Amotl2 // angiomotin-like 2 // 9 F1|9 // 56332 /// ENSMUST00000035121 // A 
1.21 1.59 
275 BC016246 // 1810029B16Rik // RIKEN cDNA 1810029B16 gene // 8|8 B3.3 // 66282 /// ENSMUS 
1.21 1.64 
276 NM_029122 // Iqca // IQ motif containing with AAA domain // 1 D|1 // 74918 /// ENSMUST0 
1.21 1.30 
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277 NR_030153 // Mir470 // microRNA 470 // X|X // 723873 1.21 1.33 
278 NM_177681 // Zfp12 // zinc finger protein 12 // 5 G2|5 // 231866 /// ENSMUST00000077485 
1.21 1.24 
279 NM_026479 // Zcchc10 // zinc finger, CCHC domain containing 10 // 11 B1.3|11 28.5 cM // 
1.21 1.70 
280 NM_001005788 // Zfp69 // zinc finger protein 69 // 4 D2.2|4 54.0 cM // 381549 /// ENSMU 
1.21 1.29 
281 NM_009087 // Polr1d // polymerase (RNA) I polypeptide D // 5 G3|5 // 20018 /// ENSMUST0 
1.21 1.60 
282 NM_001253847 // Cbll1 // Casitas B-lineage lymphoma-like 1 // 12 A3|12 // 104836 /// NM 
1.21 1.38 
283 BC063063 // 2410018L13Rik // RIKEN cDNA 2410018L13 gene // 12 A1.3|12 // 69732 
1.21 1.40 
284 NM_172908 // Ovch2 // ovochymase 2 // 7 E3|7 // 244199 /// ENSMUST00000106755 // Ovch2 
1.21 1.25 
285 NM_026235 // Larp6 // La ribonucleoprotein domain family, member 6 // 9 B|9 // 67557 // 
1.21 1.29 
286 AK082708 // Gm16487 // predicted gene 16487 // --- // 791285 1.21 1.21 
287 NM_001033039 // Klhdc9 // kelch domain containing 9 // 1 H3|1 93.3 cM // 68874 /// ENSM 
1.21 1.25 
288 ENSMUST00000050833 // Ino80e // INO80 complex subunit E // 7 F3|7 // 233875 /// NM_1535 
1.21 1.24 
289 NM_001013369 // Pfdn4 // prefoldin 4 // 2 H3|2 99.0 cM // 109054 /// ENSMUST00000075087 
1.20 1.82 
290 NM_026821 // D4Bwg0951e // DNA segment, Chr 4, Brigham & Women's Genetics 0951 expresse 
1.20 1.49 
291 NM_147000 // Olfr173 // olfactory receptor 173 // 16 C2|16 // 259002 /// ENSMUST0000004 
1.20 1.28 
292 NR_045618 // Gm9958 // predicted gene 9958 // 5|5 // 791294 1.20 1.52 
293 NM_023680 // Tnfrsf22 // tumor necrosis factor receptor superfamily, member 22 // 7 F5| 
1.20 1.29 
294 NM_146641 // Olfr1164 // olfactory receptor 1164 // 2 E1|2 // 258634 /// ENSMUST0000009 
1.20 1.32 
295 NM_011836 // Lamc3 // laminin gamma 3 // 2 B|2 // 23928 /// ENSMUST00000028187 // Lamc3 
1.20 1.27 
296 NM_001141965 // Naa20 // N(alpha)-acetyltransferase 20, NatB catalytic subunit // 2 H1| 
1.20 1.21 
297 NM_001161855 // 4933416C03Rik // RIKEN cDNA 4933416C03 gene // 10 D2|10 // 619332 /// E 
1.20 1.29 
298 NR_029731 // Mirlet7f-1 // microRNA let7f-1 // 13|13 // 387252 1.20 1.29 














1 NM_025980 // Nrarp // Notch-regulated ankyrin repeat protein // 2 A3|2 // 67122 /// ENS 1.40 4.44 
2 NM_008407 // Itih3 // inter-alpha trypsin inhibitor, heavy chain 3 // 14|14 A2-C1 // 16 1.71 3.47 
3 ENSMUST00000037048 // Mmd2 // monocyte to macrophage differentiation-associated 2 // 5  1.25 2.83 
4 NM_001014395 // Fbxw22 // F-box and WD-40 domain protein 22 // 9 F2|9 // 382156 /// ENS 1.33 1.96 
5 ENSMUST00000167204 // Dclk1 // doublecortin-like kinase 1 // 3|3 D // 13175 1.39 1.95 
6 NM_001011750 // Olfr294 // olfactory receptor 294 // 7 D3|7 // 257904 /// ENSMUST000000 1.30 1.84 
7 NM_026376 // Plxnd1 // plexin D1 // 6 E3|6 // 67784 1.74 2.23 
8 ENSMUST00000041042 // Tbc1d10a // TBC1 domain family, member 10a // 11 A1|11 // 103724  1.33 1.82 
9 BC051076 // BC051076 // cDNA sequence BC051076 // 5 E1|5 // 243090 1.21 1.70 
10 ENSMUST00000162664 // Nckap5 // NCK-associated protein 5 // 1 E3|1 // 210356 /// ENSMUS 1.34 1.82 
11 NM_001013770 // Lipo1 // lipase, member O1 // 19 C1|19 // 381236 /// ENSMUST00000112508 1.38 1.84 
12 NM_172290 // Ntm // neurotrimin // 9 A4|9 // 235106 /// ENSMUST00000075069 // Ntm // ne 1.48 1.94 
13 NM_181395 // Pxdn // peroxidasin homolog (Drosophila) // 12 A2|12 // 69675 /// ENSMUST0 1.71 2.15 
14 NM_008624 // Mras // muscle and microspikes RAS // 9 E3.3|9 // 17532 /// ENSMUST0000003 1.30 1.74 
15 NM_018760 // Slc4a4 // solute carrier family 4 (anion exchanger), member 4 // 5|5 E2 // 1.33 1.72 
16 NM_177364 // Sh3pxd2b // SH3 and PX domains 2B // 11 A4|11 // 268396 /// ENSMUST0000003 1.31 1.70 
17 NM_009381 // Thrsp // thyroid hormone responsive SPOT14 homolog (Rattus) // 7|7 E3 // 2 1.44 1.82 
18 NM_008362 // Il1r1 // interleukin 1 receptor, type I // 1 B|1 19.5 cM // 16177 /// ENSM 1.54 1.91 
19 NM_010497 // Idh1 // isocitrate dehydrogenase 1 (NADP+), soluble // 1 C2|1 29.8 cM // 1 1.22 1.58 
20 NM_011436 // Sorl1 // sortilin-related receptor, LDLR class A repeats-containing // 9 B 1.21 1.57 
21 NM_009115 // S100b // S100 protein, beta polypeptide, neural // 10 C1|10 41.0 cM // 202 1.21 1.56 
22 NM_025524 // Krtap3-3 // keratin associated protein 3-3 // 11 D|11 // 66380 /// ENSMUST 1.31 1.66 
23 ENSMUST00000081265 // Ebf1 // early B cell factor 1 // 11 B1.1|11 20.0 cM // 13591 ///  1.35 1.69 
24 BC112909 // 5930403N24Rik // RIKEN cDNA 5930403N24 gene // 10 B1|10 // 320504 1.21 1.55 
25 NM_011371 // St6galnac1 // ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-ac 1.20 1.53 
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26 ENSMUST00000105363 // Gamt // guanidinoacetate methyltransferase // 10 C1|10 43.0 cM // 1.21 1.53 
27 NM_024441 // Hspb2 // heat shock protein 2 // 9 A5.3|9 29.0 cM // 69253 /// ENSMUST0000 1.28 1.59 
28 NR_033496 // Lrp8 // low density lipoprotein receptor-related protein 8, apolipoprotein 1.26 1.56 
29 NM_007709 // Cited1 // Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-te 1.71 2.01 
30 ENSMUST00000001027 // Aox1 // aldehyde oxidase 1 // 1 C1-C2|1 23.2 cM // 11761 1.21 1.51 
31 NM_008606 // Mmp11 // matrix metallopeptidase 11 // 10 C1|10 40.9 cM // 17385 /// ENSMU 1.27 1.56 
32 NM_138685 // Wfdc15b // WAP four-disulfide core domain 15B // 2 H3|2 // 192201 /// ENSM 1.23 1.52 
33 NM_007428 // Agt // angiotensinogen (serpin peptidase inhibitor, clade A, member 8) //  1.65 1.93 
34 NM_026523 // Nmb // neuromedin B // 7 D3|7 // 68039 /// ENSMUST00000026817 // Nmb // ne 1.21 1.49 
35 NM_011658 // Twist1 // twist homolog 1 (Drosophila) // 12 B-C1|12 16.0 cM // 22160 ///  1.24 1.52 
36 NM_022417 // Itm2c // integral membrane protein 2C // 1 C5|1 // 64294 /// ENSMUST000000 1.20 1.47 
37 NM_026840 // Pdgfrl // platelet-derived growth factor receptor-like // 8 A4|8 // 68797  1.21 1.48 
38 NM_001256259 // 4930524N10Rik // RIKEN cDNA 4930524N10 gene // X F3|X // 75071 /// ENSM 1.38 1.64 
39 NM_010304 // Gna15 // guanine nucleotide binding protein, alpha 15 // 10 C1|10 43.0 cM  1.20 1.46 
40 NM_001170847 // Rbm20 // RNA binding motif protein 20 // 19 D2|19 // 73713 /// ENSMUST0 1.21 1.46 
41 NM_198170 // Szt2 // seizure threshold 2 // 4 D2.1|4 // 230676 /// ENSMUST00000075406 / 1.29 1.54 
42 NM_172473 // Hace1 // HECT domain and ankyrin repeat containing, E3 ubiquitin protein l 1.26 1.50 
43 NM_009142 // Cx3cl1 // chemokine (C-X3-C motif) ligand 1 // 8 C5|8 46.0 cM // 20312 /// 1.23 1.47 
44 NR_015566 // A330023F24Rik // RIKEN cDNA A330023F24 gene // 1|1 // 320977 1.20 1.43 
45 BC100510 // Gm2511 // predicted gene 2511 // 7 B4|7 // 100039946 1.22 1.45 
46 NM_013661 // Sema5b // sema domain, seven thrombospondin repeats (type 1 and type 1-lik 1.24 1.47 
47 XM_621234 // Olfr766 // olfactory receptor 766 // 10 D3|10 // 546487 1.28 1.50 
48 BC035950 // BC043934 // cDNA sequence BC043934 // 9 E3.3|9 // 270185 1.25 1.47 
49 NM_001005510 // Syne2 // synaptic nuclear envelope 2 // 12 C3|12 33.0 cM // 319565 ///  1.28 1.49 
50 NM_001162884 // Igsf10 // immunoglobulin superfamily, member 10 // 3 D|3 // 242050 ///  1.32 1.54 
51 NM_010419 // Hes5 // hairy and enhancer of split 5 (Drosophila) // 4 E2|4 81.5 cM // 15 1.25 1.46 
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52 NR_033548 // D030047H15Rik // RIKEN cDNA D030047H15 gene // --- // 100037396 1.53 1.74 
53 NR_033568 // 9430041J12Rik // RIKEN cDNA 9430041J12 gene // 7|7 // 77323 1.54 1.74 
54 ENSMUST00000117160 // Cdh13 // cadherin 13 // 8 E1|8 64.0 cM // 12554 /// NM_019707 //  1.24 1.44 
55 NM_009404 // Tnfsf9 // tumor necrosis factor (ligand) superfamily, member 9 // 17 D|17  1.23 1.42 
56 NM_001114174 // Fam189a2 // family with sequence similarity 189, member A2 // 19 B|19 / 1.36 1.56 
57 NM_001011779 // Olfr286 // olfactory receptor 286 // 15 F1|15 // 629524 /// ENSMUST0000 1.25 1.44 
58 NM_001164763 // Rarres1 // retinoic acid receptor responder (tazarotene induced) 1 // 3 1.37 1.56 
59 NM_013584 // Lifr // leukemia inhibitory factor receptor // 15 A1|15 4.6 cM // 16880 // 1.21 1.38 
60 NM_177872 // Adamts3 // a disintegrin-like and metallopeptidase (reprolysin type) with  1.73 1.90 
61 BC052447 // 4930402H24Rik // RIKEN cDNA 4930402H24 gene // 2 F3|2 // 228602 /// ENSMUST 1.23 1.40 
62 NM_021452 // Kcnmb4 // potassium large conductance calcium-activated channel, subfamily 1.33 1.50 
63 NM_015790 // Icosl // icos ligand // 10 C1|10 // 50723 /// ENSMUST00000105393 // Icosl  1.23 1.40 
64 NM_001166721 // Vmn1r176 // vomeronasal 1 receptor 176 // 7 A3|7 // 546943 /// ENSMUST0 1.24 1.41 
65 NM_177167 // Ppm1e // protein phosphatase 1E (PP2C domain containing) // 11 C|11 // 320 1.21 1.38 
66 NM_008716 // Notch3 // notch 3 // 17 B1|17 20.0 cM // 18131 /// ENSMUST00000087723 // N 1.59 1.76 
67 NM_008827 // Pgf // placental growth factor // 12 D|12 39.0 cM // 18654 /// ENSMUST0000 1.35 1.51 
68 NM_008800 // Pde1b // phosphodiesterase 1B, Ca2+-calmodulin dependent // 15 F3|15 // 18 2.22 2.39 
69 NM_033145 // Lcn8 // lipocalin 8 // 2 A3|2 // 78076 /// ENSMUST00000038482 // Lcn8 // l 1.25 1.42 
70 NM_001080814 // Fat3 // FAT tumor suppressor homolog 3 (Drosophila) // 9 A2|9 // 270120 1.24 1.40 
71 NM_011448 // Sox9 // SRY-box containing gene 9 // 11 E2|11 69.5 cM // 20682 /// ENSMUST 1.21 1.37 
72 NM_026677 // Rab13 // RAB13, member RAS oncogene family // 3 F1|3 45.0 cM // 68328 ///  1.21 1.36 
73 NM_009730 // Atrn // // 2 F1|2 73.9 cM // 11990 /// ENSMUST00000028781 // Atr 1.21 1.36 
74 NM_199146 // Trim30d // tripartite motif-containing 30D // 7 E3|7 // 209387 /// ENSMUST 1.31 1.46 
75 NM_007703 // Elovl3 // elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, 1.31 1.46 
76 NM_023707 // 1810009J06Rik // RIKEN cDNA 1810009J06 gene // 6 B1|6 // 73626 /// ENSMUST 1.27 1.42 
77 NM_001145452 // Arhgef33 // Rho guanine nucleotide exchange factor (GEF) 33 // 17 E3|17 1.24 1.39 
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78 NM_008762 // Olfr15 // olfactory receptor 15 // 16 A1|16 // 18312 /// ENSMUST0000008091 1.23 1.37 
79 NM_001085477 // Olfr765 // olfactory receptor 765 // 10 D3|10 // 544748 /// ENSMUST0000 1.25 1.39 
80 NM_008360 // Il18 // interleukin 18 // 9 A5.3|9 29.0 cM // 16173 /// ENSMUST00000059081 1.22 1.36 
81 NM_011469 // Sprr2b // small proline-rich protein 2B // 3 F1|3 45.2 cM // 20756 /// ENS 1.38 1.52 
82 NM_146726 // Olfr514 // olfactory receptor 514 // 7 E3|7 // 258721 /// ENSMUST000000847 1.22 1.35 
83 NM_009917 // Ccr5 // chemokine (C-C motif) receptor 5 // 9 F|9 72.0 cM // 12774 /// ENS 1.25 1.39 
84 NM_009917 // Ccr5 // chemokine (C-C motif) receptor 5 // 9 F|9 72.0 cM // 12774 /// ENS 1.25 1.39 
85 NM_001137547 // Usp51 // ubiquitin specific protease 51 // X F3|X // 635253 /// ENSMUST 1.20 1.33 
86 NM_025979 // Mastl // microtubule associated serine/threonine kinase-like // 2 A3|2 //  1.23 1.35 
87 NM_146470 // Olfr1392 // olfactory receptor 1392 // 11 B1|11 // 258462 /// ENSMUST00000 1.26 1.39 
88 NM_178405 // Atp1a2 // ATPase, Na+/K+ transporting, alpha 2 polypeptide // 1 H3|1 94.2  1.55 1.67 
89 NM_183166 // Gm4884 // predicted gene 4884 // 7 B3|7 // 233164 /// ENSMUST00000164422 / 1.42 1.54 
90 NM_011977 // Slc27a1 // solute carrier family 27 (fatty acid transporter), member 1 //  1.49 1.61 
91 NM_027298 // Ccdc89 // coiled-coil domain containing 89 // 7|7 E1 // 70054 /// ENSMUST0 1.31 1.43 
92 NM_010738 // Ly6a // lymphocyte antigen 6 complex, locus A // 15 D3|15 42.7 cM // 11045 1.22 1.34 
93 ENSMUST00000056129 // Npas4 // neuronal PAS domain protein 4 // 19 A|19 // 225872 /// A 1.32 1.44 
94 NM_025359 // Tspan13 // tetraspanin 13 // 12|12 B2 // 66109 /// ENSMUST00000020896 // T 1.22 1.33 
95 NM_001105187 // Vmn2r74 // vomeronasal 2, receptor 74 // 7 D3|7 // 546980 /// ENSMUST00 1.21 1.33 
96 NM_016695 // Mpp2 // membrane protein, palmitoylated 2 (MAGUK p55 subfamily member 2) / 1.30 1.42 
97 NM_025877 // Slc25a23 // solute carrier family 25 (mitochondrial carrier; phosphate car 1.21 1.32 
98 NM_007395 // Acvr1b // activin A receptor, type 1B // 15 F2|15 60.4 cM // 11479 /// ENS 1.22 1.32 
99 AK080381 // 9330175E14Rik // RIKEN cDNA 9330175E14 gene // 8 C5|8 // 320377 1.23 1.34 
100 ENSMUST00000070518 // Nkg7 // natural killer cell group 7 sequence // 7|7 B2 // 72310 / 1.33 1.43 
101 NM_173394 // Ticam2 // toll-like receptor adaptor molecule 2 // 18 C|18 // 225471 /// E 1.21 1.32 
102 NM_008813 // Enpp1 // ectonucleotide pyrophosphatase/phosphodiesterase 1 // 10 A4|10 19 1.36 1.47 
103 NM_027808 // Alpk1 // alpha-kinase 1 // 3|3 H1 // 71481 /// ENSMUST00000029662 // Alpk1 1.38 1.49 
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104 NM_146334 // Olfr1330 // olfactory receptor 1330 // 4 D2|4 // 258331 /// ENSMUST0000009 1.22 1.33 
105 ENSMUST00000044217 // Syne2 // synaptic nuclear envelope 2 // 12 C3|12 33.0 cM // 31956 1.33 1.43 
106 NM_198111 // Akap6 // A kinase (PRKA) anchor protein 6 // 12 C1|12 // 238161 /// ENSMUS 1.34 1.44 
107 ENSMUST00000087321 // Ppp1r3c // protein phosphatase 1, regulatory (inhibitor) subunit  1.34 1.45 
108 NM_001166251 // Mgll // monoglyceride lipase // 6 D1|6 // 23945 /// ENSMUST00000163271  1.35 1.45 
109 NR_046014 // A530006G24Rik // RIKEN cDNA A530006G24 gene // 2 G2|2 // 381384 1.21 1.31 
110 NM_053108 // Glrx // glutaredoxin // 13 C1|13 44.0 cM // 93692 /// ENSMUST00000022082 / 1.21 1.32 
111 NM_026189 // Eepd1 // endonuclease/exonuclease/phosphatase family domain containing 1 / 1.22 1.32 
112 NM_008402 // Itgav // integrin alpha V // 2 D|2 46.0 cM // 16410 /// ENSMUST00000028499 1.34 1.44 
113 NM_147088 // Olfr569 // olfactory receptor 569 // 7 E3|7 // 259092 /// ENSMUST000000781 1.22 1.31 
114 NM_009557 // Zfp46 // zinc finger protein 46 // 4 D3|4 65.9 cM // 22704 /// ENSMUST0000 1.22 1.32 
115 NM_183389 // Duxbl // double homeobox B-like // 14 A3|14 // 278672 /// NM_001177538 //  1.21 1.31 
116 NM_183389 // Duxbl // double homeobox B-like // 14 A3|14 // 278672 /// NM_001177538 //  1.21 1.31 
117 NR_033550 // Gm10248 // predicted gene 10248 // --- // 791307 1.24 1.33 
118 NM_172809 // Sacs // sacsin // 14 D1|14 26.75 cM // 50720 /// ENSMUST00000089394 // Sac 1.23 1.32 
119 ENSMUST00000012426 // Wnt8a // wingless-related MMTV integration site 8A // 18|18 B3 // 1.27 1.36 
120 NM_008020 // Fkbp2 // FK506 binding protein 2 // 19 A|19 // 14227 /// NM_001166368 // F 1.23 1.32 
121 NM_009528 // Wnt7b // wingless-related MMTV integration site 7B // 15 E2|15 46.9 cM //  1.26 1.35 
122 ENSMUST00000031901 // Trpv5 // transient receptor potential cation channel, subfamily V 1.22 1.30 
123 ENSMUST00000028389 // Frzb // frizzled-related protein // 2 C3|2 49.75 cM // 20378 ///  1.46 1.55 
124 NM_145942 // Hmgcs1 // 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 // 13 66.0 cM|1 1.40 1.48 
125 NM_153776 // Tmem121 // transmembrane protein 121 // 12 F1|12 // 69195 /// ENSMUST00000 1.23 1.32 
126 BC005613 // Lpp // LIM domain containing preferred translocation partner in lipoma // 1 1.23 1.31 
127 NM_009367 // Tgfb2 // transforming growth factor, beta 2 // 1 H5|1 101.5 cM // 21808 // 1.39 1.47 
128 ENSMUST00000170808 // Vmn2r22 // vomeronasal 2, receptor 22 // 6 F2|6 // 546913 1.46 1.55 
129 NM_146094 // Fads1 // fatty acid desaturase 1 // 19 A|19 // 76267 /// ENSMUST0000001080 1.21 1.30 
130 NM_001014397 // Gm13154 // predicted gene 13154 // 4 E1|4 // 1.34 1.42 
 114 
433804 
131 NM_008997 // Rab11b // RAB11B, member RAS oncogene family // 17 B1|17 18.3 cM // 19326  1.21 1.29 
132 NM_146831 // Olfr133 // olfactory receptor 133 // 17 B1|17 // 258828 /// ENSMUST0000011 1.32 1.40 
133 NM_147114 // Olfr575 // olfactory receptor 575 // 7 E3|7 // 259118 /// ENSMUST000000848 1.27 1.35 
134 NR_030262 // Mir539 // microRNA 539 // 12|12 // 723917 1.23 1.31 
135 NM_033144 // Sept8 // septin 8 // 11 B1.3|11 28.75 cM // 20362 /// NM_001252332 // Sept 1.29 1.37 
136 NM_019696 // Cpxm1 // carboxypeptidase X 1 (M14 family) // 2 F1|2 // 56264 /// ENSMUST0 1.21 1.28 
137 NM_029061 // Ccdc7 // coiled-coil domain containing 7 // 8 E2|8 // 74703 /// ENSMUST000 1.30 1.38 
138 NM_172890 // Slc6a11 // solute carrier family 6 (neurotransmitter transporter, GABA), m 1.28 1.36 
139 ENSMUST00000022921 // Angpt1 // angiopoietin 1 // 15 B3.1|15 14.3 cM // 11600 /// NM_00 1.49 1.57 
140 NM_134437 // Il17rd // interleukin 17 receptor D // 14 A3|14 // 171463 /// ENSMUST00000 1.24 1.31 
141 NM_011545 // Tcf21 // transcription factor 21 // 10 A3|10 16.0 cM // 21412 /// ENSMUST0 1.32 1.39 
142 NM_011158 // Prkar2b // protein kinase, cAMP dependent regulatory, type II beta // 12|1 1.23 1.29 
143 ENSMUST00000040227 // Cldnd2 // claudin domain containing 2 // 7|7 B2 // 74276 /// NM_0 1.32 1.39 
144 NM_001048196 // Krtap4-1 // keratin associated protein 4-1 // 11 D|11 // 665891 /// ENS 1.24 1.30 
145 NM_175174 // Klhl5 // kelch-like 5 (Drosophila) // 5 C3.1|5 // 71778 /// ENSMUST0000010 1.23 1.29 
146 NR_027881 // 6530411M01Rik // RIKEN cDNA 6530411M01 gene // 17|17 // 67791 1.29 1.35 
147 NM_008624 // Mras // muscle and microspikes RAS // 9 E3.3|9 // 17532 /// ENSMUST0000003 1.22 1.28 
148 NR_045177 // 2900055J20Rik // RIKEN cDNA 2900055J20 gene // 18 B3|18 // 73001 1.20 1.27 
149 ENSMUST00000026613 // Gusb // glucuronidase, beta // 5 G1.3|5 72.0 cM // 110006 /// NM_ 1.21 1.27 
150 NM_018826 // Irx5 // Iroquois related homeobox 5 (Drosophila) // 8 C5|8 43.3 cM // 5435 1.21 1.27 
151 ENSMUST00000028807 // Ivd // isovaleryl coenzyme A dehydrogenase // 2 E4-E5|2 // 56357  1.24 1.30 
152 NM_177819 // Fam135b // family with sequence similarity 135, member B // 15 D3|15 // 70 1.35 1.41 
153 NM_175406 // Atp6v0d2 // ATPase, H+ transporting, lysosomal V0 subunit D2 // 4 A3|4 //  1.22 1.28 
154 NM_001159535 // Cacna1c // calcium channel, voltage-dependent, L type, alpha 1C subunit 1.36 1.42 
155 NR_003185 // Sprr2j-ps // small proline-rich protein 2J, pseudogene // 3 F1|3 45.2 cM / 1.24 1.30 
156 NM_198663 // C87499 // expressed sequence C87499 // 4 C4|4 // 381590 /// ENSMUST0000005 1.26 1.32 
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157 NR_003517 // Pisd-ps1 // phosphatidylserine decarboxylase, pseudogene 1 // 11 A1|11 //  1.29 1.35 
158 ENSMUST00000052500 // 4930412D23Rik // RIKEN cDNA 4930412D23 gene // X E3|X // 73934 1.27 1.32 
159 NM_001081428 // Fam184a // family with sequence similarity 184, member A // 10 B3|10 // 1.26 1.31 
160 NM_146995 // Olfr202 // olfactory receptor 202 // 16 C2|16 // 258997 /// ENSMUST0000004 1.22 1.27 
161 NM_001076791 // Zfp874b // zinc finger protein 874b // 13 B3|13 // 408067 1.41 1.46 
162 DQ284430 // 1700003O11Rik // RIKEN cDNA 1700003O11 gene // 18|18 // 75632 1.23 1.28 
163 NM_144854 // ORF63 // open reading frame 63 // 16 C3.3|16 // 224419 /// ENSMUST00000026 1.32 1.37 
164 NM_001024617 // Inpp4b // inositol polyphosphate-4-phosphatase, type II // 8 C2|8 38.0  1.44 1.48 
165 NM_020578 // Ehd3 // EH-domain containing 3 // 17 E2|17 43.25 cM // 57440 /// ENSMUST00 1.44 1.49 
166 NR_045335 // Gm13582 // predicted gene 13582 // 2 C1.2|2 // 100038493 1.31 1.36 
167 NM_009223 // Snn // stannin // 16|16 A2 // 20621 /// ENSMUST00000089011 // Snn // stann 1.20 1.25 
168 NM_009480 // Usf1 // upstream transcription factor 1 // 1 H|1 93.3 cM // 22278 /// ENSM 1.27 1.31 
169 ENSMUST00000171664 // 4930433I11Rik // RIKEN cDNA 4930433I11 gene // 7 B3|7 // 243944 1.36 1.41 
170 NM_001011834 // Olfr1152 // olfactory receptor 1152 // 2 D|2 // 258103 /// ENSMUST00000 1.21 1.25 
171 NM_010424 // Hfe // hemochromatosis // 13 A2-A4|13 15.0 cM // 15216 /// ENSMUST00000091 1.26 1.30 
172 NM_023210 // Anp32e // acidic (leucine-rich) nuclear phosphoprotein 32 family, member E 1.22 1.26 
173 NM_001110300 // Ap1m2 // adaptor protein complex AP-1, mu 2 subunit // 9 A3|9 9.0 cM // 1.21 1.25 
174 NM_146119 // Fam129b // family with sequence similarity 129, member B // 2 B|2 // 22773 1.38 1.42 
175 NM_010143 // Ephb3 // Eph receptor B3 // 16|16 B1-B4 // 13845 /// ENSMUST00000006112 // 1.22 1.26 
176 NM_146408 // Olfr1065 // olfactory receptor 1065 // 2 D|2 // 258403 /// ENSMUST00000099 1.20 1.24 
177 NR_027838 // Atp2a2 // ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 // 5 F| 1.21 1.25 
178 NM_008100 // Gcg // glucagon // 2 C1.3|2 36.0 cM // 14526 /// ENSMUST00000102733 // Gcg 1.24 1.27 
179 NM_032006 // Mmp1a // matrix metallopeptidase 1a (interstitial collagenase) // 9|9 A1-A 1.42 1.45 
180 NM_001039238 // Dcpp2 // demilune cell and parotid protein 2 // 17 A3.3|17 // 630537 // 1.25 1.29 
181 NM_080465 // Kcnn2 // potassium intermediate/small conductance calcium-activated channe 1.61 1.64 
182 ENSMUST00000167042 // U2af1l4 // U2 small nuclear RNA auxiliary factor 1-like 4 // 7 B1 1.21 1.24 
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183 NM_029048 // Spdyb // speedy homolog B (Xenopus laevis) // 5 G2|5 // 74673 /// ENSMUST0 1.20 1.23 
184 ENSMUST00000078842 // Mucl1 // mucin-like 1 // 15 F3|15 58.1 cM // 20771 1.21 1.24 
185 NM_001012269 // Olfr1513 // olfactory receptor 1513 // 14 C2|14 // 258008 /// ENSMUST00 1.21 1.24 
186 NM_001030305 // Pmp2 // peripheral myelin protein 2 // 3 A1|3 3.9 cM // 18857 /// ENSMU 1.40 1.42 
187 NM_008552 // Mas1 // MAS1 oncogene // 17 A1|17 7.45 cM // 17171 /// ENSMUST00000089015  1.33 1.36 
188 NM_025758 // Asb17 // ankyrin repeat and SOCS box-containing 17 // 3 H3|3 // 66772 ///  1.27 1.29 
189 ENSMUST00000073109 // Ctdspl // CTD (carboxy-terminal domain, RNA polymerase II, polype 1.41 1.43 
190 BC080695 // BC080695 // cDNA sequence BC080695 // 4 E1|4 // 329986 /// ENSMUST000001057 1.34 1.36 
191 NM_009553 // Zscan2 // zinc finger and SCAN domain containing 2 // 7 D3|7 42.0 cM // 22 1.22 1.24 
192 NM_001099323 // Zkscan16 // zinc finger with KRAB and SCAN domains 16 // 4 B3|4 // 1000 1.32 1.34 
193 NM_001081175 // Itpkb // inositol 1,4,5-trisphosphate 3-kinase B // 1 H5|1 100.0 cM //  1.30 1.32 
194 NM_001042719 // Ddhd1 // DDHD domain containing 1 // 14 C1|14 // 114874 /// NM_176845 / 1.27 1.30 
195 NM_175347 // Srl // sarcalumenin // 16 A1|16 // 106393 /// ENSMUST00000023161 // Srl // 1.21 1.23 
196 NM_022325 // Ctsz // cathepsin Z // 2 H4|2 103.5 cM // 64138 /// ENSMUST00000016400 //  1.23 1.24 
197 NM_007472 // Aqp1 // aquaporin 1 // 6 B3|6 27.0 cM // 11826 /// ENSMUST00000004774 // A 1.24 1.26 
198 NM_030721 // Acox3 // acyl-Coenzyme A oxidase 3, pristanoyl // 5 B1|5 // 80911 /// ENSM 1.20 1.22 
199 NM_011942 // Lypla2 // lysophospholipase 2 // 4 D3|4 // 26394 /// ENSMUST00000067567 // 1.35 1.37 
200 NM_177872 // Adamts3 // a disintegrin-like and metallopeptidase (reprolysin type) with  1.35 1.36 
201 NM_001081143 // Gnat3 // guanine nucleotide binding protein, alpha transducing 3 // 5 A 1.28 1.30 
202 NM_025797 // Cyb5 // cytochrome b-5 // 18 E4|18 55.0 cM // 109672 /// ENSMUST0000016018 1.32 1.33 
203 NM_013544 // H2-M10.1 // histocompatibility 2, M region locus 10.1 // 17 B1|17 19.84 cM 1.40 1.42 
204 NM_029726 // Trdn // triadin // 10 A4|10 // 76757 /// ENSMUST00000095762 // Trdn // tri 1.20 1.22 
205 NM_029629 // Fahd2a // fumarylacetoacetate hydrolase domain containing 2A // 2|2 F3 //  1.21 1.22 
206 NM_008720 // Npc1 // Niemann Pick type C1 // 18 A1|18 4.0 cM // 18145 /// ENSMUST000000 1.24 1.25 
207 AK135004 // Gm10561 // predicted gene 10561 // 1 C1.2|1 // 628004 1.30 1.31 
208 NM_177857 // Dennd2c // DENN/MADD domain containing 2C // 3 F2.2|3 // 329727 /// ENSMUS 1.23 1.24 
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209 NM_029662 // Mfsd2a // major facilitator superfamily domain containing 2A // 4|4 D1 //  1.25 1.26 
210 NM_001161817 // Myo1b // myosin IB // 1 C1.1|1 24.8 cM // 17912 /// ENSMUST00000018561  1.28 1.29 
211 NM_146754 // Olfr556 // olfactory receptor 556 // 7 E3|7 // 258749 /// ENSMUST000000982 1.23 1.24 
212 NM_008669 // Naga // N-acetyl galactosaminidase, alpha // 15 E|15 46.0 cM // 17939 ///  1.20 1.21 
213 NM_010640 // Klk1b11 // kallikrein 1-related peptidase b11 // 7 B4|7 23.16 cM // 16613  1.22 1.23 
214 NM_177571 // Gm13103 // predicted gene 13103 // 4 E1|4 // 194225 /// ENSMUST00000094522 1.31 1.32 
215 NM_009150 // Selenbp1 // selenium binding protein 1 // 3 F2.1|3 43.25 cM // 20341 /// E 1.23 1.24 
216 NM_013808 // Csrp3 // cysteine and glycine-rich protein 3 // 7 B4|7 // 13009 /// ENSMUS 1.27 1.27 
217 NM_001005510 // Syne2 // synaptic nuclear envelope 2 // 12 C3|12 33.0 cM // 319565 ///  1.24 1.25 
218 NM_001002896 // Bfsp2 // beaded filament structural protein 2, phakinin // 9 F1|9 // 10 1.22 1.22 
219 XR_141235 // D830044D21Rik // RIKEN cDNA D830044D21 gene // 14 B|14 // 320621 1.28 1.29 
220 AK137946 // Gm10673 // predicted gene 10673 // --- // 100038559 1.29 1.30 
221 NM_029357 // Pcdh1 // protocadherin 1 // 18 B3|18 18.0 cM // 75599 /// ENSMUST000000571 1.32 1.32 
222 NM_009128 // Scd2 // stearoyl-Coenzyme A desaturase 2 // 19 C3|19 43.0 cM // 20250 ///  1.35 1.35 
223 ENSMUST00000078239 // Akr1c20 // aldo-keto reductase family 1, member C20 // 13 A1|13 / 1.22 1.22 
224 NM_148925 // Fyco1 // FYVE and coiled-coil domain containing 1 // 9 F|9 71.3 cM // 1728 1.25 1.25 
225 ENSMUST00000069800 // Fut2 // fucosyltransferase 2 // 7 B4|7 23.2 cM // 14344 /// NM_01 1.25 1.25 
226 NM_026988 // Ptms // parathymosin // 6 F2|6 // 69202 /// ENSMUST00000032216 // Ptms //  1.21 1.20 
227 NM_008483 // Lamb2 // laminin, beta 2 // 9 F1|9 60.0 cM // 16779 /// ENSMUST00000065014 1.30 1.29 
228 ENSMUST00000099946 // Net1 // neuroepithelial cell transforming gene 1 // 13 A1|13 // 5 1.38 1.38 
229 NM_010117 // Rhbdf1 // rhomboid family 1 (Drosophila) // 11 A4|11 16.0 cM // 13650 ///  1.21 1.20 
230 NM_146513 // Olfr95 // olfactory receptor 95 // 17 B1|17 // 258506 /// ENSMUST000000607 1.24 1.23 
231 NM_001162884 // Igsf10 // immunoglobulin superfamily, member 10 // 3 D|3 // 242050 ///  1.35 1.35 
232 NM_146845 // Olfr1098 // olfactory receptor 1098 // 2 E1|2 // 258842 /// ENSMUST0000009 1.33 1.32 
233 NM_026840 // Pdgfrl // platelet-derived growth factor receptor-like // 8 A4|8 // 68797  1.36 1.34 
234 NM_173023 // Catsperb // cation channel, sperm-associated, beta // 12 E|12 // 271036 // 1.32 1.31 
235 NM_008579 // Meig1 // meiosis expressed gene 1 // 2 A1|2 // 1.50 1.48 
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104362 /// ENSMUST000000646 
236 NM_001190444 // Aamp // angio-associated migratory protein // 1 C3|1 41.0 cM // 227290  1.22 1.20 
237 NM_001081407 // Plb1 // phospholipase B1 // 5 B1|5 // 665270 /// ENSMUST00000101376 //  1.23 1.21 
238 NM_001163141 // Krtap24-1 // keratin associated protein 24-1 // 16 C3.3|16 // 239932 // 1.32 1.30 
239 NM_019975 // Hacl1 // 2-hydroxyacyl-CoA lyase 1 // 14 B|14 // 56794 /// ENSMUST00000022 1.28 1.26 
240 XM_985917 // Gm626 // predicted gene 626 // 14 B|14 // 268729 /// XM_001481294 // Gm626 1.27 1.24 
241 NM_178736 // Elmod2 // ELMO domain containing 2 // 8 C2|8 // 244548 /// NM_001170691 // 1.28 1.25 
242 NM_146145 // Jak1 // Janus kinase 1 // 4 C6|4 46.3 cM // 16451 /// ENSMUST00000102781 / 1.23 1.20 
243 NM_178681 // Dgkb // diacylglycerol kinase, beta // 12 A3|12 // 217480 /// ENSMUST00000 1.49 1.46 
244 NM_001166273 // Cspg5 // chondroitin sulfate proteoglycan 5 // 9 F2|9 // 29873 /// ENSM 1.28 1.25 
245 ENSMUST00000113476 // Rasgrp2 // RAS, guanyl releasing protein 2 // 19 A|19 // 19395 // 1.28 1.25 
246 NM_011079 // Phkg1 // phosphorylase kinase gamma 1 // 5 G1.3|5 72.0 cM // 18682 /// ENS 1.30 1.27 
247 NM_010593 // Jup // junction plakoglobin // 11 D|11 60.0 cM // 16480 /// ENSMUST0000000 1.26 1.22 
248 NR_033139 // AI427809 // expressed sequence AI427809 // 4 B2|4 // 381524 /// NR_033140  1.56 1.52 
249 ENSMUST00000053252 // Ctxn1 // cortexin 1 // 8 A1.1|8 13.0 cM // 330695 /// BC028881 // 1.35 1.31 
250 ENSMUST00000039775 // Lgi4 // leucine-rich repeat LGI family, member 4 // 7 B1|7 15.2 c 1.51 1.47 
251 NM_015737 // Galnt4 // UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosa 1.24 1.20 
252 NM_145853 // Tpcn1 // two pore channel 1 // 5 F|5 // 252972 /// ENSMUST00000046426 // T 1.41 1.36 
253 AK009122 // 2310003L06Rik // RIKEN cDNA 2310003L06 gene // 5 E1|5 // 74248 /// XM_14440 1.32 1.28 
254 NM_145584 // Spon1 // spondin 1, (f-spondin) extracellular matrix protein // 7 F1|7 //  1.35 1.30 
255 NM_172782 // Nxt2 // nuclear transport factor 2-like export factor 2 // X F2|X // 23708 1.26 1.21 
256 NM_177872 // Adamts3 // a disintegrin-like and metallopeptidase (reprolysin type) with  1.31 1.26 
257 NM_172701 // Oscp1 // organic solute carrier partner 1 // 4 D2.2|4 // 230751 /// AB2869 1.30 1.25 
258 AJ311773 // Art3 // ADP-ribosyltransferase 3 // 5 E2|5 52.0 cM // 109979 /// ENSMUST000 1.70 1.65 
259 NM_007528 // Bcl6b // B cell CLL/lymphoma 6, member B // 11|11 B4 // 12029 /// ENSMUST0 1.33 1.28 
260 NM_008861 // Pkd2 // polycystic kidney disease 2 // 5 E5|5 55.0 cM // 18764 /// ENSMUST 1.27 1.22 
261 NM_175114 // Trak1 // trafficking protein, kinesin binding 1 // 9 1.35 1.29 
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F4|9 71.0 cM // 67095 
262 NM_145473 // Csdc2 // cold shock domain containing C2, RNA binding // 15 E1|15 // 10585 1.57 1.51 
263 NM_178214 // Hist2h2be // histone cluster 2, H2be // 3 F1-F2|3 // 319190 /// ENSMUST000 1.30 1.24 
264 NM_053268 // Rasa2 // RAS p21 protein activator 2 // 9|9 E4 // 114713 /// ENSMUST000000 1.41 1.35 
265 NM_133974 // Cdcp1 // CUB domain containing protein 1 // 9 F4|9 // 109332 /// ENSMUST00 1.27 1.20 
266 NM_001204983 // Gm9766 // predicted gene 9766 // 10|10 // 100038725 1.45 1.38 
267 NM_019395 // Fbp1 // fructose bisphosphatase 1 // 13|13 B3-C1 // 14121 /// ENSMUST00000 1.28 1.21 
268 NM_018732 // Scn3a // sodium channel, voltage-gated, type III, alpha // 2 C1.3|2 36.0 c 1.31 1.24 
269 NM_001005227 // Olfr1200 // olfactory receptor 1200 // 2 E1|2 // 257887 /// ENSMUST0000 1.28 1.21 
270 NM_010008 // Cyp2j6 // cytochrome P450, family 2, subfamily j, polypeptide 6 // 4 C5|4  1.30 1.22 
271 NM_021345 // Ptplad1 // protein tyrosine phosphatase-like A domain containing 1 // 9|9  1.42 1.35 
272 NM_001081171 // Lama5 // laminin, alpha 5 // 2 H4|2 106.0 cM // 16776 /// ENSMUST000000 1.28 1.20 
273 NM_001102455 // Aplp2 // amyloid beta (A4) precursor-like protein 2 // 9 A2-B|9 13.0 cM 1.31 1.23 
274 NM_027975 // Fam83d // family with sequence similarity 83, member D // 2 H1|2 // 71878  1.34 1.26 
275 NM_001081977 // Rnf144a // ring finger protein 144A // 12|12 A3 // 108089 /// ENSMUST00 1.36 1.28 
276 NM_001159544 // Frk // fyn-related kinase // 10 B1|10 // 14302 /// ENSMUST00000170771 / 1.50 1.42 
277 NM_025817 // Tril // TLR4 interactor with leucine-rich repeats // 6 B3|6 // 66873 /// E 1.38 1.30 
278 NM_009117 // Saa1 // serum amyloid A 1 // 7 B4|7 23.5 cM // 20208 /// ENSMUST0000012808 1.33 1.25 
279 NM_029758 // Fam49a // family with sequence similarity 49, member A // 12 A1.1|12 2.5 c 1.47 1.38 
280 NM_029706 // Cpb1 // carboxypeptidase B1 (tissue) // 3 A2|3 13.0 cM // 76703 /// ENSMUS 1.36 1.28 
281 NM_153526 // Insig1 // insulin induced gene 1 // 5 B1|5 // 231070 /// ENSMUST0000005915 1.33 1.25 
282 NM_007988 // Fasn // fatty acid synthase // 11 E2|11 72.0 cM // 14104 /// ENSMUST000000 1.29 1.21 
283 NM_001144992 // 2810459M11Rik // RIKEN cDNA 2810459M11 gene // 1 C5|1 // 72792 /// NM_0 1.64 1.55 
284 NM_007535 // Bcl2a1c // B cell leukemia/lymphoma 2 related protein A1c // 9 F3|9 // 120 1.31 1.22 
285 NM_172442 // Dtx4 // deltex 4 homolog (Drosophila) // 19 A|19 // 207521 /// ENSMUST0000 1.34 1.24 
286 NM_016721 // Iqgap1 // IQ motif containing GTPase activating protein 1 // 7 D3|7 39.0 c 1.33 1.24 
287 NR_015543 // 2810055G20Rik // RIKEN cDNA 2810055G20 gene 1.50 1.40 
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// 16 C3.1|16 // 77994 
288 NM_010234 // Fos // FBJ osteosarcoma oncogene // 12 D2|12 40.0 cM // 14281 /// ENSMUST0 1.45 1.35 
289 NM_001206335 // Itfg3 // integrin alpha FG-GAP repeat containing 3 // 17 A3.3|17 // 106 1.32 1.22 
290 NM_172484 // Nckap5 // NCK-associated protein 5 // 1 E3|1 // 210356 /// ENSMUST00000161 1.53 1.43 
291 NM_009892 // Chi3l3 // chitinase 3-like 3 // 3 F2.2|3 50.5 cM // 12655 /// ENSMUST00000 1.37 1.27 
292 NM_175328 // Slc6a15 // solute carrier family 6 (neurotransmitter transporter), member  1.50 1.39 
293 NR_046286 // H2-T10 // histocompatibility 2, T region locus 10 // 17 B1|17 19.96 cM //  1.31 1.20 
294 NM_177089 // Tacc1 // transforming, acidic coiled-coil containing protein 1 // 8 A2|8 / 1.37 1.26 
295 BC025646 // Fam81a // family with sequence similarity 81, member A // 9 D|9 // 76886 // 1.71 1.60 
296 ENSMUST00000068880 // Paqr8 // progestin and adipoQ receptor family member VIII // 1|1  1.47 1.36 
297 NM_027784 // 5530400C23Rik // RIKEN cDNA 5530400C23 gene // 6 G1|6 // 232426 /// ENSMUS 1.61 1.50 
298 ENSMUST00000035129 // Ephb1 // Eph receptor B1 // 9 F1|9 // 270190 /// ENSMUST000000851 1.45 1.34 
299 NM_027154 // Tmbim1 // transmembrane BAX inhibitor motif containing 1 // 1 C3|1 // 6966 1.35 1.24 
300 NM_201529 // Lmo7 // LIM domain only 7 // 14 E2.3|14 48.5 cM // 380928 /// ENSMUST00000 1.45 1.34 
301 NM_025654 // Rdm1 // RAD52 motif 1 // 11 D|11 // 66599 /// ENSMUST00000010506 // Rdm1 / 1.34 1.23 
302 NM_144520 // Sec14l2 // SEC14-like 2 (S. cerevisiae) // 11 A1|11 // 67815 /// ENSMUST00 1.34 1.22 
303 NM_001025576 // Ccdc141 // coiled-coil domain containing 141 // 2 C3|2 // 545428 /// EN 1.40 1.28 
304 NM_178796 // A530064D06Rik // RIKEN cDNA A530064D06 gene // 17 C|17 // 328830 /// ENSMU 1.89 1.77 
305 NM_201406 // Pigs // phosphatidylinositol glycan anchor biosynthesis, class S // 11 B5| 1.34 1.22 
306 ENSMUST00000026225 // Sema4g // sema domain, immunoglobulin domain (Ig), transmembrane  1.34 1.22 
307 NM_001163314 // Pgap1 // post-GPI attachment to proteins 1 // 1 C1.1|1 // 241062 1.60 1.47 
308 NM_009982 // Ctsc // cathepsin C // 7|7 D3-E1.1 // 13032 /// ENSMUST00000032779 // Ctsc 1.94 1.81 
309 NM_026369 // Arpc5 // actin related protein 2/3 complex, subunit 5 // 1|1 A3 // 67771 / 1.36 1.23 
310 AF318068 // Defb5 // defensin beta 5 // 8 A1.3|8 // 81007 1.36 1.23 
311 NM_022030 // Sv2a // synaptic vesicle glycoprotein 2 a // 3|3 F2 // 64051 /// ENSMUST00 1.37 1.23 
312 NM_023612 // Esm1 // endothelial cell-specific molecule 1 // 13 D2.2|13 // 71690 /// EN 1.40 1.26 
313 AK032909 // Atp6v0a2 // ATPase, H+ transporting, lysosomal V0 subunit A2 // 5 F|5 // 21 1.34 1.20 
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314 NM_198651 // 4430402I18Rik // RIKEN cDNA 4430402I18 gene // 19 C1|19 // 381218 /// ENSM 1.43 1.29 
315 NM_008822 // Pex7 // peroxisomal biogenesis factor 7 // 10 A3|10 // 18634 /// ENSMUST00 1.42 1.28 
316 ENSMUST00000025078 // Map3k8 // mitogen-activated protein kinase kinase kinase 8 // 18  1.36 1.22 
317 ENSMUST00000022099 // Lpcat1 // lysophosphatidylcholine acyltransferase 1 // 13 C1|13 / 1.48 1.33 
318 NM_010332 // Ednra // endothelin receptor type A // 8 C2|8 // 13617 /// ENSMUST00000034 1.41 1.26 
319 NM_009912 // Ccr1 // chemokine (C-C motif) receptor 1 // 9 F|9 71.6 cM // 12768 /// ENS 1.46 1.31 
320 NM_001081279 // Mfhas1 // malignant fibrous histiocytoma amplified sequence 1 // 8 A4|8 1.44 1.29 
321 NM_053272 // Dhcr24 // 24-dehydrocholesterol reductase // 4 C7|4 // 74754 /// ENSMUST00 1.51 1.36 
322 NM_024281 // Rrbp1 // ribosome binding protein 1 // 2 G1|2 // 81910 /// ENSMUST00000016 1.40 1.25 
323 AY512912 // Gm12511 // predicted gene 12511 // 4 B3|4 // 791419 1.40 1.24 
324 NM_001172160 // Flrt3 // fibronectin leucine rich transmembrane protein 3 // 2 F3|2 //  1.36 1.20 
325 BC158045 // Synpo2 // synaptopodin 2 // 3|3 G3 // 118449 /// ENSMUST00000051443 // Synp 1.73 1.57 
326 NM_007644 // Scarb2 // scavenger receptor class B, member 2 // 5|5 E3 // 12492 /// ENSM 1.41 1.26 
327 NM_172893 // Parp12 // poly (ADP-ribose) polymerase family, member 12 // 6 B1|6 // 2437 1.37 1.21 
328 NM_008381 // Inhbb // inhibin beta-B // 1 E2.3|1 64.1 cM // 16324 /// ENSMUST0000003876 1.56 1.40 
329 ENSMUST00000162269 // Plch1 // phospholipase C, eta 1 // 3 E1|3 // 269437 /// ENSMUST00 1.50 1.33 
330 NM_026062 // Fam69a // family with sequence similarity 69, member A // 5 E5|5 // 67266  1.42 1.25 
331 NM_177872 // Adamts3 // a disintegrin-like and metallopeptidase (reprolysin type) with  1.58 1.40 
332 NM_001024606 // Pdp2 // pyruvate dehyrogenase phosphatase catalytic subunit 2 // 8 D3|8 1.38 1.21 
333 BC132286 // 4933433C11Rik // RIKEN cDNA 4933433C11 gene // 2 A3|2 // 74472 /// ENSMUST0 1.38 1.20 
334 NM_029999 // Lbh // limb-bud and heart // 17 E2|17 // 77889 /// ENSMUST00000024857 // L 1.46 1.28 
335 NM_021274 // Cxcl10 // chemokine (C-X-C motif) ligand 10 // 5 E2|5 53.0 cM // 15945 /// 1.43 1.26 
336 NM_133821 // Phlpp1 // PH domain and leucine rich repeat protein phosphatase 1 // 1 E2. 1.39 1.21 
337 AK084042 // D130079A08Rik // RIKEN cDNA D130079A08 gene // 14 E2.3|14 // 320671 /// XR_ 1.45 1.27 
338 ENSMUST00000068233 // Kcnmb4 // potassium large conductance calcium-activated channel,  1.55 1.37 
339 NM_031874 // Rab3d // RAB3D, member RAS oncogene family // 9|9 A2-A3 // 19340 /// ENSMU 1.51 1.33 
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340 NM_001081009 // Parp8 // poly (ADP-ribose) polymerase family, member 8 // 13 D2.3|13 71 1.39 1.21 
341 NR_029728 // Mirlet7c-1 // microRNA let7c-1 // 16|16 // 387246 1.95 1.76 
342 ENSMUST00000154208 // Dhrs3 // dehydrogenase/reductase (SDR family) member 3 // 4 E1|4  1.51 1.33 
343 NM_009808 // Casp12 // caspase 12 // 9 A1|9 1.11 cM // 12364 /// BC028979 // Casp12 //  1.56 1.37 
344 NM_138752 // Plekhg2 // pleckstrin homology domain containing, family G (with RhoGef do 1.45 1.25 
345 ENSMUST00000105574 // Agrn // agrin // 4 E2|4 80.0 cM // 11603 /// NM_021604 // Agrn // 1.76 1.57 
346 NM_001025576 // Ccdc141 // coiled-coil domain containing 141 // 2 C3|2 // 545428 /// EN 1.55 1.35 
347 NM_178589 // Tnfrsf21 // tumor necrosis factor receptor superfamily, member 21 // 17|17 1.40 1.20 
348 NM_001204915 // Reep3 // receptor accessory protein 3 // 10 B5.1|10 30.0 cM // 28193 // 1.51 1.31 
349 NM_030127 // Htra3 // HtrA serine peptidase 3 // 5|5 B1 // 78558 /// ENSMUST00000087629 1.42 1.22 
350 NM_172476 // Tmc7 // transmembrane channel-like gene family 7 // 7 F2|7 // 209760 /// E 1.54 1.34 
351 NM_008509 // Lpl // lipoprotein lipase // 8 B3.3|8 33.0 cM // 16956 /// ENSMUST00000015 1.62 1.41 
352 NM_173775 // Ccdc37 // coiled-coil domain containing 37 // 6 D1|6 // 243538 /// ENSMUST 1.49 1.28 
353 NM_009835 // Ccr6 // chemokine (C-C motif) receptor 6 // 17 A1|17 // 12458 /// ENSMUST0 1.42 1.21 
354 AK136967 // Gm10808 // predicted gene 10808 // --- // 100038470 /// XR_141286 // Gm1080 1.56 1.35 
355 NM_022434 // Cyp4f14 // cytochrome P450, family 4, subfamily f, polypeptide 14 // 17 B1 1.48 1.26 
356 NM_001113474 // Lair1 // leukocyte-associated Ig-like receptor 1 // 7 A1|7 4.5 cM // 52 1.48 1.27 
357 ENSMUST00000032175 // Aldh1l1 // aldehyde dehydrogenase 1 family, member L1 // 6 D1|6 / 1.57 1.34 
358 ENSMUST00000029935 // Gbp3 // guanylate binding protein 3 // 3 H1|3 // 55932 /// NM_018 1.48 1.25 
359 NM_001105183 // Vmn2r70 // vomeronasal 2, receptor 70 // 7 D3|7 // 670940 /// ENSMUST00 1.50 1.27 
360 NM_021426 // Nkain4 // Na+/K+ transporting ATPase interacting 4 // 2 H4|2 // 58237 ///  1.53 1.29 
361 NM_001199151 // Sncaip // synuclein, alpha interacting protein (synphilin) // 18 D1|18  1.52 1.28 
362 NM_177784 // Klhl23 // kelch-like 23 (Drosophila) // 2 C2|2 // 277396 /// ENSMUST000000 1.61 1.36 
363 NM_001171010 // Slc14a1 // solute carrier family 14 (urea transporter), member 1 // 18  1.59 1.33 
364 NM_011633 // Traf5 // TNF receptor-associated factor 5 // 1 H6|1 105.0 cM // 22033 ///  1.49 1.23 
365 NM_027868 // Slc41a3 // solute carrier family 41, member 3 // 6|6 D2 // 71699 /// ENSMU 1.52 1.25 
366 NM_197988 // 1190005I06Rik // RIKEN cDNA 1190005I06 gene // 1.68 1.41 
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8 E1|8 // 68918 /// ENSMUST 
367 AK138039 // Gm10757 // predicted gene 10757 // --- // 100038551 /// XR_141985 // Gm1075 1.67 1.39 
368 ENSMUST00000096084 // Ccdc136 // coiled-coil domain containing 136 // 6 A3.3|6 // 23266 1.54 1.26 
369 NM_001081206 // Dgki // diacylglycerol kinase, iota // 6 B1|6 // 320127 1.51 1.23 
370 NM_153151 // Acat3 // acetyl-Coenzyme A acetyltransferase 3 // 17 A1|17 7.55 cM // 2245 1.49 1.21 
371 NM_011122 // Plod1 // procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 // 4 E2|4 76.5 1.51 1.23 
372 XM_143371 // Dchs2 // dachsous 2 (Drosophila) // 3 E3|3 // 229459 1.76 1.47 
373 NM_175437 // Pion // pigeon homolog (Drosophila) // 5 A3|5 // 212167 /// ENSMUST0000003 1.50 1.21 
374 NM_008706 // Nqo1 // NAD(P)H dehydrogenase, quinone 1 // 8 D3|8 53.3 cM // 18104 /// EN 1.61 1.32 
375 NM_008255 // Hmgcr // 3-hydroxy-3-methylglutaryl-Coenzyme A reductase // 13 D1|13 49.0  1.53 1.23 
376 NM_009525 // Wnt5b // wingless-related MMTV integration site 5B // 6 F1|6 56.2 cM // 22 1.53 1.24 
377 NM_001143834 // Grm5 // glutamate receptor, metabotropic 5 // 7 E1|7 // 108071 /// ENSM 1.74 1.45 
378 NM_144938 // C1s // complement component 1, s subcomponent // 6 F2|6 // 50908 /// ENSMU 1.50 1.20 
379 NM_153807 // Acsf2 // acyl-CoA synthetase family member 2 // 11 D|11 // 264895 /// ENSM 1.64 1.33 
380 NM_008131 // Glul // glutamate-ammonia ligase (glutamine synthetase) // 1 G2|1 // 14645 1.91 1.59 
381 NM_153560 // Fam102a // family with sequence similarity 102, member A // 2 B|2 // 98952 1.66 1.33 
382 ENSMUST00000103164 // Acsf2 // acyl-CoA synthetase family member 2 // 11 D|11 // 264895 1.79 1.44 
383 NM_177872 // Adamts3 // a disintegrin-like and metallopeptidase (reprolysin type) with  1.74 1.37 
384 NM_001011852 // Olfr1029 // olfactory receptor 1029 // 2 D|2 // 258154 /// ENSMUST00000 1.70 1.32 
385 NM_011693 // Vcam1 // vascular cell adhesion molecule 1 // 3 G1|3 50.8 cM // 22329 ///  1.66 1.26 
386 ENSMUST00000127587 // Tlcd1 // TLC domain containing 1 // 11 B5|11 // 68385 /// NM_0267 1.72 1.30 
387 NM_008398 // Itga7 // integrin alpha 7 // 10 D3|10 72.0 cM // 16404 /// ENSMUST00000099 1.86 1.42 
388 NM_011173 // Pros1 // protein S (alpha) // 16 C1.3|16 // 19128 /// ENSMUST00000023629 / 1.74 1.29 
389 BC150846 // 1700084C01Rik // RIKEN cDNA 1700084C01 gene // 1 H3|1 // 78465 /// BC172001 1.69 1.23 
390 ENSMUST00000108271 // Mecom // MDS1 and EVI1 complex locus // 3 A3|3 14.4 cM // 14013 / 1.67 1.21 
391 NM_001081401 // Adamts3 // a disintegrin-like and metallopeptidase (reprolysin type) wi 1.75 1.27 
392 NM_145360 // Idi1 // isopentenyl-diphosphate delta isomerase // 1.72 1.23 
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13 A1|13 // 319554 ///  
393 NM_012006 // Acot1 // acyl-CoA thioesterase 1 // 12 D1|12 33.0 cM // 26897 /// ENSMUST0 1.87 1.37 
394 NM_010218 // Fjx1 // four jointed box 1 (Drosophila) // 2 E2|2 // 14221 /// ENSMUST0000 1.92 1.40 
395 ENSMUST00000169107 // Fat3 // FAT tumor suppressor homolog 3 (Drosophila) // 9 A2|9 //  1.75 1.23 
396 NM_175236 // Adhfe1 // alcohol dehydrogenase, iron containing, 1 // 1 A2|1 // 76187 /// 1.84 1.31 
397 NM_021432 // Nap1l5 // nucleosome assembly protein 1-like 5 // 6|6 C1 // 58243 /// ENSM 1.86 1.26 
398 NM_017469 // Gucy1b3 // guanylate cyclase 1, soluble, beta 3 // 3 E3|3 // 54195 /// NM_ 2.07 1.45 
399 NM_010473 // Hrc // histidine rich calcium binding protein // 7 B4|7 20.4 cM // 15464 / 1.86 1.22 
400 NM_177872 // Adamts3 // a disintegrin-like and metallopeptidase (reprolysin type) with  2.12 1.45 
401 NM_013904 // Hey2 // hairy/enhancer-of-split related with YRPW motif 2 // 10 A4|10 // 1 2.30 1.56 
402 NM_153145 // Abca8a // ATP-binding cassette, sub-family A (ABC1), member 8a // 11 E1|11 2.04 1.24 
403 NM_178725 // Lrrc4c // leucine rich repeat containing 4C // 2 E1|2 // 241568 /// ENSMUS 2.45 1.60 
404 NM_009780 // C4b // complement component 4B (Chido blood group) // 17 B1|17 18.8 cM //  2.16 1.24 
405 NM_001081278 // Tbc1d4 // TBC1 domain family, member 4 // 14 E2.3|14 // 210789 /// ENSM 2.48 1.48 
406 NM_009252 // Serpina3n // serine (or cysteine) peptidase inhibitor, clade A, member 3N  2.76 1.50 
407 NM_021324 // Ttyh1 // tweety homolog 1 (Drosophila) // 7 A1|7 // 57776 /// ENSMUST00000 1.48 2.29 
408 NM_134022 // 6330403K07Rik // RIKEN cDNA 6330403K07 gene // 11 B4|11 // 103712 /// BC06 1.43 1.83 
409 NM_009696 // Apoe // apolipoprotein E // 7 A3|7 4.0 cM // 11816 /// ENSMUST00000174064  1.40 1.76 
410 NM_144847 // Nrbp2 // nuclear receptor binding protein 2 // 15 D3|15 // 223649 /// ENSM 1.46 1.78 
411 NM_172775 // Plxnb1 // plexin B1 // 9 F2|9 // 235611 /// ENSMUST00000072093 // Plxnb1 / 1.55 1.83 
412 NM_175260 // Myh10 // myosin, heavy polypeptide 10, non-muscle // 11 B3|11 40.0 cM // 7 1.21 1.44 
413 NM_010277 // Gfap // glial fibrillary acidic protein // 11 D|11 62.0 cM // 14580 /// EN 1.31 1.51 
414 NM_009911 // Cxcr4 // chemokine (C-X-C motif) receptor 4 // 1 E4|1 67.4 cM // 12767 /// 1.25 1.44 
415 NM_172961 // Abat // 4-aminobutyrate aminotransferase // 16|16 A3 // 268860 /// ENSMUST 1.55 1.73 
416 NM_009657 // Aldoc // aldolase C, fructose-bisphosphate // 11 B5|11 44.98 cM // 11676 / 1.36 1.49 
417 NM_019699 // Fads2 // fatty acid desaturase 2 // 19|19 B // 56473 /// ENSMUST0000002556 1.36 1.49 
418 NM_007407 // Adcyap1r1 // adenylate cyclase activating 1.57 1.70 
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polypeptide 1 receptor 1 // 6 B3 
419 NM_001199186 // Slc44a2 // solute carrier family 44, member 2 // 9 A3|9 // 68682 /// NM 1.23 1.35 
420 NM_013515 // Stom // stomatin // 2 B-C1|2 24.0 cM // 13830 /// ENSMUST00000028241 // St 1.41 1.52 
421 ENSMUST00000005493 // Slc1a3 // solute carrier family 1 (glial high affinity glutamate  1.44 1.50 
422 NM_001205181 // Abhd4 // abhydrolase domain containing 4 // 14 C2|14 // 105501 /// NM_1 1.23 1.29 
423 NM_013864 // Ndrg2 // N-myc downstream regulated gene 2 // 14 C2|14 // 29811 /// ENSMUS 1.78 1.83 
424 NM_199241 // Sema6d // sema domain, transmembrane domain (TM), and cytoplasmic domain,  1.24 1.28 
425 NM_015740 // Bloc1s1 // biogenesis of lysosome-related organelles complex-1, subunit 1  1.28 1.32 
426 NM_013415 // Atp1b2 // ATPase, Na+/K+ transporting, beta 2 polypeptide // 11 B3|11 40.0 1.25 1.29 
427 NM_009976 // Cst3 // cystatin C // 2 G3|2 84.0 cM // 13010 /// ENSMUST00000028938 // Cs 1.41 1.45 
428 NM_008817 // Peg3 // paternally expressed 3 // 7 A2-B1|7 6.5 cM // 18616 /// ENSMUST000 1.23 1.24 
429 ENSMUST00000159021 // Arhgef4 // Rho guanine nucleotide exchange factor (GEF) 4 // 1 B| 1.25 1.24 
430 NM_026819 // Dhrs1 // dehydrogenase/reductase (SDR family) member 1 // 14 C3|14 22.5 cM 1.34 1.33 
431 NM_024461 // 1810037I17Rik // RIKEN cDNA 1810037I17 gene // 3 G1|3 // 67704 /// BC08691 1.29 1.28 
432 ENSMUST00000086868 // Gpam // glycerol-3-phosphate acyltransferase, mitochondrial // 19 1.64 1.63 
433 NM_008377 // Lrig1 // leucine-rich repeats and immunoglobulin-like domains 1 // 6 D2|6  1.62 1.61 
434 NM_011857 // Odz3 // odd Oz/ten-m homolog 3 (Drosophila) // 8|8 B2 // 23965 /// ENSMUST 1.23 1.21 
435 NM_007657 // Cd9 // CD9 antigen // 6 F3|6 58.0 cM // 12527 /// ENSMUST00000032492 // Cd 1.30 1.28 
436 NM_025821 // Carhsp1 // calcium regulated heat stable protein 1 // 16 A1|16 1.7 cM // 5 1.31 1.28 
437 NM_010329 // Pdpn // podoplanin // 4 E1|4 // 14726 /// ENSMUST00000030317 // Pdpn // po 1.52 1.49 
438 NM_008548 // Man1a // mannosidase 1, alpha // 10 B3|10 // 17155 /// ENSMUST00000003843  1.33 1.29 
439 NM_001146120 // Psap // prosaposin // 10 B4|10 35.0 cM // 19156 /// NM_011179 // Psap / 1.34 1.30 
440 NM_026037 // Mboat2 // membrane bound O-acyltransferase domain containing 2 // 12 A1.3| 1.25 1.21 
441 NM_008133 // Glud1 // glutamate dehydrogenase 1 // 14 B|14 15.5 cM // 14661 /// ENSMUST 1.26 1.22 
442 NR_029535 // Mir99a // microRNA 99a // 16|16 // 387229 1.48 1.44 
443 NM_028392 // Ppp2r2b // protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 5 1.27 1.23 
444 NM_027008 // Kctd5 // potassium channel tetramerisation domain containing 5 // 17 A3.3| 1.31 1.26 
 126 
445 NM_019880 // Mtch1 // mitochondrial carrier homolog 1 (C. elegans) // 17 A3.3|17 // 564 1.27 1.22 
446 NM_008410 // Itm2b // integral membrane protein 2B // 14 D3|14 32.5 cM // 16432 /// ENS 1.40 1.33 
447 NM_207237 // Man1c1 // mannosidase, alpha, class 1C, member 1 // 4 D3|4 // 230815 /// E 1.30 1.22 
448 NM_177740 // Rgma // RGM domain family, member A // 7 D1|7 // 244058 /// ENSMUST0000009 1.48 1.39 
449 NM_013872 // Pmm1 // phosphomannomutase 1 // 15 E1|15 // 29858 /// ENSMUST00000023112 / 1.31 1.21 
450 NM_018804 // Syt11 // synaptotagmin XI // 3 F1|3 42.0 cM // 229521 /// ENSMUST000001075 1.31 1.21 
451 NM_010926 // Cox4nb // COX4 neighbor // 8 E1|8 64.0 cM // 18117 /// ENSMUST00000034277  1.31 1.21 
452 NM_001008231 // Daam2 // dishevelled associated activator of morphogenesis 2 // 17 C|17 1.42 1.26 
453 NM_007514 // Slc7a2 // solute carrier family 7 (cationic amino acid transporter, y+ sys 2.02 1.86 
454 NM_001171026 // Os9 // amplifyied in osteosarcoma // 10 D3|10 // 216440 /// ENSMUST00000 1.38 1.22 
455 NM_021356 // Gab1 // growth factor receptor bound protein 2-associated protein 1 // 8 C 1.50 1.34 
456 NM_001098171 // Pcdh10 // protocadherin 10 // 3|3 C // 18526 /// NM_011043 // Pcdh10 // 1.37 1.21 
457 NM_010847 // Mxi1 // Max interacting protein 1 // 19 D|19 49.5 cM // 17859 /// NM_00100 1.62 1.43 
458 ENSMUST00000034630 // Fez1 // fasciculation and elongation protein zeta 1 (zygin I) //  1.41 1.21 
459 NM_153781 // Pygb // brain glycogen phosphorylase // 2 G3|2 84.0 cM // 110078 /// ENSMU 1.43 1.23 
460 NM_007789 // Ncan // neurocan // 8 B3.3|8 33.5 cM // 13004 /// ENSMUST00000002412 // Nc 1.57 1.38 
461 NM_001168304 // Cdk19 // cyclin-dependent kinase 19 // 10 B1|10 // 78334 /// ENSMUST000 1.46 1.25 
462 NM_008885 // Pmp22 // peripheral myelin protein 22 // 11 B3|11 34.45 cM // 18858 /// EN 1.88 1.66 
463 NM_025610 // Asrgl1 // asparaginase like 1 // 19 A|19 // 66514 /// ENSMUST00000049948 / 1.49 1.27 
464 NM_021391 // Ppp1r1a // protein phosphatase 1, regulatory (inhibitor) subunit 1A // 15| 1.50 1.21 
465 NM_010288 // Gja1 // gap junction protein, alpha 1 // 10 B4|10 29.0 cM // 14609 /// ENS 1.67 1.35 
466 ENSMUST00000169713 // Plce1 // phospholipase C, epsilon 1 // 19 D1|19 // 74055 1.68 1.32 
467 ENSMUST00000111230 // Tagln2 // transgelin 2 // 1 H3|1 94.2 cM // 21346 /// NM_178598 / 1.69 1.24 
468 NM_007901 // S1pr1 // sphingosine-1-phosphate receptor 1 // 3 G1|3 // 13609 /// ENSMUST 1.85 1.40 
469 NM_007904 // Ednrb // endothelin receptor type B // 14 E2.3|14 51.0 cM // 13618 /// ENS 1.80 1.33 
470 NM_134006 // Rdh5 // retinol dehydrogenase 5 // 10 D3|10 72.0 cM // 19682 /// ENSMUST00 1.91 1.35 
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471 NM_153098 // Cd109 // CD109 antigen // 9 E1|9 // 235505 /// ENSMUST00000093812 // Cd109 2.40 1.73 
472 NM_007705 // Cirbp // cold inducible RNA binding protein // 10 C1|10 44.0 cM // 12696 / 2.00 1.27 
473 NM_008131 // Glul // glutamate-ammonia ligase (glutamine synthetase) // 1 G2|1 // 14645 2.36 1.59 
474 NM_011271 // Rnase1 // ribonuclease, RNase A family, 1 (pancreatic) // 14 B-C1|14 18.5  3.28 1.65 
Table 2-4. Supplementary Table 2: Gene Expression increased ≥ 1.2-fold by 
Immobilized Jagged-1. 
 
Annotation Cluster 1 Enrichment Score: 2.93 Count P_Value 
UP SEQ FEATURE domain:Helix-loop-helix motif 8 4.3E-4 
INTERPRO Basic helix-loop-helix dimerisation region bHLH 8 5.4E-4 
SMART HLH 8 6.2E-4 
UP SEQ FEATURE DNA-binding region:Basic motif 9 7.1E-4 
INTERPRO Helix-loop-helix DNA-binding 7 7.5E-4 
SP PIR KEYWORDS neurogenesis 6 3.5E-2 
Table 2-5. Supplementary Table 3: Functional Annotation Cluster 1 Enriched in the 
Annotation of Genes Decreased by Immobilzed Jagged-1. 
GENE 
SYMBOL GENE NAME 
Ets1 E26 avian leukemia oncogene 1, 5' domain 
Gsx1 GS homeobox 1 
Helt Hey-like transcription factor (zebrafish) 
2410018L13Rik RIKEN cDNA 2410018L13 gene 
Zfp738 RIKEN cDNA 3830402I07 gene 
A630089N07Ri
k RIKEN cDNA A630089N07 gene 
E430018J23Rik RIKEN cDNA E430018J23 gene; RIKEN cDNA 9130019O22 gene 
Sox4 SRY-box containing gene 19; SRY-box containing gene 4 
Sp7 Sp7 transcription factor 7 
Taf1d TATA box binding protein (Tbp)-associated factor, RNA polymerase I, D; predicted gene 13487 
Ascl1 achaete-scute complex homolog 1 (Drosophila) 
Atoh8 atonal homolog 8 (Drosophila) 
Chd7 chromodomain helicase DNA binding protein 7 
Dlx1 distal-less homeobox 1 
Etv5 ets variant gene 5 
Vopp1 expressed sequence AW146242 
Hoxd12 homeo box D12 
Irf2bp2 interferon regulatory factor 2 binding protein 2 
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Table 2-6. Supplementary Table 4: GOTERM_BP_FAT regulation of transcription. 
Myt1 myelin transcription factor 1 
Myc myelocytomatosis oncogene 
Nr1d1 nuclear receptor subfamily 1, group D, member 1 
Nfxl1 nuclear transcription factor, X-box binding-like 1 
Nfyc nuclear transcription factor-Y gamma 
Olig1 oligodendrocyte transcription factor 1 
Olig2 oligodendrocyte transcription factor 2 
Phox2b paired-like homeobox 2b 
Itgb3bp predicted gene 3507; integrin beta 3 binding protein (beta3-endonexin); similar to integrin beta 3 binding protein 
Gm4983 predicted gene 4983 
Gm6907 predicted gene 6907; predicted gene 6904; predicted gene 4902; DNA segment, Chr 14, ERATO Doi 668, expressed; PHD finger protein 11 
Pus1 pseudouridine synthase 1 
Maml2 similar to Maml2 protein; mastermind like 2 (Drosophila) 
Six1 sine oculis-related homeobox 1 homolog (Drosophila) 
Six4 sine oculis-related homeobox 4 homolog (Drosophila) 
Sim1 single-minded homolog 1 (Drosophila) 
Shh sonic hedgehog 
Top2a topoisomerase (DNA) II alpha 
Tfdp2 transcription factor Dp 2 
Tle3 transducin-like enhancer of split 3, homolog of Drosophila E(spl) 
Maff v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian) 
Mycn v-myc myelocytomatosis related oncogene, neuroblastoma derived (avian) 
Zfp12 zinc finger protein 12 
Zfp451 zinc finger protein 451 
Zfp62 zinc finger protein 62 
Zfp69 zinc finger protein 69 
Zfp719 zinc finger protein 719 
GENE 
SYMBOL GENE NAME 
Ets1 E26 avian leukemia oncogene 1, 5' domain 
Gsx1 GS homeobox 1 
Helt Hey-like transcription factor (zebrafish) 
Sox4 SRY-box containing gene 19; SRY-box containing gene 4 
Sp7 Sp7 transcription factor 7 
Taf1d TATA box binding protein (Tbp)-associated factor, RNA polymerase I, D; predicted gene 13487 
Ascl1 achaete-scute complex homolog 1 (Drosophila) 
Atoh8 atonal homolog 8 (Drosophila) 
Chd7 chromodomain helicase DNA binding protein 7 
Dlx1 distal-less homeobox 1 
Etv5 ets variant gene 5 
Hoxd12 homeo box D12 
Myt1 myelin transcription factor 1 
Myc myelocytomatosis oncogene 
Nr1d1 nuclear receptor subfamily 1, group D, member 1 
Nfyc nuclear transcription factor-Y gamma 
Olig1 oligodendrocyte transcription factor 1 
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Table 2-7. Supplementary Table 5: SP PIR KEYWORDS: dna-binding. 
 
GENE 
SYMBOL GENE NAME 
Helt Hey-like transcription factor (zebrafish) 
Ascl1 achaete-scute complex homolog 1 (Drosophila) 
Atoh8 atonal homolog 8 (Drosophila) 
Myc myelocytomatosis oncogene 
Olig1 oligodendrocyte transcription factor 1 
Olig2 oligodendrocyte transcription factor 2 
Sim1 single-minded homolog 1 (Drosophila) 
Mycn v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) 






Hmgcr 3-hydroxy-3-methylglutaryl-Coenzyme A reductase 
Abca8a ATP-binding cassette, sub-family A (ABC1), member 8a 
Atp1b2 ATPase, Na+/K+ transporting, beta 2 polypeptide 
Cd109 CD109 antigen 
Cd9 CD9 antigen 
Cdcp1 CUB domain containing protein 1 
Ephb1 Eph receptor B1 
Ephb3 Eph receptor B3 
Fat3 FAT tumor suppressor homolog 3 (Drosophila) 
Naga N-acetyl galactosaminidase, alpha 
Npc1 Niemann Pick type C1 
Notch3 Notch gene homolog 3 (Drosophila) 
Rgma RGM domain family, member A 
Galnt4 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4 
Acvr1b activin A receptor, type 1B 
Adcyap1r1 adenylate cyclase activating polypeptide 1 receptor 1 
Olig2 oligodendrocyte transcription factor 2 
Phox2b paired-like homeobox 2b 
Prm2 protamine 2 
Six1 sine oculis-related homeobox 1 homolog (Drosophila) 
Six4 sine oculis-related homeobox 4 homolog (Drosophila) 
Sim1 single-minded homolog 1 (Drosophila) 
Top2a topoisomerase (DNA) II alpha 
Tfdp2 transcription factor Dp 2 
Maff v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian) 
Mycn v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) 
Zfp451 zinc finger protein 451 
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Agrn agrin 
Os9 amplified in osteosarcoma 
Aplp2 amyloid beta (A4) precursor-like protein 2 
Angpt1 angiopoietin 1 
Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 
Aqp1 aquaporin 1 
Atrn attractin 
Cdh13 cadherin 13 
Cacna1c calcium channel, voltage-dependent, L type, alpha 1C subunit 
Cpxm1 carboxypeptidase X 1 (M14 family) 
Ctsc cathepsin C 
Ctsz cathepsin Z 
Catsperb cation channel, sperm-associated, beta 
Ccr6 chemokine (C-C motif) receptor 6 
Cxcr4 chemokine (C-X-C motif) receptor 4 
Cspg5 chondroitin sulfate proteoglycan 5 
Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 
Elovl3 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3 
Ednra endothelin receptor type A 
Ednrb endothelin receptor type B 
Fjx1 four jointed box 1 (Drosophila) 
Frzb frizzled-related protein 
Fut2 fucosyltransferase 2 
Gusb glucuronidase, beta 
Grm5 glutamate receptor, metabotropic 5 
Hfe hemochromatosis 
Icosl icos ligand 
Igsf10 immunoglobulin superfamily, member 10 
Inhbb inhibin beta-B 
Itm2b integral membrane protein 2B 
Itm2c integral membrane protein 2C 
Itga7 integrin alpha 7 
Itfg3 integrin alpha FG-GAP repeat containing 3 
Itgav integrin alpha V 
Itih3 inter-alpha trypsin inhibitor, heavy chain 3 
Il1r1 interleukin 1 receptor, type I 
Il17rd interleukin 17 receptor D 
Klk1b11 kallikrein 1-related peptidase b11 
Lama5 laminin, alpha 5 
Lamb2 laminin, beta 2 
Lgi4 leucine-rich repeat LGI family, member 4 
Lrig1 leucine-rich repeats and immunoglobulin-like domains 1 
Lifr leukemia inhibitory factor receptor 
Lair1 leukocyte-associated Ig-like receptor 1 
Lcn8 lipocalin 8 
Lpl lipoprotein lipase; similar to Lipoprotein lipase precursor (LPL) 
Lrp8 low density lipoprotein receptor-related protein 8, apolipoprotein e receptor 
Man1a mannosidase 1, alpha 
Mmp1a matrix metallopeptidase 1a (interstitial collagenase) 
Ncan neurocan; similar to Neurocan 
Ntm neurotrimin 
Odz3 odd Oz/ten-m homolog 3 (Drosophila) 
Olfr15 olfactory receptor 15 
 131 
Pmp22 peripheral myelin protein 22 
Pxdn peroxidasin homolog (Drosophila) 
Pigs phosphatidylinositol glycan anchor biosynthesis, class S 
Plb1 phospholipase B1 
Pgf placental growth factor 
Pdgfrl platelet-derived growth factor receptor-like 
Plxnb1 plexin B1 
Pdpn podoplanin 
Pkd2 polycystic kidney disease 2 
Pgap1 post-GPI attachment to proteins 1 
Kcnmb4 potassium large conductance calcium-activated channel, subfamily M, beta member 4 
Plod1 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 
Psap prosaposin 
Pros1 protein S (alpha) 
Rhbdf1 rhomboid family 1 (Drosophila) 
Srl sarcalumenin 
Scarb2 scavenger receptor class B, member 2 
Sema4g sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4G 
Sema5b sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B 
Sema6d sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D 
Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N 
St6galnac1 
similar to Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 (GalNAc 
alpha-2,6-sialyltransferase I) (ST6GalNAc I) (Sialyltransferase 7A); predicted 
gene 11735; ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 1 
C4b 
similar to Complement C4 precursor; complement component 4A (Rodgers blood 
group); similar to complement C4; complement component 4B (Childo blood 
group) 
C1s similar to Complement component 1, s subcomponent; complement component 1, s subcomponent 
Mas1 similar to MAS1 oncogene; MAS1 oncogene 
Sorl1 similar to sortilin-related receptor, LDLR class A repeats-containing; sortilin-related receptor, LDLR class A repeats-containing 
Slc1a3 solute carrier family 1 (glial high affinity glutamate transporter), member 3 
Slc14a1 solute carrier family 14 (urea transporter), member 1 
Slc4a4 solute carrier family 4 (anion exchanger), member 4 
Slc44a2 solute carrier family 44, member 2 
Slc6a15 solute carrier family 6 (neurotransmitter transporter), member 15 
Slc6a11 solute carrier family 6 (neurotransmitter transporter, GABA), member 11 
Slc7a2 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 
S1pr1 sphingosine-1-phosphate receptor 1 
Spon1 spondin 1, (f-spondin) extracellular matrix protein 
Sv2a synaptic vesicle glycoprotein 2 a 
Tspan13 tetraspanin 13 
Tgfb2 transforming growth factor, beta 2 
Tmc7 transmembrane channel-like gene family 7; similar to Tmc7 protein 
Tnfsf9 tumor necrosis factor (ligand) superfamily, member 9 
Tnfrsf21 tumor necrosis factor receptor superfamily, member 21 
Ttyh1 tweety homolog 1 (Drosophila) 
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Vcam1 vascular cell adhesion molecule 1 
Wnt5b wingless-related MMTV integration site 5B 
Wnt7b wingless-related MMTV integration site 7B 
Wnt8a wingless-related MMTV integration site 8A 
Table 2-9. Supplementary Table 7: UP_SEQ_FEATURE: glycosylation site:N-
linked (GlcNAc...). 
Annotation Cluster 1 Enrichment Score: 3.99 Count P_Value 
 UP_SEQ_FEATURE glycosylation site:N-linked (GlcNAc...) 115 2.5E-7 
 SP_PIR_KEYWORDS glycoprotein 119 3.0E-7 
 UP_SEQ_FEATURE signal peptide 96 1.6E-5 
 SP_PIR_KEYWORDS signal 96 1.9E-5 
 SP_PIR_KEYWORDS disulfide bond 76 8.7E-4 
 UP_SEQ_FEATURE disulfide bond 72 1.9E-3 
 SP_PIR_KEYWORDS Secreted 44 1.3E-2 
 GOTERM_CC_FAT extracellular region 53 2.3E-2 
Annotation Cluster 2 Enrichment Score: 3.88 Count P_Value 
 GOTERM_BP_FAT calcium ion homeostasis 12 8.4E-6 
 GOTERM_BP_FAT ion homeostasis 21 9.4E-6 
 GOTERM_BP_FAT cation homeostasis 16 1.6E-5 
 GOTERM_BP_FAT di-, tri-valent inorganic cation homeostasis 14 2.3E-5 
 GOTERM_BP_FAT chemical homeostasis 23 2.4E-5 
 GOTERM_BP_FAT metal ion homeostasis 12 2.4E-5 
 GOTERM_BP_FAT cellular calcium ion homeostasis 11 3.4E-5 
 GOTERM_BP_FAT cellular metal ion homeostasis 11 7.7E-5 
 GOTERM_BP_FAT cellular di-, tri-valent inorganic cation homeostasis 12 2.0E-4 
 GOTERM_BP_FAT cellular ion homeostasis 17 2.6E-4 
 GOTERM_BP_FAT cellular chemical homeostasis 17 3.5E-4 
 GOTERM_BP_FAT cellular cation homeostasis 12 6.0E-4 
 GOTERM_BP_FAT homeostatic process 26 1.4E-3 
 GOTERM_BP_FAT cellular homeostasis 18 1.8E-3 
 GOTERM_BP_FAT cytosolic calcium ion homeostasis 4 5.2E-2 
Annotation Cluster 3 Enrichment Score: 3.4 Count P_Value 
 GOTERM_BP_FAT vasculature development 18 4.6E-5 
 GOTERM_BP_FAT blood vessel morphogenesis 15 1.4E-4 
 GOTERM_BP_FAT blood vessel development 16 3.8E-4 
 GOTERM_BP_FAT angiogenesis 9 9.9E-3 
Annotation Cluster 4 Enrichment Score: 3.01 Count P_Value 
 SP_PIR_KEYWORDS membrane 154 6.1E-5 
 UP_SEQ_FEATURE topological domain:Cytoplasmic 87 1.7E-4 
 UP_SEQ_FEATURE transmembrane region 119 1.7E-4 
 SP_PIR_KEYWORDS transmembrane 144 3.1E-4 
 UP_SEQ_FEATURE topological domain:Extracellular 66 3.0E-3 
 GOTERM_CC_FAT intrinsic to membrane 159 1.7E-2 
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 GOTERM_CC_FAT integral to membrane 152 3.1E-2 
Annotation Cluster 5 Enrichment Score: 2.79 Count P_Value 
 GOTERM_BP_FAT cell adhesion 27 3.5E-4 
 GOTERM_BP_FAT biological adhesion 27 3.6E-4 
 GOTERM_BP_FAT cell-cell adhesion 13 6.8E-3 
 SP_PIR_KEYWORDS cell adhesion 17 7.9E-3 
Annotation Cluster 6 Enrichment Score: 2.11 Count P_Value 
 INTERPRO Plexin 6 3.7E-4 
 SMART PSI 6 2.7E-3 
 INTERPRO Plexin/semaphorin/integrin 6 2.7E-3 
 SMART Sema 5 3.8E-3 
 INTERPRO Semaphorin/CD100 antigen 5 3.9E-3 
 UP_SEQ_FEATURE domain:Sema 4 2.1E-2 
 KEGG_PATHWAY Axon guidance 8 7.4E-2 
 INTERPRO WD40/YVTN repeat-like 10 2.0E-1 
Annotation Cluster 7 Enrichment Score: 2.03 Count P_Value 
 GOTERM_BP_FAT cholesterol metabolic process 8 9.2E-4 
 SP_PIR_KEYWORDS lipid synthesis 9 1.3E-3 
 GOTERM_BP_FAT cholesterol biosynthetic process 5 1.5E-3 
 GOTERM_BP_FAT sterol metabolic process 8 1.6E-3 
 GOTERM_BP_FAT lipid biosynthetic process 16 1.9E-3 
 GOTERM_BP_FAT sterol biosynthetic process 5 4.2E-3 
 SP_PIR_KEYWORDS Cholesterol biosynthesis 4 6.2E-3 
 GOTERM_BP_FAT steroid metabolic process 10 1.0E-2 
 SP_PIR_KEYWORDS sterol biosynthesis 4 1.4E-2 
 GOTERM_BP_FAT steroid biosynthetic process 6 2.1E-2 
 SP_PIR_KEYWORDS Steroid biosynthesis 4 5.3E-2 
 KEGG_PATHWAY Terpenoid backbone biosynthesis 3 5.7E-2 
 GOTERM_BP_FAT isoprenoid biosynthetic process 3 8.5E-2 
 GOTERM_BP_FAT isoprenoid metabolic process 3 3.0E-1 
Annotation Cluster 8 Enrichment Score: 1.96 Count P_Value 
 GOTERM_BP_FAT response to wounding 19 8.0E-4 
 GOTERM_BP_FAT inflammatory response 12 1.2E-2 
Table 2-10. Supplementary Table: Functional Annotation Clusters Enriched in the 
Annotation of Genes Increased by Immobilized Jagged-1. 
Gene Symbol Gene Title 
Gja1 Gap junction membrane channel protein α1(Connexin 30) 
S100b S100 protein, β polypeptide, neural 
Ppp1r3c Protein phosphatase 1, regulatory subunit 3C(PTG) 
Slc14a1 Solute carrier family 14 (urea transporter), member 1 
Slc6a11 Solute carrier family 6 (GABA transporter), member 11 (GAT4) 
Ednrb Endothelin receptor type B 
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Hes5 Hairy and enhancer of split 5 
Sox9 SRY-box containing gene 9 
Table 2-11. Supplementary Table 9: Genes Increased by Immobilized Jagged-1 in 
AstroRad-NSC also enriched in protoplasmic astrocytes in vivo according to Lovett et. 
al. (2008). Listed genes are enriched in protoplasmic astrocytes and up-regulated in 
AstroRad-NSC in response to Jagged-1. 
Gene Symbol Gene Title 
In the top 50 changes in MCAO reactive astrocytes AND up-regulated by Jagged-1 in AstroRad-NSCs 
Gfap glial fibrillary acidic protein 
Serpina3n  serine (or cysteine) peptidase inhibitor, clade A, member 3N 
Ifi202b interferon activated gene 202B 
Cxcl10 chemokine (C-X-C motif) ligand 10 
Cd109 CD109 antigen 
Other genes up-regulated in MCAO reactive astrocytes and by Jagged-1 in AstroRad-NSCs 
C1s complement component 1, s subcomponent 
Il1r1 interleukin 1 receptor, type I 
Pde1b phosphodiesterase 1B, Ca2+-calmodulin dependent 
Plce1 phospholipase C, epsilon 1 
Tagln2 transgelin 2 
Table 2-12. Supplementary Table 10: Genes Increased by Immobilized Jagged-1 in 
AstroRad-NSC also increase in MCAO reactive astrocytes in vivo according to 
Zamanian et. al. (2012). Listed are genes up-regulated in reactive astrocytes 1 day after 
MCAO and up-regulated in AstroRad-NSC in response to Jagged-1. 
Gene Symbol Gene Title 
Top2a Topoisomerase (DNA) II alpha 
Gadd45g Growth arrest and DNA-damage-inducible 45 gamma 
Ccnd1 Cyclin D1 
Myc Myelocytomatosis oncogene 
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Table 2-13. Supplementary Table 11: Genes Decreased by Immobilized Jagged-1 in 
AstroRad-NSC also increase in reactive astrocytes in vivo according to Zamanian et. al. 
(2012). Listed are genes up-regulated in astrocytes 1 day after MCAO but down-
regulated in AstroRad-NSC in response to Jagged-1. 
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CHAPTER 3. NOTCH1-STAT3-ETBR SIGNALING CONTROLS REACTIVE 
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Defining the signaling network that controls reactive astrogliosis may provide novel 
treatment targets for patients with diverse CNS injuries and pathologies. We report that 
the radial glial cell antigen RC2 identifies the majority of proliferating reactive astrocytes 
after stroke. These cells highly expressed endothelin receptor type B (ETBR) and the 
Notch1 ligand, Jagged-1. To study signaling in adult reactive astrocytes, we developed a 
new model based on Reactive astrocyte-derived Neural Stem Cells (Rad-NSCs) isolated 
from GFAP-CreERTM-Notch1 conditional knockout (cKO) mice. By loss- and gain-of-
function studies and promoter activity assays, we found that Jagged-1/Notch1 signaling 
increased ETBR expression indirectly by raising the level of phosphorylated STAT3, a 
previously unidentified EDNRB transcriptional activator. Similar to inducible transgenic 
GFAP-CreERTM-Notch1-cKO mice, GFAP-CreERTM-ETBR-cKO mice exhibited a defect 
in reactive astrocyte proliferation after cerebral ischemia. Our results indicate that the 
Notch1-STAT3-ETBR axis connects a signaling network that promotes reactive astrocyte 




Reactive astrogliosis occurs after most forms of CNS injury, including cerebral ischemia 
and trauma, but the signaling network that regulates reactive astrocyte proliferation and 
function(s) in vivo is complex and remains poorly understood. Early after CNS injury, 
reactive astrocytes perform a variety of beneficial roles, many of which relate to the 
supportive functions of mature astrocytes during the maintenance of normal tissue 
homeostasis. These activities include regulation of extracellular ion and fluid levels, pH, 
and the blood brain barrier (BBB). Responding to CNS injury, reactive astrocytes reduce 
immune cell infiltration into parenchymal tissue and provide neuroprotection through 
uptake of the main excitatory neurotransmitter, glutamate, and by secreting numerous 
growth factors, neurotrophins, cytokines, and hormones (Sofroniew, 2009; Voskuhl et al., 
2009; Shimada et al., 2011). Late after CNS injury, newly proliferated reactive astrocytes 
contribute to formation of the glial scar. The glial scar is often viewed as a negative 
consequence of CNS injury due to its ability to impede axonal re-growth. However, it 
also serves a positive, protective function and its structure and cellular composition are 
important determinants of CNS remodeling and repair. Given the fundamental roles of 
reactive astrocytes both early and late after CNS injury, delineation of the 
paracrine/autocrine signaling network that controls reactive astrogliosis in vivo may lead 
to therapeutic strategies that maintain or repair the BBB, control immune cell infiltration, 
provide neuroprotection and/or reduce or modify glial scarring. 
Astrocytes undergo dramatic changes in gene expression, morphology 
(hypertrophy), and proliferation based on the size and duration of CNS injury. The pool 
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of proliferating reactive astrocytes performs key activities that impact tissue preservation, 
repair/remodeling and functional outcome. For example, specific deletion of proliferating 
reactive astrocytes after brain injury leads to increased immune cell infiltration and 
neuronal degeneration and inability to repair the BBB. Similarly, specific astroglial 
deletion after spinal cord injury results in increased immune cell infiltration, neuronal 
death, demyelination, and motor deficit (Faulkner et al. 2004). 
In relation to their distance from cell/tissue damage, subpopulations of reactive 
astrocytes typically exhibit increased expression of several different intermediate 
filament proteins that include Glial Fibrillary Acidic Protein (GFAP) and nestin, and an 
intermediate filament-associated protein that is bound by the RC2 monoclonal antibody. 
The RC2 antigen (hereafter called RC2) is reported to be a post-translational modification 
of nestin. In cortical development, RC2 is expressed by proliferating radial glial cells, 
specialized neural stem/progenitor cells that provide scaffolding for migrating 
neuroblasts. Radial glial cell identity and function are regulated by Notch signaling. We 
have shown that Notch1 signaling regulates reactive astrocyte proliferation after cortical 
stroke (Shimada et al., 2011). 
In addition to Notch1, Signal Transducer and Activator of Transcription 3 
(STAT3) is activated during CNS injury and phosphorylated STAT3 (p-STAT3) 
transduces signals for multiple molecules secreted or released from damaged cells such as 
EGF and factors that bind the gp130 receptor (e.g. IL-6, LIF, CNTF). STAT3 is required 
for gliogenesis during CNS development and studies with Cre-loxP-based conditional 
knockout (cKO) mouse models have shown that STAT3 is also a key signaling 
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component for reactive astrogliosis. Using a non-inducible nestin-Cre-STAT3-cKO 
model, Okada et al. (2006) reported that mice with spinal cord injury had increased 
immune cell infiltration, demyelination, and severe motor deficit. GFAP-Cre-STAT3-
cKO mice with spinal cord injury had reactive astrocytes with reduced expression of 
GFAP and hypertrophy; this correlated with disrupted glial scar formation and attenuated 
motor recovery. 
Proliferation of reactive astrocytes is stimulated by many peptides and proteins 
released during CNS injury that include endothelin (ET-1), epidermal growth factor 
(EGF), and fibroblast growth factor (FGF). Notably, some factors such as ET-1, EGF, 
and IL-6 are released by reactive astrocytes themselves into the injury environment and 
act in an autocrine as well as paracrine manner. ET-1 signaling through endothelin 
receptor type B (ETBR) is reported to have mitogenic effects on both cultured primary 
astrocytes and glioblastoma cell lines. In addition, pharmacological inhibition of ETBR 
was reported to reduce reactive astrocyte proliferation in vivo after brain stab injury and 
lysolecithin-induced focal demyelination. Other factors known to trigger reactive 
astrogliosis include (but are not limited to): IL-1, IL-10, LIF, CNTF, BMP, TGF-β, TNF-
α, INF-γ, lipopolysaccharide, glutamate, adenosine triphosphate, nitric oxide, and 
reactive oxygen species. 
Although RC2 is rarely expressed in cortical tissue of healthy adults, it is re-
expressed by a subpopulation of proliferative reactive astrocytes early after brain injury. 
Here we show that RC2+ reactive astrocytes represent the majority of proliferating 
reactive astrocytes after stroke and report a sorting scheme for prospective isolation of 
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RC2+ reactive astrocytes directly from injured CNS tissue based on cell surface Jagged-1 
(Notch1 ligand). In addition to expressing Jagged-1 and Notch1, RC2-positive reactive 
astrocytes expressed high levels of ETBR. Investigating whether Notch1 signaling 
interacted with ETBR, we found that Jagged-1 increased ETBR levels in an indirect 
manner, through STAT3. Experiments with transgenic inducible GFAP-CreERTM-ETBR-
cKO mice demonstrated that ETBR was necessary for reactive astrocyte proliferation 
after stroke and the deficit observed in GFAP-CreERTM-ETBR-cKO mice closely 
resembled that of GFAP-CreERTM-Notch1-cKO mice. Our results identify ETBR as a 
transcriptional target of STAT3 and demonstrate a Notch1-STAT3-ETBR axis that 
promotes reactive astrogliosis after brain injury. 
Results 
RC2+/ETBR+ cells represent the majority of proliferating reactive astrocytes early 
after cerebral ischemia 
To better understand astroglial signaling and receptors that control reactive astrogliosis, 
we focused on the subpopulation of RC2+ reactive astrocytes that form immediately 
adjacent to the infarct core early after cerebral ischemia (Shimada et al., 2010). Studying 
the timing of reactive astrogliosis, we observed GFAP+/RC2+ reactive astrocytes in the 
peri-infarct area at 1, 3, and 14 d after stroke, but did not detect the RC2 antigen by 
immunohistochemistry at 28 d after stroke (i.e. within the glial scar when proliferation 
has subsided) (Figure 3-1). At 3 d after distal middle artery occlusion (dMCAO), the 
majority (73%) of proliferating GFAP+/Ki67+ reactive astrocytes co-expressed RC2 
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(RC2+/GFAP+/Ki67+, 1857 ± 321.0 cells/mm2; RC2-/GFAP+/Ki67+, 698.6 ± 195.0 
cells/mm2; mean ± SEM, n=3; Figure 3-2A). RC2+ reactive astrocytes stained strongly 
for ETBR, a receptor expressed at a comparatively low level in distal parenchymal 
GFAP+ cells and other cortical cell types (Figure 3-2B). Nearly all RC2+ reactive 
astrocytes in the cortical peri-infarct area expressed ETBR (99 ± 1%, n=3).  
 
Notch1 signaling regulates the number of RC2+/ETBR+ reactive astrocytes 
Tamoxifen (TM)-inducible GFAP-CreERTM mice express CreER under control of the 2.2 
kb human GFAP promoter. Using this mouse strain to target reactive astrocytes, we 
reported previously that Notch1 determines, in part, reactive astrocyte proliferation after 
stroke . To examine whether Notch1 signaling affected proliferation specifically in 
RC2+/ETBR+ reactive astrocytes, we performed dMCAO surgery on GFAP-CreERTM-
Notch1-cKO mice and performed double immunohistochemistry for RC2 and ETBR. At 
30 d after tamoxifen (TM) administration and 3 d after dMCAO, there was a significant 
reduction in the number of RC2+/ETBR+ cells in TM-treated mice compared with corn oil 
(vehicle)-treated mice (Vehicle, 5254 ± 557.5 cells/mm2; TM, 2685 ± 60.75 cells/mm2; 
mean ± SEM, n=3 mice per group, p < 0.05; Figure 3-2C). To determine if Notch 
signaling regulated proliferating RC2+/ETBR+ reactive astrocytes in other models of brain 
injury, we counted the number of RC2+ reactive astrocytes in cortical tissue 3 d after 
stereotaxic injection of dibenzazepine (DBZ), a Gamma secretase inhibitor (GSI) that 
inhibits cleavage of Notch1. In the brain stab model, we observed significantly less RC2+ 
reactive astrocytes surrounding the stab injury in DBZ-injected mice compared with 
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vehicle-injected control mice (DBZ, 602.7 ± 118.1 cells/mm2; DMSO, 1835.0 ± 209.7 
cells/mm2; mean ± SEM , n=3, p=0.01; Figure 3-8). 
To further investigate Notch1 signaling in RC2+/ETBR+ reactive astrocytes, we 
next asked whether they expressed Jagged-1, a Notch1 ligand presented on the cell 
surface that induces Notch1 signaling in adjacent cells. We isolated reactive astrocytes 
from peri-infarct tissues by magnetic-activated cell sorting (MACS) with antibodies 
against Glutamate Aspartate Transporter-1 (GLAST)(Shimada et al., 2012). At 3 d after 
stroke, FACS phenotyping of GLAST+ reactive astrocytes from cortical tissues of 
C57BL/6J mice demonstrated that cell surface Jagged-1 expression was markedly 
upregulated on cells from the ischemic ipsilateral side of the brain compared with cells 
from the contralateral side (Figure 3-3A and Figure 3-9). Depending on the absence or 
presence of injury, we observed that cortical GLAST+ cells partitioned into Jagged-1Neg 
and Jagged-1Lo cells or Jagged-1Neg, Jagged-1Lo, and Jagged-1Hi cells, respectively 
(Figure 3-3A). These results demonstrated that Jagged-1 levels could be used to segregate 
3 major subpopulations of reactive astrocytes after brain injury.  
As RC2 is a cytoskeletal protein and FACS-compatible antibodies for ETBR were 
not available, we fixed and stained cells post-sort that were allowed to adhere for 24 hr in 
culture. Notably, GLAST+/ Jagged-1Neg cells adhered initially but did not survive the 24 
hr of culture (data not shown). GLAST+/Jagged-1Lo and GLAST+/Jagged-1Hi cells 
adhered, survived, and expressed RC2, ETBR, and nestin (Figure 3-3B and data not 
shown).  
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Differential Jagged-1 expression on reactive astrocytes from the peri-infarct area 
suggested that the GLAST+ subpopulations varied in their level of Notch1 signaling. 
Based on their close proximity to the infarct core and their dependence on Notch1 
signaling, we hypothesized that proliferating RC2+/ETBR+ reactive astrocytes belonged to 
the GLAST+/Jagged-1Hi category of GLAST+ cells isolated from the peri-infarct area. To 
test this idea, we pooled live cell isolates from peri-infarct cortical tissue (n=3 animals 
per group) and employed the above MACS/FACS strategy to assay GLAST+/Jagged-1+ 
cells from GFAP-CreERTM-Notch1-cKO mice. Compared with control (vehicle)-treated 
GFAP-CreERTM-Notch1-cKO mice, we observed ablation of the GLAST+/Jagged-1Hi cell 
population in TM-treated GFAP-CreERTM-CreERTM-Notch1-cKO mice (Figure 3-3C). 
Injured (ipsilateral) cortex from C57BL/6J mice and GFAP-CreERTM-Notch1-cKO 
vehicle treated mice, which should be ostensibly normal, displayed similar percentages of 
GLAST+/Jagged-1Hi cells (C57BL/6J: 6.89%; GFAP-CreERTM-Notch1-cKO [vehicle]: 
8.37%; Figure 3-9). These results suggested that Jagged-1/Notch1 signaling could occur 
between adjacent astrocytes in the peri-infarct area to promote astroglial proliferation and 
that Jagged-1/Notch1 signaling might interact with ETBR-based signaling in RC2+/ETBR+ 
reactive astrocytes. 
Immobilized Jagged-1 induces ETBR and promotes proliferation in adult reactive 
astrocytes 
Although there is a conventional method to isolate and culture astrocytes from neonatal 
mice, primary adult cortical reactive astrocytes survive poorly in culture. We recently 
reported the isolation and expansion of self-renewing, multi-potent Rad-NSCs derived 
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from the cortical peri-infarct area after stroke. To avoid possible differences between 
neonatal and adult astrocytes, we sought to develop a method to study signaling in adult 
astrocytes based on re-differentiated Reactive astrocyte-derived Neural Stem Cells (Rad-
NSCs). After re-differentiation of Rad-NSCs in medium containing 10% FCS for 7 d, we 
obtained cultures that were 80% GFAP+ /Tuj1- astrocytes (GFAP+, 82 ± 5.3%; Tuj1+, 7± 
2.2%, SEM, Figure 3-4A). For clarity, we hereafter refer to the Rad-NSC-derived 
astrocytes as AstroRad-NSC. When maintained in serum-containing medium, most AstroRad-
NSC expressed nestin and a few expressed RC2 (Figure 3-1); this suggested that AstroRad-
NSC might be used to model reactive astrocyte signaling after brain injury. Jagged-
1/Notch1 signaling requires mechanical tension between cell surface Jagged-1 and 
Notch1 that are presented on the membranes of adjacent cells. Accordingly, to promote 
Jagged-1/Notch1 signaling, we plated AstroRad-NSC onto immobilized Jagged-1. After 48 
hr, immobilized Jagged-1 dramatically increased the number of RC2+/Ki67+ reactive 
astrocytes (Figure 3-4C). To test whether exposure to Jagged-1 could alter expression of 
ETBR, we plated AstroRad-NSCand post-natal day 2 (PND 2) astrocytes onto immobilized 
Jagged-1. Exposure to immobilized Jagged-1 markedly increased the level of ETBR for 
both AstroRad-NSC (Figure 3-4D) and PND 2 astrocytes (Figure 3-4E). 
Regulation of EDNRB promoter activity 
To investigate whether Notch Intracellular Domain 1 (NICD1)-mediated signaling might 
directly influence ETBR levels through enhanced transcription of EDNRB (EDNRB = 
gene for ETBR), we analyzed the DNA sequence in the EDNRB promoter. By promoter 
mapping, we did not find CSL sequences within 10 kB of the ETBR coding sequence, 
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indicating that the EDNRB promoter may not be directly regulated by NICD1. In 
contrast, we located multiple consensus sequences for STAT3 in both the human and 
murine EDNRB promoter that satisfied the TTM(N)3DAA (D: A, G, or T; M: A or C; N: 
A, G, T or C) motif  or the TTC(N)4GAA motif  (Figure 3-5A, Table 3-1). To test for 
transcriptional regulation by STAT3, a pGL4 luciferase reporter vector containing human 
EDNRB promoter sequence was transfected into HEK 293 cells (-3022 bp to +160 bp; 
Figure 3-5A’). We found that incubation of 293 cells in IL-6 or LIF, cytokines that bind 
gp130 and signal through STAT3, led to a significant increase in EDNRB promoter 
activity (ANOVA, F=8.51, n=3, p=0.0002; Figure 3-5). Notably, this effect also occurred 
after exposure of cells to EGF, which signals through EGFR/JAK2/STAT3, but not via 
gp130/JAK2/STAT3 (Figure 3-5). Next, we incubated the 293 cells in IL-6, LIF, or EGF 
with the addition of “STATTIC”, a STAT3-specific pharmacological inhibitor that 
destabilizes phosphorylated STAT3 (p-STAT3) and prevents STAT3-mediated effects. 
We observed (in all cases) that STATTIC attenuated the induction of EDNRB promoter 
activity expected to occur after cytokine/growth factor incubation (Figure 3-5B, left). In 
some cases, a decrease in cell number due to inhibitor toxicity may appear to represent a 
reduction in promoter activity. To control for this possibility, we assayed cell viability on 
replicate plates under similar conditions of cytokine treatment and STATTIC. By assay 
of cellular metabolism (MTS), treatment of 293 cells with STATTIC was minimally 
cytotoxic (Figure 3-5B, right).  
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EDNRB promoter activity is enhanced by coincident NICD1/p-STAT3 signaling  
HES1 and HES5, transcription factors acting downstream of Notch1 signaling, were 
shown to stabilize JAK2 and STAT3 complex formation and increase the level of p-
STAT3 during glial development. Furthermore, Kamakura et al. (2004) showed that 
STAT3 activity was critical for Notch-induced differentiation of embryonic radial glial 
cells and astrocytes. To examine whether Notch1 signaling altered EDNRB transcription 
by enhancing STAT3 activity, we next performed co-transfections of NICD1 expression 
vector with the pGL4-EDNRB promoter/Luc reporter. Acknowledging that experiments 
in 293 cells (embryonic kidney) could differ from glial cell responses, we examined U87 
human glioma cells. By immunoblotting, U87 cells expressed low but detectable levels of 
ETBR relative to AstroRad-NSC (Figure 3-5C). U87 cells transfected with pGL4-EDNRB 
promoter/Luc reporter and incubated in EGF exhibited EDNRB promoter activity that 
was enhanced by co-transfection with NICD1 expression plasmid (ANOVA, F=14.71 
,n=3, p = 0.0001; Figure 3-5D). Furthermore, the action of EGF and EGF/NICD1 on 
EDNRB promoter activity in U87 cells was attenuated in the presence of STATTIC 
(Figure 3-5D). These data indicated that Notch1 signaling (NICD1) could enhance 
STAT3 activity, perhaps by stabilizing p-STAT3 in the manner shown by Kamakura et 
al. (2004). 
Notch1 signaling stabilizes/increases p-STAT levels in adult reactive astrocytes 
To examine whether increased phosphorylation of STAT3 (p-STAT3) in adult reactive 
astrocytes could induce ETBR expression, we incubated AstroRad-NSC in medium 
supplemented with IL-6. As expected, exposure of adult reactive astrocytes to IL-6 
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increased the level of p-STAT3 and also GFAP, a protein regulated at the transcriptional 
level by STAT3 (Figure 3-6A). Importantly, we also observed an increase in ETBR levels 
following IL-6 exposure (Figure 3-6A). To determine whether Notch1 stabilized STAT3 
signaling or promoted STAT3 activation, we performed a loss-of-function experiment by 
treating AstroRad-NSC from GFAP-CreERTM-Notch1-cKO mice with 4-OH-TM (hereafter 
OHTM) to remove Notch1 and blotted for p-STAT3. To test a different factor known to 
stimulate gp130 and JAK2/STAT3 signaling, we first incubated both treated and control 
cells with Leukemia Inhibitory Factor (LIF). In the presence of LIF, we observed reduced 
NICD1 and p-STAT3 levels after 5-8 d of OHTM treatment compared with vehicle 
control (Figure 3-6B). 
Jagged-1/Notch1 signaling controls the level of ETBR. 
To test for effects of Notch signaling on ETBR, we exposed AstroRad-NSC to GSI. By real-
time quantitative reverse-transcriptase polymerase chain reaction (real-time qRT-PCR) 
assays, incubation of reactive astrocytes in DBZ significantly reduced EDNRB 
transcription (Figure 3-6 6C). Furthermore, separate treatment of AstroRad-NSC using two 
different GSI (DAPT and L-685,485) resulted in reduced levels of ETBR (Figure 3-6D). 
To more specifically evaluate the effects of Notch1 signaling on ETBR in adult reactive 
astrocytes, we produced AstroRad-NSC using clonal Rad-NSCs isolated from the peri-
infarct areas of GFAP-CreERTM-Notch1-cKO mice (Shimada et al., 2012). By gene 
expression assays, treatment of GFAP-CreERTM-Notch1-cKO reactive astrocytes with 
OHTM reduced mRNA for ETBR and GFAP; this was coincident with reduced transcript 
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levels for NICD1 (Figure 3-6E). Furthermore, OHTM treatment of GFAP-CreERTM-
Notch1-cKO reactive astrocytes also reduced ETBR protein expression (Figure 3-6F). 
ETBR controls reactive astrocyte proliferation in vivo after stroke 
To examine the specific role of ETBR in the proliferation and/or function of reactive 
astrocytes, we generated GFAP-CreERTM-ETBR-cKO mice (Figure 3-10). To examine 
whether ETBR cKO affected the reactive astrocyte population, we obtained stereological 
counts within the peri-infarct area for the number of GFAP+/ETBR+ cells 30 d after TM 
administration and 3 d after dMCAO. The number of GFAP+/ETBR+ cells was 
significantly decreased in TM-treated GFAP-CreERTM-ETBR-cKO mice compared with 
vehicle-treated control mice (Vehicle: 6703 ± 447.5 cells/mm2, TM: 4233 ± 460.4 
cells/mm2, mean ± SEM, n=3 mice per group, p = 0.018; Figure 3-7A). Of interest, for 
RC2-negative/GFAP+ cells, we found no difference in cell number between TM- and 
vehicle-treated GFAP-CreERTM-ETBR-cKO mice (Vehicle: 1552 ± 176.1 cells/mm2, TM: 
1743 ± 410.4 cells/mm2, mean ± SEM, n=5 mice per group p < 0.05; Figure 3-7B). 
However, for RC2-positive/GFAP+ cells, TM-treatment led to significantly reduced cell 
numbers relative to vehicle-treated controls (Vehicle: 3318 ± 372.6 cells/mm2, TM: 1335 
± 353.0 cells/mm2, mean ± SEM, n=5 mice per group, p=0.01; Figure 3-7B).  
Astroglial-specific deletion of ETBR prior to injury decreased the amount of 
proliferating Ki67+/GFAP+ reactive astrocytes at 30 d after TM administration and 3 d 
after injury (Vehicle: 2504 ± 288.9 cells/mm2, TM: 829.9 ± 111.7 cells/mm2, mean ± 
SEM, n=5 mice per group, p < 0.01; Figure 3-7D and E). By triple 
immunohistochemistry, we observed a significant decrease in RC2-
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positive/Ki67+/GFAP+ reactive astrocytes in GFAP-CreERTM-ETBR-cKO mice at 3 d 
after dMCAO (Vehicle: 1896 ± 193.4 cell/mm2, TM: 388.2 ± 115.8 cell/mm2, mean ± 
SEM, n=5 mice per group, p < 0.01; Figure 3-7D). However, loss of ETBR did not affect 
the number of RC2-negative/Ki67+/GFAP+ reactive astrocytes, highlighting the 
importance of ETBR-based signaling for RC2+ reactive astrocytes localized in close 
proximity to the site of cortical injury (Vehicle: 607.1 ± 125.4 cells/mm2, Tm: 441.7 ± 
79.60 cells/mm2, mean ± SEM, n=5 mice per group, p < 0.05; Figure 3-7D). In terms of 
reactive astrocyte proliferation in the peri-infarct area, the results in GFAP-CreERTM-
ETBR-cKO mice phenocopied those observed for GFAP-CreERTM-Notch1-cKO after 
stroke. 
Discussion 
Here we demonstrated a novel Notch1-STAT3-ETBR signaling axis that controls reactive 
astrocyte proliferation after brain injury. Importantly, our findings with STAT3 and 
ETBR suggest that Jagged-1/Notch1 signaling may amplify the transcription of myriad 
STAT3 targets after CNS injury.  
During reactive astrogliosis, gene transcription is upregulated to generate proteins 
involved with reactive astrocyte formation and function(s) (Hamby et al., 2012; 
Zamanian et al., 2012). For some proteins such as GFAP, CNS injury promotes signaling 
through Notch1, EGFR and/or gp130 that drives gene transcription via both canonical 
Notch (CSL) binding promoter elements and STAT3 binding cis-elements (Ge et al., 
2002). Notably, we did not find CSL elements in the EDNRB promoter. Instead, we 
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found that Jagged-11/Notch1 signaling in reactive astrocytes acted indirectly to promote 
ETBR expression by increasing the level of p-STAT3.  
Gene and protein expression patterns can be unique to populations of reactive 
astrocytes that form in response to different types of CNS injury (Egnaczyk et al., 2003; 
Hamby et al., 2012; Zamanian et al., 2012). However, the primary signaling networks 
that control reactive astrogliosis may be common to many forms of CNS injury. For 
example, most brain injuries result in local release of ET-1 and ETBR-mediated signaling 
as well as secretion of growth factors/cytokines with signals transduced by STAT3 
(Koyama and Michinaga, 2012). ET-1 was recently shown to promote Jagged-1 
expression in cultured astrocytes and also to alter Notch signaling in vivo during the first 
week after a demyelinating injury (Hammond et al., 2014). When combined with those of 
Hammond et al. (2012), our observations support an interesting model for reactive 
astrogliosis. Hypothetically, with CNS injury and release of ET-1 from endothelial cells, 
astrocytes, and other cell types, increased Jagged-1 and Jagged-1/Notch1 signaling would 
increase the level of p-STAT3, EDNRB transcription and cell surface ETBR in adjacent 
astrocytes. In the case of stroke, where the ischemic penumbra expands deeper into 
cortical and striatal tissues during the days following the initial occlusive event, a 
paracrine/autocrine system that increases ETBR levels ahead of and prior to ligand 
exposure may serve to enhance tissue preservation by propagating astroglial proliferation 
and inductive signaling several cell layers in front of the expanding zone of 
necrosis/apoptosis. 
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With a series of complementary approaches, we identified a simple cell surface epitope 
profile (GLAST+/Jagged-1+) for prospective isolation of 3 different reactive astrocyte 
subpopulations directly from cortical peri-infarct tissue after stroke. Of special interest, 
GLAST+/Jagged-1Hi cells corresponded to the subset of proliferative RC2+/nestin+/ETBR+ 
reactive astrocytes lying immediately adjacent to the infarct core; these cells required 
both Notch1 and ETBR for proliferation and/or survival. Notch signaling stabilizes 
phosphorylated STAT3 in both healthy somatic cells and transformed cells (Kamakura et 
al., 2004; Lee et al., 2009). Blockade of Notch signaling with GSIs was reported to 
reduce the growth of tumor “neurospheres” and stem-like glioblastoma cells in 
xenografts and to prolong host survival (Fan et al., 2010). Autocrine signaling through 
ETBR is critical for self-renewal and survival of glioblastoma stem cells (tumor initiating 
cells) (Liu et al., 2011) and pharmacological antagonists of ETBR were shown to decrease 
proliferation and survival of glioma cells and oligodendroglioma cells (Paolillo et al., 
2010; Wan et al., 2014). Our data from adult reactive astrocytes, neonatal astrocytes, and 
U87 glioma cells provides evidence that paracrine/autocrine signaling through 
Notch1/STAT3/ETBR may be operative in a wide variety of proliferating cell populations 
that arise after tissue injury or following cellular transformation. Mechanistic 
understanding of the signaling network(s) that regulate cell proliferation after injury may 






All animal work was approved by the University of Vermont College of Medicine’s 
Office of Animal Care in accordance with the American Association for Accreditation of 
Laboratory Animal Care and National Institutes of Health guidelines. Adult male 
C57BL/6J mice (6–8 wks of age) were obtained from Taconic Farms. We obtained 
GFAP-CreERTM mice from Dr. Suzanne Baker (St. Jude Children’s Research Hospital, 
Memphis, TN) (Chow et al., 2008). Notch1tm2Rko/GridJ mice (Notch1-flox mice, 
Cat#006951) and B6;129-Ednrbtm1Nat/J (EDNRB-flox mice, Cat#011080) were from 
JAX.  Genotyping was performed with the REDExtract-N-Amp Tissue PCR Kit (XNAT-
1KT; Sigma). We used the following primers: Notch1, forward-5’-
TGCCCTTTCCTTAAAAGTGG-3’, reverse-5’-GCCTACTCCGACACCCAA TA-3’; 
EDNRB, forward-5’-AGGAGACTGAATGCAGACCAGC, reverse-5’-CATGTTACA 
GCTTGCTC CTGTG; GFAP-CreERTM, forward-5’-AGCGATCGCTGCCAGGAT-3’, 
reverse-5’-ACCAGCGTTTTCG TTCTGCC-3’.  
dMCAO surgery  
Mice were anesthetized with isoflurane (1–5%; Webster Veterinary) and body 
temperature was maintained with a heated pad. Focal cerebral ischemia was produced by 
permanently occluding the middle cerebral artery (MCA) (Shimada et al., 2010; Bakondi 
et al., 2011; Shimada et al., 2012). Under low-power magnification, the left temporo-
parietal region of the head was shaved, and an incision was made between the left orbit 
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and the left ear in the shape of a “U.” An incision was made superiorly on the upper 
margin of the temporal muscle forward. The MCA was observed through the 
semitranslucent skull. A small burr hole (1–2 mm) was drilled into the outer surface of 
the skull just over the MCA. The inner layer of skull was removed with fine forceps. The 
MCA was then encircled with 10–0 monofilament nylon suture (7V33; S & T), ligated, 
and transected superior to the ligation point. The small flap of temporo-parietal skin 
covering the skull was closed with Vetbond (3M Animal Care). For conditional knockout 
mouse studies, animals received 0.1 mg/g of tamoxifen (TM; T5648; Sigma) dissolved in 
9:1 corn oil:absolute ethanol (vehicle) or vehicle alone by intraperitoneal injection for 3 
consecutive days from d 0 to 3, followed by a 7 d or 20 d washout period, then subjected 
to dMCAO. Mice were euthanized at various time points after dMCAO. Brain tissue was 
then either processed for immunohistochemistry or cell isolation (see below).   
Immunohistochemistry 
Mice subjected to dMCAO were perfused with PBS and 4% paraformaldehyde (PFA), 
fixed in 4% PFA overnight at 4°C, and then incubated in 30% sucrose for 2 d at 4°C. 
Brain tissue was placed in OCT compound and cut into 30 µm frozen sections on a 
cryostat (Leica). Frozen sections were dried for 30 min at 37°C, and incubated in PBS for 
15 min. Sections were then blocked in blocking buffer (5% normal goat serum, 0.5% 
Triton X-100 in PBS) for 1 h at room temperature. Sections were incubated in the 
following primary antibodies overnight at 4°C: ETBR (1:150, SAB2700741; Sigma), 
GFAP (rabbit) (1:1000, Z0334; DAKO), GFAP (mouse) (1:250, G3893; Sigma), or RC2 
(1:50, University of Iowa Hybridoma Bank). Staining for Ki67 (1:500, Sp6 clone, 
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ab16667; Abcam) was performed at room temperature overnight.  After 3 PBS washes, 
sections were incubated in secondary antisera (Alexa Fluor 488 or Alexa Fluor 594, 
1:1000; Invitrogen) for 1 h at room temperature. Cell nuclei were stained with DAPI 
(Vector Laboratories). Isotype stains for rabbit IgG, mouse IgG, and mouse IgM (each at 
2 µg /ml) were used as negative controls for immunohistochemical stains as in Shimada 
et al. (2010). Photomicrographs were obtained with a confocal microscope (Zeiss LSM 
510 META; Zeiss Microimaging) or an epi-fluorescence deconvolution microscope with 
an automated x,y,z stage (Leica DM6000B; Leica) and Leica FW4000 software. 
Immunocytochemistry 
Cells were fixed with 4% PFA at 4°C for 10 min, rinsed several times with PBS, and 
blocked in blocking buffer (5% normal goat serum, 0.1% Triton X-100 in PBS) for 30 
min. Primary antibodies were incubated at 4°C overnight or 1 hr at RT: β-tubulin III 
(1:500, PRB-435P, Tuj1; Covance), ETBR (1:400, SAB2700741; Sigma), GFAP (rabbit) 
(1:1000, Z0334; DAKO), GFAP (Mus) (1:500, G3893; Sigma), or RC2 (1:150, 
University of Iowa Hybridoma Bank).  
Cell counts 
 Infarct area was defined by tissue autofluorescence, whereas the peri-infarct area was 
defined by the presence of RC2+ or GFAP+ reactive astrocytes. This area typically 
extends 200 µm radially from the infarct core.  One out of every ten sections was 
quantified for each animal.  All cell counts were performed with observers blinded to 
slide (sample) identity.  Cell numbers were assessed using stereology and 
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StereoInvestigator software (MBF Biosciences, Williston, VT).  The Fractionator Probe 
method was used in the cortical peri-infarct area. Under low magnification (100X), the 
area of interest was identified and the boundary contour was drawn using the software-
pointing device.  Spacing between sampling sites (grid size) was set such that 12-24 
sampling sites were counted per section. Cells were then counted at high magnification 
(400X). For RC2+ and GFAP+ cell quantification, cell identity was ascertained by DAPI 
localization. We defined the outer peri-infarct area as the cortical tissue that covered from 
200 to 400 µm radially from of the infarct core. All data were expressed as means and 
standard error means (SEM). StereoInvestigator was used in conjunction with a Nikon 
Optiphot 2 microscope, a Hitachi HVC20 camera, a Heidenhahn focus encoder, and a 
motorized, computer-driven X–Z stage (all microscope attachments provided by MBF 
Biosciences).    
Isolation and culture of Rad-NSCs 
For isolation of Rad-NSCs, brains were removed 3 d after dMCAO, placed into a 
polyacrylic brain block (Acrylic Matrices, RBMA-200C; World Precision Instruments), 
and cut coronally into 1 mm sections. The sections were transferred into alpha-MEM 
(Invitrogen) in 6-well plates. The cortical peri-infarct area was dissected under a light 
microscope. Tissues from the anterior lateral ventricle, posterior lateral ventricle, 
hippocampal arch, dentate gyrus, white matter, and third ventricle were carefully 
excluded. The tissues containing the peri-infarct area were harvested, diced into ~1 mm3 
pieces, and digested in enzyme digestion solution containing 200 U papain 
(Worthington), 20 ug/ml DNase (Worthington), 1.5 mM EDTA (Fisher Scientific), 1.5 
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mM CaCl2 (Sigma), 2 mg L-cysteine (Sigma), and DMEM/F12 media (Lonza), at 37°C 
for 20 min. Following enzymatic digestion, the tissues were triturated two times in 
trituration solution: 5 ml DMEM/F12 medium containing 15 mg trypsin inhibitor 
(Invitrogen) and 15 mg bovine serum albumin (BSA; Fisher Scientific). Cells were 
resuspended in DMEM/F12 medium containing 0.9 M sucrose and centrifuged to remove 
myelin (300 × g for 10 min). Cells were grown at a low density (10,000 cells/ml) in NSC 
growth medium containing 10 ng/ml Epidermal Growth Factor (EGF; BD Biosciences), 
20 ng/ml basic Fibroblast Growth Factor (bFGF; recombinant human bFGF produced in 
our laboratory), 1× B27 supplement (Invitrogen), 2 mM L-glutamine (Mediatech), and 
100 U/ml penicillin/100 ug/ml streptomycin, in NeurobasalA (Invitrogen) in 12-well 
plates (Nunc Thermo Fisher Scientific).  To generate clonal spheres, individual small 
spheres (10–100 cells) were pipetted under microscopy into separate 24-well plates 1 wk 
after plating. Clonally-isolated neurospheres were expanded and passaged in NSC growth 
medium for further studies.  
Isolation of postnatal day 2 (PND2) astrocytes 
Primary astroglial cultures were prepared from C57BL/6J mice (PND 0-3) as described 
previously (Shimada et al., 2011). 
Isolation of reactive astrocytes or Rad-NSCs by Magnetic Activated Cells Sorting 
To isolate GLAST+  cells from peri-infarct ipsilateral cortical tissue and contralateral 
cortical tissue after dMCAO, we dissected and dissociated tissue to obtain a single-cell 
suspension (as above). Cell suspensions were blocked for 20 min at 4°C with anti-mouse 
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FCR to prevent non-specific binding of mouse antibodies to FCR+ cells (130-092-575; 
Miltenyi Biotec). We then performed Magnetic-Activated Cell Sorting (MACS) using 
antibody to GLAST according to the manufacturer’s instructions (130–095-822; Miltenyi 
Biotec). Positive fractions from MACS isolates were lysed for immunoblotting, subject to 
Fluorescence Activated Cell Sorting (FACS) or cultured in NSC medium to obtain Rad-
NSCs. 
Fluorescence Activated Cell Sorting of GLAST+ Cells after isolation by MACS 
 GLAST+ cells from ipsi- and contralateral cortex (1 × 106 cells/ml) were incubated in 2 
µg/ml of anti-CD339 (Jagged-1) conjugated to phycoerythrin (clone HMJ1-29, NBP2-
00234; NovusBio) or a matching isotype control (2 µg/ml, NB120-18474PE; NovusBio) 
for 30 min at 4°C in DMEM containing 0.5% bovine serum albumin and 2 mM EDTA. 
Cells were washed 3 times with PBS and resuspended in PBS for FACS. FACS was 
performed with a BD FACSAria cell sorter equipped with a 488 nm (blue) Coherent 
Sapphire laser. Forward scatter and side scatter gates were chosen to exclude debris, 
doublets and cell aggregates. The remaining events were sorted based on 3 gates: Jagged 
1Neg, Jagged 1Lo, and Jagged 1Hi. In some cases, cells were sorted into Complete Culture 
Medium (10% CCM) consisting of 1× Alpha-Minimum Essential Medium (Corning 
Cellgro) supplemented with 10% Fetal Bovine Serum (FBS), 2 mM L-glutamine 
(Corning Cellgro), and 100 U/ml penicillin/100 ug/ml streptomycin (Mediatech). Isolated 
cells were plated into 10% CCM at 1.66 × 105 cells/cm2 into wells containing 12 mm 
glass coverslips; these were previously coated with mouse laminin and poly-D lysine (5 




Total protein was extracted from cells with a RIPA cell lysis buffer containing: 1.0% 
Triton-X 100, 0.1% SDS, 0.5% Deoxycholate, 50 mM Tris HCL, 150 mM NaCl, 5 mM 
EDTA, 1× Protease inhibitor Cocktail (Roche), and 1× phosphatase inhibitor Cocktail 
(Sigma) when required. Protein concentrations were determined with a Bio-Rad DC 
Protein Assay (Bio Rad). Protein preparations were separated by SDS-PAGE and 
transferred to immobilon-P membrane (PVDF; Millipore). The membrane was blocked 
with 5% w/v dry milk/1× PBS and then incubated with primary antibody diluted in 
blocking buffer overnight at 4°C or at room temperature for anti-GAPDH. After washes, 
the membrane was incubated with a horseradish peroxidase-conjugated secondary 
antibody for 1 h at room temperature. The blot was visualized with Western Lightning 
Plus-ECL (NEL103001EA; Pierce), and exposed to Kodak x-ray film. Equivalence of 
protein loading was verified by probing for GAPDH. We used the following primary 
antibodies: GFAP (1:2000, Z0334; DAKO), GFAP (1:1000, G3893; Sigma), cleaved 
NICD1 (1:1000; AB8925; Abcam), ETRB (1:500, SAB2700741; Sigma), GAPDH 
(1:2500, MAB374; Millipore), and GAPDH (1:2500, G9545; Sigma). Films were 
scanned at 600 dpi for densitometry (ImageJ software).   
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Ex Vivo differentiation of astrocytes from Rad-NSCs 
 Rad-NSCs were expanded in NSC medium as neurospheres and dissociated with trypsin-
EDTA. Dissociated cells were plated in 10% CCM at a density of 5.5 × 105 cells/cm2 into 
100 mm2 dishes (NUNC) previously coated with laminin/poly-D-lysine (5ug/ml each, 
BD Biosciences). Under the above conditions, the plated cells differentiated for 7 d with 
medium changes every 2 d.  
Experiments with Rad-NSCs 
For conditional knockout of Notch1 in reactive astrocytes that were re-differentiated from 
Rad-NSCs of GFAP-CreERTM-Notch1-cKO mice, 10% CCM was removed and replaced 
with 10% CCM containing 1 uM 4-OH-TM (Sigma) or ethanol (vehicle control). This 
treatment was refreshed every 2 d for 5-8 days. For experiments with Gamma-secretase 
inhibitors (GSI), cells were treated with (5S)-(tert-Butoxycarbonylamino)-6-phenyl-(4R)-
hydroxy-(2R)-benzylhexanoyl)-L-leucy-L-phenylalaninamide (L-685,458, L1790; 
Sigma), N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT, 
D5942; Sigma), Dibenzazepine (DBZ, 565789; Millipore) or dimethylsulfoxide (DMSO; 
vehicle) for 2 d. For cytokine stimulation, astrocytes re-differentiated from Rad-NSCs 
were treated with Interleukin-6 (IL-6, 50 ng/ml, I1395; Sigma), Epidermal growth factor 
(EGF, 20 ng/ml, 354052; BD bioscience), or Leukemia Inhibitory Factor (LIF, 20 ng/ml, 




NICD1 coding sequence was removed from pCLEN (Addgene plasmid: 17704) and 
cloned into lentiviral vector pWPT-GFP (Addgene plasmid: 12255). For improved 
efficiency we generated a translational fusion between NICD1 and GFP using a viral F2A 
self-cleaving peptide (Carey et al., 2009). By PCR-based cloning we placed an F2A 
sequence between the NICD1 3’-end coding sequence and the 5’-end GFP coding 
sequence in such a way that bicistronic mRNA was translated into single polypeptide 
chain. The single chain undergoes self-cleavage into functional NICD1 and GFP proteins 
directly following translation. The human EDNRB promoter sequence including the 
region from -3022 to +160 relative to the transcriptional start was subcloned into Kpn1 
and Xho1 sites of vector pGL4.20[luc2/Puro] (Promega) to allow for selection of 
puromycin-resistant cells. 
Luciferase promoter assays  
Human embryonic kidney 293 cells were grown in 10% CCM to 70% confluence and 
transfected with the pGL4:hEDNRB promoter construct in 2% CCM with Lipofectamine 
3000 (Life technologies). The vector pWPT-GFP (cat# 12255, Addgene) was co-
transfected as an indicator of transfection efficiency. At 24 hr after transfection, more 
than 75% of cells expressed GFP (data not shown). After 24 hr the cells were seeded into 
96-well plates at a density of 10,000 cells/well and allowed to recover another 24 hr. At 
45 hr post-transfection, 2% CCM was replaced with 2% CCM containing various 
cytokines (e.g. IL-6, LIF, EGF). The plate was then allowed to incubate for a further 3 hr 
before luciferase activity was assessed by adding ONE-Glo reagent (Cat# E6110, 
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Promega). Luminescence was measured with an appropriately configured Synergy HT 
Multimode Microplate reader (BioTek Instruments, Inc.; Winooski, VT). 
MTS assay 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit was used as per the 
manufacturer’s instructions (Promega). Relative absorbance at λ = 490nm was quantified 
with a Synergy HT fluorescence plate reader. 
Real-time Quantitative Reverse-transcriptase Polymerase Chain Reaction 
 RNA was extracted from cells using a HighPure RNA Isolation kit (Roche, Cat: 
11828665001). After first-strand cDNA synthesis with the SuperScript® III RT-PCR 
System (Life Technologies), relative quantification real-time PCR was performed as 
described by Tharp et al., (2012) with minor modifications. Several TaqMan (Life 
Technologies) gene expression kits and assays for mouse were employed: Notch1-FAM, 
Mm00435249_m1; GFAP-FAM, Mm01253033_m1; EDNRB-FAM, Mm00432989_m1, 
GAPDH-VIC, Mm99999915_g1). The cDNA input template was diluted 1:12 and 
GAPDH-VIC probe was added to each well as an internal control. All samples were run 
in triplicate. Real-time qRT-PCR was performed on an Applied Biosystems 7300 Real-
Time PCR System with standard settings (Applied Biosystems Inc, Foster City, CA). 
Gene expression was normalized to internal GAPDH controls and fold change was 
calculated using the 2(-Delta Delta C[T]) method (Livak and Schmittgen, 2001).  
Statistical analysis  
Statistical analyses were performed with GraphPad Prism software (version 6.0e). 
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Individual groups were compared by Student’s t-test (unpaired). Multiple comparisons 
were made by analysis of variance (ANOVA) with Bonferroni post-hoc testing. P values 
of less than 0.05 were considered significant.  
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Figures and Tables 
 
 
Figure 3-1. RC2+ reactive astrocytes appear within 1 day after focal ischemic 
cortical injury but are undetectable 30 days later. 
A, A’) RC2+ reactive astrocytes (green) at 1 d after dMCAO. Arrows: RC2+ reactive 
astrocytes that co-express GFAP (red). Note “bushy” astrocyte morphology. B, B’) RC2+ 
reactive astrocytes have acquired a hypertrophic, stellate morphology by 3 d after 
dMCAO. C,C’) At 14 days following injury, GFAP+ reactive astrocytes that express RC2 












































infarct core (dotted line). D, D’) At 30 days after injury, RC2 expression is undetectable 
in the GFAP+ reactive astrocytes that compose the glial scar. Scale bars (A, B, C, D)= 
100 µm. Scale bars (A’, B’, C’, D’) = 50 µm. 
 
Figure 3-2. RC2 marks Notch1-dependent reactive astrocytes that proliferate after 
injury and express high levels of ETBR. 
A) At 3 d after dMCAO, the majority of GFAP+/Ki67+ reactive astrocytes surrounding 
























































Ki67 and GFAP, but not RC2 (white arrowhead). B) RC2+ astrocytes expressed high 
levels of ETBR (white arrows) relative to distal astrocytes and other cell types. C) 
Conditional deletion of astroglial Notch1 in GFAP-CreERTM-Notch1-cKO mice 
significantly decreased the number of RC2+/ETBR+ astrocytes in the peri-infarct area 3 d 
after dMCAO. *p < 0.05, n = 3. Scale bars, 50 µm. 
 
Figure 3-3. Cell surface Jagged-1 levels identify distinct subpopulations of GLAST+ 
reactive astrocytes after cortical injury. 
Ipsilateral!
Jagged1-PE! Jagged1-PE!
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A) Jagged-1 phenotype of GLAST+ cells isolated by MACS from pooled contralateral 
and ipsilateral cortical tissues of C57BL/6J mice 3 d following ischemic injury (n=4 
mice; ipsi- and contralateral tissues dissected from the same animals). Upper-left: 
Contralateral GLAST+ cells divide into 2 populations; Jagged-1Neg and Jagged-1Lo 
(blue line). Note that the signal from isotype control staining (red line) overlaps the signal 
for the Jagged-1Neg cells (see also lower-left panel). Upper-right: Cell surface Jagged-1 
levels markedly increase on a portion of ipsilateral GLAST+ cells after stroke, forming a 
3rd additional population of Jagged-1Hi cells (see signal intensity above 105). Lower-left: 
We isolated the Jagged-1Hi cells by FACS (gate = black rhombus). B) Post-FACS, 
Jagged-1Hi cells adhered to substrate and were cultured for 24 hours, then fixed and 
stained for RC2 (green) and ETBR (red). C) GFAP-CreERTM-Notch1-cKO mice were 
treated with vehicle (Corn oil) or tamoxifen (TM)(n=3 mice per treatment group, pooled 
by ipsi- or contralateral cortical tissue). Left: GLAST+ cells isolated from contralateral 
cortices of oil-treated GFAP-CreERTM-Notch1-cko mice lacked the population of Jagged-
1Hi cells, similar to C57bl/6 control animals (compare to phenotype in [A], lower-left 
panel). Middle: Similar to the phenotype obtained for ipsilateral cortices of typical 
C57BL/6J mice 3 d after dMCAO, a population of GLAST+/Jagged-1Hi cells (black oval) 
was observed for GFAP-CreERTM-Notch1-cko mice treated with oil (compare to [A], 
upper-right panel). FACS phenotype is shown for 4.06 × 105 cells. Right: Astroglial 
deletion of Notch1 in TM-treated GFAP-CreERTM-Notch1-cko mice results largely 
removed the GLAST+/Jagged-1Hi cell population (red oval). FACS phenotype is shown 









































































Figure 3-4. Primary reactive astrocytes proliferate and increase ETBR expression 
when exposed to immobilized Jagged-1. 
A) Passage 3-5 Rad-NSCs differentiated for 7 d provided enriched cultures of GFAP 
(red)-positive adult reactive astrocytes, termed AstroRad-NSC. Differentiation in medium 
containing 10% serum resulted in minor neuronal cell contamination (see Tuj1 stain, 
green). Scale bar, 200 µm. B) Subpopulations of AstroRad-NSC expressed GFAP (left 
image, red), nestin (right image, red), and RC2 (green in both). All RC2+ cells co-
expressed nestin (see white arrows). Scale bar, 50 µm. C) AstroRad-NSC plated onto 
immobilized Jagged 1-Fc chimera proliferated and expressed Ki67 (white circles, left 
image), whereas AstroRad-NSC plated onto control surfaces did not proliferate or express 
Ki67 (right image). Scale bar, 100µm. D,E) By immunoblot, ETBR protein levels 
increased after cells were plated onto immobilized Jagged 1-FC for 2 d; this was 




Figure 3-5. Transcriptional activity at the human EDNRB promoter is increased by 
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Label STAT3 Binding 
Motif 
A TTC(N)4GAA 
1 – 9  TTM(N)3DAA 
+ + + - - - 
- - - + + + 
- + + - + + 

































































A) Mouse and human promoter sequences of the EDNRB gene contain multiple putative 
STAT3 binding sites.  Schematic indicates relative positions of sites (arrows with labels) 
upstream of the transcriptional start site (0 kb) that match STAT3 binding motif 
TTM(N)3DAA (D: A, G, or T; M: A or C; N: A, G, T or C) (numbered 1 through 9) or 
motif TTC(N)4GAA (N: A, G, T or C) (labeled “A”) (Table 3-1). A’) Schematic of 
reporter construct for the human EDNRB promoter (pGL4-hEDNRB-prom) used for 
transfection experiments and luciferase activity assays. A 3.5 kb span of the hEDNRB 
promoter was cloned upstream of the firefly luciferase gene (LUC). +160bp indicates the 
position of the start codon. B) Relative luciferase activity (RLA) of HEK 293 cells 
transiently-transfected with pGL4-hEDNRB-prom. After 3 hrs of incubation in IL-6 (50 
ng/ml), LIF (20 ng/ml) or EGF (20 ng/ml), luciferase activity significantly increased 
relative to control (PBS/DMSO). STATTIC, a specific STAT3 inhibitor, abrogated these 
effects. *p < 0.05 vs. DMSO/PBS; †p < 0.05 vs. with relevant DMSO/growth factor or 
DMSO/cytokine, ANOVA, mean ± SEM, n=3. Right: Note that STATTIC did not affect 
cell viability (MTS assay). C) Expression of ETBR by AstroRad-NSC and the U87 human 
glioma cell line. D) Compared to U87 glioma cells transfected with control vector, U87 
glioma cells transfected with NICD1 significantly increased RLA. However, this was not 
the case for NICD1-transfected cells incubated in EGF with STATTIC or STATTIC 




Figure 3-6. Astroglial ETBR levels change in a correlated manner with STAT3 
activation and are modified by presence/absence of Notch1. 
A) Incubation of AstroRad-NSC in IL-6 (50 ng/ml) for 2 d increased the level of activated, 
phosphorylated STAT3 (p-STAT3), ETBR and GFAP protein. B) AstroRad-NSC generated 
from Rad-NSC of GFAP-CreERTM-Notch1-cko mice exhibited decreased cleavage of 
Notch1 intracellular domain (NICD1) after exposure to 4-OH Tamoxifen (OHTM) for 5 
Figure 6!





























































































































































































or 8 d in comparison with vehicle-treated control cells (ethanol, EtOH). LIF (20 ng/ml) 
induced p-STAT3 levels were reduced in AstroRad-NSC after conditional deletion of 
Notch1 (Left: Immunoblot; Right: Normalized band densities from immunoblot [ratio of 
p-STAT3 to T-STAT3]). C) Compared with vehicle (DMSO) treatment, exposure to the 
Gamma-secretase inhibitor DBZ for 24 hr decreased EDNRB gene expression in AstroRad-
NSC (unpaired t-test, *p < 0.001, mean ± SEM, n=3). D) ETBR levels were decreased in 
AstroRad-NSC after 2 d incubation in DAPT or L-685,458 (two different GSI). E) 
Conditional knockout of Notch1 significantly reduced EDNRB gene expression in 
AstroRad-NSC. *p < 0.01, ANOVA, mean ± SEM, n=3. F) AstroRad-NSC differentiated from 
different clonal Rad-NSC lines had decreased levels of ETBR protein after Notch1 was 
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Figure 3-7. Conditional knockout of ETBR depletes proliferative astrocytes in the 
peri-infarct area 3 d after stroke. 
A) Conditional knockout of astroglial ETBR significantly decreased the number of 
GFAP+/ETBR+ reactive astrocytes in the peri-infarct area 3 d following stroke. Left: 
Representative, low magnification images. Right: Cell numbers. *p < 0.05, unpaired t-
test, mean ± SEM, n = 3 mice per group. Scale bar, 200 µm. B) GFAP+/RC2+ reactive 
astrocytes, which make up the majority of proliferating reactive astrocytes 3 d following 
stroke (see Figure 2), were significantly decreased by conditional knockout of ETBR. 
GFAP+ astrocytes that were negative for RC2 expression were not reduced in number. *p 
< 0.01, ANOVA with Bonferroni, mean ± SEM, n=5 mice per group. NS= not 
significant. C) Conditional knockout of ETBR reduced the number of reactive astrocytes 
that were actively dividing (Ki67-positive) 3 d following injury. Left column: 
Representative images at low magnification. Scale bar, 100 µm. Middle column: 
Representative images of the proximal peri-infarct area. Scale bar, 30 µm. Right 
column: Representative images of the distal peri-infarct area. Scale bar, 30 µm. D) The 
number of reactive astrocytes actively dividing in the peri-infarct area was significantly 
reduced by conditional deletion of ETBR. Of interest, RC2-positive/GFAP+/Ki67+ (triple-
positive) reactive astrocytes were significantly reduced in number within the peri-infarct 
area, whereas  the number of RC2-negative, GFAP+/Ki67+ reactive astrocytes was not 
affected. *p < 0.01, ANOVA, mean ± SEM, n=5 mice per group. NS= not significant. 
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Binding Motif Species (ID) Sequence, promoter position (bp) 
TTC(N)4GAA Human (A) TTCATTTGAA, -1175 
Mouse (A) TTCATGGGAA, -1512 
TTM(N)3DAA  Human (1) TTCCCCAAA, -3012 
(2) TTACAATAA, -2971 
(3) TTAAGTGAA, -2875 
(4) TTACCTTAA, -2695 
(5) TTATAAAAA, -2609 
(6) TTCCATTAA, -1904 
(7) TTACCTGAA, -1298 
(8) TTAAAAAAA, -688 
(9) TTACGTGAA, -320 
Mouse (1) TTAAAAAAA, -2973 
(2) TTCCCCAAA, -973 
(3) TTAGTAAAA, -330 
(4) TTAGCTAAA, -155 
Table 3-1. Supplementary Table 1. STAT3 DNA-binding consensus sequences are 
found in the human and murine EDNRB promoter. 
Promoter sites in mouse and man satisfying STAT3 binding motifs TTM(N)3DAA (D: 
A, G, or T; M: A or C; N: A, G, T or C) or  TTC(N)4GAA (N: A, G, T or C). Positions 
are relative to the transcriptional start sequence for transcript variant 1 in both human and 
mouse EDNRB. Human EDNRB sequence data was obtained from Genebank 
 184 
(http://www.ncbi.nlm.nih.gov/genbank/) accession ID NG_011630 with the 
transcriptional start point (position 0) located at 61,797 bp in sequence context. Mouse 
EDNRB sequence data was obtained from Genebank accession ID NC_000080.6 with the 
transcriptional start point located at 5,254 bp in sequence context. See Figure 3 for the 
corresponding graphic to this table. 
 
Figure 3-8. Supplementary Figure 1: Formation of RC2
+
 reactive astrocytes 3 d 
following cortical stab injury is attenuated by inhibition of Gamma Secretase. 
A-A’) RC2
+
 reactive astrocytes (green) surround injury at 3 d after needle stab.  Arrows: 
RC2
+
 reactive astrocytes. A’) DBZ injection reduces the presence of RC2
+
 cells. B) 
Quantification of RC2
+
 cells in the peri-infarct area. DBZ treatment significantly reduced 




































the number of RC2
+
 cells after injury. *p < 0.05, unpaired t-test, mean ± SEM, n=3. Scale 
bars, 50 µm. 
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Supplemental Figure 2 






C57BL/6J GFAP-CreERTM-Notch1-cKO  
vehicle 
























Figure 3-9. Supplementary Figure 2: GLAST+ cells isolated by MACS express cell-
surface Jagged-1. 
All plots are smoothed x-y graphs of GLAST
+
 cells subjected to flow cytometry. Cells 
are plotted by PE fluorescence level and the forward scatter of light (FSC). A) GLAST+ 
input from MACS gated by side scatter (SSC) and FSC. B) Jagged-1 phenotype of 
GLAST+ cells isolated by MACS from pooled contralateral cortical tissues of C57BL/6J 
mice (n=4) at 3 d following dMCAO. Monoclonal antibody directed toward the 
extracellular domain of Jagged-1 yields a population of cells that are immunoreactive in 
contralateral cortex that are not observed with isotype control staining (Left). C) 
GLAST+ cells from contralateral cortex of GFAP-CreERTM-Notch1-cKO mice treated 
with tamoxifen (TM) or oil (vehicle) show similar populations of GLAST+/Jagged-1+ 
immunoreactive cells (pooled n=3 mice per treatment group). D) GLAST+ cells from 
ipsilateral (injured) cortex 3 d after stroke from C57BL/6J and GFAP-CreERTM-Notch1-
cKO vehicle treated mice show similar percentages of Jagged-1Hi cells (gate indicated by 
the black rectangle). 
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Figure 3-10. Supplementary Figure 3: Representative genotyping of hGFAP-




























































Mutant  =~290 bp 
Heterozygote = ~290 bp and 230 bp 
Wild type = 230 bp 
 
Note: Numbers 1, 2 and 3 for GFAP and EDNRB PCR 
reactions correspond to the same individual mice. 
Mouse #2 has the GFAP-ETBR-cKO genotype 







CHAPTER 4. CONCLUSIONS AND FUTURE DIRECTIONS. 
 
The goal of this dissertation was to identify and characterize targets of Jagged-1/Notch 
signaling that impart reactive astrocytes with the ability to respond and modulate the 
injury environment after ischemic stroke. This was accomplished through investigation of 
targets from a transcriptome analysis of adult astrocytes (AstroRad-NSC) exposed to 
immobilized Jagged-1. The induction of Notch signaling in AstroRad-NSC was verified by 
up-regulation of gene expression for the HES family of transcription factors and by the 
antagonism of expression for transcription factors associated with oligodendrocyte and 
neuronal differentiation (e.g. bHLHs). Importantly, Jagged-1/Notch signaling up-
regulated genes expressed by reactive astrocytes after CNS injury. Moreover, multiple 
gene-members of functional groups were up-regulated together, including groups of 
genes that encode proteins known to affect function extracellular solute and ion balance, 
the inflammatory response, the formation of extracellular matrix typical to the glial scar, 
and glutamate processing. Analysis of results from the Jagged-1 forward signaling screen 
suggests that Notch signaling promotes a variety of reactive astrocyte functions.  
We chose to investigate GLAST, a astrocyte-specific glutamate transporter, 
whose transcription was up-regulated by Jagged-1 in our screen. The regulation of 
GLAST level appears to be transcriptionally-controlled by Notch1. We confirmed that 
loss of Notch1 corresponded with decreased Glast mRNA and protein expression in 
cultured AstroRad-NSC.  Importantly, we showed that GLAST protein levels were decreased 
in acutely-isolated adult reactive astrocytes using transgenic mice with a conditional 
deletion of Notch1 in astrocytes. In regard to function, cultured AstroRad-NSC were able to 
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take up glutamate from the extracellular space; this action was attenuated by inhibition of 
γ-secretase. Our results imply that Jagged-1/Notch1 signaling in reactive astrocytes up-
regulates GLAST and could be a master regulator of glutamate up take and processing: a 
function of reactive astrocytes that is essential for maintaining extracellular glutamate 
levels following stroke.   
Further experimentation is required to establish the full role of Notch signaling in 
glutamate processing in reactive astrocytes. Other genes associated with glutamate 
metabolism in astrocytes, such as Glutamate synthase (Glul) and Glutamate 
Dehydrogenase 1 (Glud1) were also up-regulated by Jagged-1/Notch signaling in our 
screen, but these targets were not verified. We hypothesize that loss of Notch1 in reactive 
astrocytes during stroke will decrease glutamate uptake and processing and increase 
extracellular glutamate levels. In turn, this will promote neuronal apoptosis due to 
excitotoxicity. Our group has already begun to investigate various methods to assay 
extracellular glutamate in the parenchyma of mice following stroke. Microdialysis has 
been used successfully to measure extracellular glutamate in the brains of mice subject to 
ischemic injury (Mitani and Tanaka, 2003). Alternatively, newly-developed fluorescence 
intensity-based glutamate sensors could be employed to assay intracellular of glutamate 
directly in reactive astrocytes transfected with DNA-constructs for sensor expression. 
Using 2-photon imaging of acute organotypic slices of injured cortex, the intensity of 
fluorescent sensors, and therefore the concentration of intracellular glutamate, could be 
determined in live tissue (Marvin et al., 2013). A combination of these two methods, and 
perhaps the addition of glutamate metabolite analyses with mass spectrometry or NMR, 
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will be essential for describing the effects that loss of Notch1 may have on glutamate up 
take and processing in vivo.  
The transcripts for cell surface receptors that increased after Jagged-1 exposure 
included Ednrb. We chose to study ETBR further for two reasons, 1) Endothelin signaling 
through ETBR is an important regulator of reactive astrocyte proliferation and function 
and 2) Notch signaling was not known to affect ETBR expression in reactive astrocytes or 
any other system. Loss-of-function experiments specifically-designed to remove Notch1 
and gain-of-function experiments with immobilized Jagged-1 confirmed regulation of 
ETBR by Jagged-1/Notch1 signaling.  The regulation of ETBR by Jagged-1/Notch1 
signaling was not direct, however, and required Notch-mediated enhancement of 
activated STAT3. Our experiments demonstrate that STAT3 promotes the transcription 
of Ednrb. Previous studies indicated that pharmacologic antagonism of ETBR reduced 
reactive astrocyte proliferation after brain injury, a phenotype our group observed in 
GFAP-Notch1-conditional KO (cKO) animals after stroke. We observed that the radial 
glial marker, RC2, co-localized with ETBR high-expressing peri-infarct reactive 
astrocytes. Seventy-five percent of RC2+ reactive astrocytes expressed Ki67+ in the peri-
infarct area, identifying RC2+ as a suitable marker for the subset of proliferating reactive 
astrocytes. Both GFAP-ETBR-cKO and GFAP-Notch1-cKO animals lost the RC2+ 
population and had fewer proliferating reactive astrocytes after stroke. Lastly, we 
described three different populations of GLAST+ astrocytes from stroke cortex based on 
their Jagged-1 surface expression. The population of Jagged-1Hi astrocytes was depleted 
in GFAP-Notch1-cKO animals following stroke, suggesting that 1) Jagged-1Hi astrocytes 
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require Notch1 for proliferation and/or survival, 2) Jagged-1Hi astrocytes are RC2+ and 
represent the proliferative subpopulation, 3) Juxtaparacrine astrocyte-to-astrocyte Jagged-
1/Notch1 signaling is involved in supporting their proliferation. Based on these data we 
propose three general astrocyte sub-types in stroke (Figure 2-1).  
Isolation of the GLAST+ Jagged-1Hi population of reactive astrocytes and 
subsequent transcriptome and epigenetic tiling analyses may elucidate many features of 
these cells that distinguish them from non-proliferative reactive astrocytes. Our group has 
shown proliferative RC2+ cells are required for the exclusion of CD45 cells from the 
parenchyma of the brain after stroke (Shimada et al., 2011). This could be due to 
numerous secreted anti-inflammatory factors produced by these cells, the physical barrier 
created by proliferative astrocytes (Wanner et al., 2013), or both. Moreover, profiling of 
proliferative Jagged-1Hi reactive astrocytes may provide insights into the cell signaling 
pathways and epigenetic changes that allow these cells re-enter the cell cycle, and that 
make them receptive to conversion into neural stem cells in culture conditions. Although 
we have not formally demonstrated Jagged-1Hi reactive astrocytes create NSCs in culture, 
Sirko et al. (2013) suggested that proliferating reactive astrocytes responding to Sonic 
Hedgehog signaling in the peri-infarct area after stroke formed multipotent neurospheres 
in culture. Their study highlights the importance of injury type in the formation of 
reactive astrocyte subsets. Astrocytes responding to neuron-specific apoptosis and models 
of Alzheimer’s disease adopted features of reactive astrocytes (increased GFAP 
expression, hypertrophy), but failed to proliferate and did not create NSCs when isolated 
and cultured. Conversely, proliferating reactive astrocytes isolated from ischemic or 
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penetrative injuries readily converted to NSCs (Sirko et al., 2013). Understanding the 
secretome, signaling and epigenetic profiles of these proliferative Jagged-1Hi reactive 
astrocytes may advance basic knowledge of reactive astrocyte biology and also uncover 
new targets for rational drug design.  
We assume that Notch signaling is increased markedly in proliferative Jagged-1Hi 
ETBRHi reactive astrocytes (Figure 2-1). Although we have not established direct 
evidence for this here, measuring instantaneous levels of Notch signaling activity is 
technically achievable. Levels of Notch signaling can be assessed with transgenic mice 
that drive expression of EGFP from a CBF1-responsive element activated during 
canonical Notch signaling (Mizutani et al., 2007). Cell-cycle analyses by flow cytometry 
could also be used to link the level of Notch signaling to reactive astrocyte proliferation. 
Furthermore, complementary immunohistochemistry experiments could be performed 
with these mice to localize cells with high levels of Notch signaling with ETBR and 
proliferation markers in the peri-infarct area. 
Our finding that Jagged1/Notch1 signaling in reactive astrocytes influences ETBR 
expression suggests a regulatory scheme for the activation and proliferation of RC2+ 
reactive astrocytes when viewed in the context of recent literature. Work from Hammond 
et al. (2014) showed that reactive astrocytes increased their Jagged-1 expression in 
response to ET-1. After chemical demyelination, ET-1 signals through ETBR, ERK and 
JNK pathways, and results in the activation of the transcription factor c-jun (Gadea et al., 
2008). C-jun binds to cis-acting AP-1 DNA elements in the Jag1 promoter (Zeng et al., 
2005). Taken with our data, this suggests a putative feed-forward loop whereby ET-1 
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signaling through ETBR increases Jagged-1, which then provides a ligand for Notch 
signaling in adjacent astrocytes. Notch signaling increases the expression of ETBR, 
through p-STAT3 activation, and in turn enhances expression of Jagged-1 through 
amplified ET-1 signaling through ETBR. We predict that Endothelin, Notch, and STAT3 
signaling all collaborate to drive the proliferation of reactive astrocytes in the peri-infarct 
area after stroke through this hypothetical feed-forward loop (Figure 4-2). Absent from 
this model is the contribution of the Sonic Hedgehog (SSH) signaling pathway, which is 
also required for normal reactive astrocyte proliferation (Sirko et al., 2013). Nevertheless, 
it is enough to disrupt ETBR or Notch1 signaling in reactive astrocytes to prevent normal 
proliferation, independent of intact SHH signaling.  
Our proposed feed-forward loop may be exploited clinically. It is now clear that 
proliferative reactive astrocytes protect surrounding healthy tissue from secondary 
damage mediated by extracellular glutamate, inflammatory cells and cytokines, and 
ischemia after severe CNS injuries like stroke. Enhancing reactive astrocyte proliferation 
could provide a novel mechanism to provide protection. Notch signaling in reactive 
astrocytes could potentially be enhanced through pharmacological methods. Pinchot and 
colleagues (2011) developed a luciferase-based high-throughput screening method 
whereby activity of a Notch downstream effector could be measured in cells exposed to 
one of 7,264 separate compounds. They found that resveratrol, a compound found in red 
wine, produced the strongest reporter response of all the compounds tested. Resveratrol 
treatment produced an up-regulation of Notch signaling by inducing expression of 
Notch2 in carcinoid cells. This approach is sub-optimal, however, due to resveratrol’s 
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potential ability induce Notch signaling in many cell types, not just astrocytes. Notch 
signaling has a tumor suppressor-like effect for some cancer cell types, whereas it 
supports the growth of others, making it unsuitable for general use as a signal to cells of 
injured or diseased tissues (reviewed in Ranganathan et al., 2011; Lobry et al., 2014). Our 
model suggests that selective stimulation of ETBR indirectly increases Notch signaling by 
up-regulating Jagged-1 levels, thereby promoting juxtaparacine signaling between 
adjacent reactive astrocytes. Importantly, drugs or biologics that promote reactive 
astrocyte proliferation through pharmacological stimulation of ETBR could provide a 





Figure 4-1. Sub-types of astrocytes in the cortex after stroke.  
A) By FACS, protoplasmic astrocytes express Jagged-1 at low or undetectable levels. 
By immunohistochemistry, they express undetectable levels of ETBR, GFAP and 
GLAST. These astrocytes are located distal to the infarct core and in contralateral 

















•  Mitotically quiescent 
•  GLAST+ 
•  Jagged-1Lo or Jagged-1Neg 
•  ETBR not detectable 
•  GFAP not detectable 
Reactive Astrocyte (RA) 
•  Mitotically silent  
•  GLAST+ 
•  Jagged-1Lo 
•  ETBRLo  
•  GFAP 
Peri-infarct RC2 RA 
•  Mitotically active 
•  GLAST+ 
•  Jagged-1Hi 
•  ETBRHi  
•  GFAP, RC2, Nestin 






Jagged-1 levels 3 days after focal ischemic stroke. ETBR and GFAP levels increase and 
are now detectable by IHC. These cells re-enter the first growth phase, but rarely divide. 
C) Peri-infarct RC2+ reactive astrocytes are directly adjacent to the infarct core and are 
mitotically active. They express high levels of ETBR by IHC and are Jagged-1Hi by flow 
cytometry. By IHC, these cells express nestin and RC2 in addition to GFAP. This sub-




























Figure 4-2. Proposed feed-forward loop to amplify Endothelin/STAT3/Notch 
signaling in proliferative RC2+ reactive astrocytes of the peri-infarct area after 
stroke. 
1) Protoplasmic astrocytes become activated and secrete ET-1 (Hammond et al., 2014) or 
become activated through direct exposure to ET-1 (Rogers et al., 2003). 2) Autocrine and 
paracrine signaling by ET-1 through ETBR activates c-jun (Gadea et al., 2008) and drives 
the expression of Jagged-1 (Zeng et al., 2005). 3) gp130-associated cytokine receptors, 
such as the IL-6 receptor, or non-gp130 receptors (e.g. EGFR), bind ligands and stimulate 
the phosphorylation of STAT3. Adjacent reactive astrocytes with ET-1-induced Jagged-1 
expression provide ample ligands for Notch signaling. Notch intracellular domain 
(NICD) increases the expression of HES1 and 5, which then physically associate with 
STAT3 to stabilize its phosphorylation (Kamakura et al., 2004; see inset). 4) p-STAT3 
increases the expression of ETBR, thereby increasing the cell’s receptivity to ET-1 and 
further increases the expression of Jagged-1 (2). 5) The feed-forward process of ETBR 
and Jagged-1 signal amplification in the presence of autocrine and paracrine ET-1 may 
drive proliferation of reactive astrocytes. 
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In response to stroke, subpopulations of cortical reactive astrocytes proliferate and 
express proteins commonly associated with neural stem/progenitor cells, such as Glial 
Fibrillary Acidic Protein (GFAP) and Nestin. To examine the stem cell-related properties 
of cortical reactive astrocytes after injury, we generated GFAP-CreERTM;tdRFP mice to 
permanently label reactive astrocytes. We isolated cells from the cortical peri-infarct area 
3 days after stroke, and cultured them in neural stem cell medium containing EGF and 
bFGF. We observed tdRFP-positive neural spheres in culture, suggestive of tdRFP-
positive reactive astrocyte-derived neural stem/progenitor cells (Rad-NSCs). Cultured 
Rad-NSCs self-renewed and differentiated into neurons, astrocytes, and 
oligodendrocytes. Pharmacological inhibition and conditional knockout mouse studies 
showed that Presenilin 1 and Notch 1 controlled neural sphere formation by Rad-NSCs 
after stroke. To examine the self-renewal and differentiation potential of Rad-NSCs in 
vivo, Rad-NSCs were transplanted into embryonic, neonatal and adult mouse brains. 
Transplanted Rad-NSCs were observed to persist in the subventricular zone and 
secondary Rad-NSCs were isolated from the host brain 28 days after transplantation.  In 
contrast with neurogenic post-natal day 4 NSCs and adult NSCs from the subventricular 
zone, transplanted Rad-NSCs differentiated into astrocytes and oligodendrocytes, but not 
neurons, demonstrating that Rad-NSCs had restricted differentiation in vivo. Our results 
indicate that Rad-NSCs are unlikely to be suitable for neuronal replacement in the 




Neural Stem Cells (NSCs) are multipotent cells that self-renew and differentiate into 
neurons, astrocytes and oligodendrocytes (Reynolds and Weiss, 1992, 1996; Morshead 
and van der Kooy, 2004; Neumeister et al., 2009). NSCs reside as astrocyte-like cells in 
neurogenic niches such as the subventricular zone (SVZ) of the lateral ventricle, and the 
subgranular zone (SGZ) of the hippocampus  (Ihrie and Alvarez-Buylla, 2008). Although 
NSCs in neurogenic niches have been well-studied, whether stem/progenitor cells reside 
in non-neurogenic niches, such as the cortex, remains under debate (Gould et al., 1999; 
Palmer et al., 1999; Kornack and Rakic, 2001; Nunes et al., 2003). 
Astrocytes are one of the major cell types in the Central Nervous System (CNS), 
and occupy 20 - 30% of brain volume in mammals. Astrocytes contribute to numerous 
homeostatic functions in the CNS (Nedergaard et al., 2003; Sofroniew, 2009).  Glial 
Fibrillary Acidic Protein (GFAP) is often used as a marker to identify astrocytes in the 
cortex, and also astrocyte-like NSCs in neurogenic niches. Although NSCs and astrocytes 
express this marker in common, GFAP-expressing adult cortical astrocytes of uninjured 
animals do not have stem/progenitor cell properties (Laywell et al., 2000).   
Following diverse CNS injuries, astrocytes are activated and described as 
“reactive astrocytes” (Sofroniew and Vinters, 2009; Robel et al., 2011). The appearance 
of reactive astrocytes is one of the most obvious phenomena observed after brain or 
spinal cord injury. Subpopulations of reactive astrocytes differentially express several 
stem cell-associated proteins such as Sox2, GFAP, Nestin, and RC2 (Pekny and Pekna, 
2004; Buffo et al., 2008; Shimada et al., 2010; Zawadzka et al., 2010). We and others 
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have demonstrated that locally-derived NSC-like cells can be generated from cortical 
tissues following injuries such as stroke, brain stab injury or laser injury (Buffo et al., 
2008; Nakagomi et al., 2009; Sirko et al., 2009; Shimada et al., 2010; Nakagomi et al., 
2011; Robel et al., 2011). Following brain stab injury, it was shown that GLAST-positive 
reactive astrocytes could de-differentiate, and form multipotent spheres in culture (Buffo 
et al., 2008). Therefore, reactive astrocytes appear to have a greater plasticity than was 
previously realized, and may provide a source of multipotent cells or a cellular target for 
regenerative medicine. Importantly, however, the signaling pathway(s) that govern the 
formation of injury-induced NSCs from cortical tissue remain unidentified. In addition, 
whether reactive astrocyte-derived NSCs are multipotent following transplantation back 
to the CNS is not known. 
Here we use lineage tracing to determine the cellular origin of cortical neural 
sphere-producing cells after stroke. We demonstrate the isolation of reactive astrocyte-
derived-NSCs (Rad-NSCs) from the cortical peri-infarct area 3 days following distal 
Middle Cerebral Artery Occlusion (dMCAO). Through pharmacological inhibition and 
conditional knockout mouse studies, we show that Presenilin 1 and Notch 1 regulate the 
generation of Rad-NSC spheres from cortical peri-infarct tissues. Following 
transplantation of Rad-NSCs back to CNS, Rad-NSCs differentiated into astrocytes and 
oligodendrocytes. However, we did not observe neuronal differentiation, suggesting that 
unmodified Rad-NSCs are restricted from neuronal differentiation in vivo, despite their 





Materials and Methods 
Mice 
All animal work was approved by the University of Vermont College of Medicine’s 
Office of Animal Care in accordance with American Association for Accreditation of 
Laboratory Animal Care and National Institutes of Health guidelines. Adult male 
C57BL/6J mice (6-8 weeks of age) were obtained from Taconic Farms, Hudson, N.Y. 
We obtained GFAP-CreERTM mice from Dr. Suzanne Baker (St. Judes Children Hospital, 
Memphis, TN) (Chow et al., 2008). The GFAP-CreERTM mice express CreERTM under 
control of the 2.2 kb human GFAP (hGFAP) promoter. We obtained ROSA26-tdRFP 
mice from Dr. Hans Joerg Fehling (University Clinics Ulm, Germany) (Luche et al., 
2007). C57BL/6-Tg(UBC-GFP)30Scha/J mice (GFP mice, Cat # 004353), B6.129(Cg)-
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J (mT/mG mice, Cat # 007676), B6;129P-
Psen1tm1Vln/J mice ( Presenilin 1-flox mice, Cat # 007605) and Notch1tm2Rko/GridJ mice 
(Notch 1-flox mice, Cat # 006951) were obtained from Jackson Laboratory. Genotyping 
was performed by PCR using REDExtract-N-Amp Tissue PCR Kit (XNAT-1KT; Sigma) 
following the manufacturer’s instructions. We used the following primers: Notch 1, 5'-
TGCCCTTTCCTTAAAAGTGG-3', 5'-GCCTACTCCGACACCCAATA-3'; tdRFP, 5'-
AAGACCGCGAAGAGTTTGTCC-3', 5'-TAAGCCTGCCCAGAAGACTCC-3', 5'-




ACCAGCGTTTTCGTTCTGCC-3’.   
Distal Permanent Middle Cerebral Artery Occlusion (dMCAO) surgery 
Adult mice (6-8 weeks) were anesthetized with isoflurane (1-5%; Webster Veterinary, 
Sterling, MA) and body temperature was maintained with a heated pad.  Focal cerebral 
ischemia was produced by permanently occluding the middle cerebral artery (MCA) 
(Bakondi and Shimada et al., 2009; Shimada et al., 2010). Under low-power 
magnification, the left temporal-parietal region of the head was shaved, and an incision 
was made between the left orbit and the left ear in the shape of a “U”.  An incision was 
made superiorly on the upper margin of the temporal muscle forward. The MCA was 
observed through the semitranslucent skull. A small burr hole (1-2mm) was drilled into 
the outer surface of the skull just over the MCA. The inner layer of skull was removed 
with fine forceps, and the dura was opened with a cruciate incision.  The MCA was then 
encircled with 10-0 monofilament nylon suture (7V33, S & T, Neuhausen, Switzerland), 
ligated and transected superior to the ligation point. The small flap of facial skin was 
closed with Vetbond (3M animal care products, St. Paul, MN). For transgenic mouse 
studies, mice received 0.1 mg/g of tamoxifen (T5648, Sigma) or corn oil by 
intraperitoneal injection for 3 consecutive days from day 0 immediately following 
dMCAO. Mice were euthanized 3 or 28 days after dMCAO. Brains were perfused with 4 
% paraformaldehyde, fixed in 4 % paraformaldehyde overnight at 4 °C, and then 
incubated in 30 % sucrose for 2 days at 4 °C. Brains were mounted with OCT compound, 
and cut into 20-30 µm frozen sections.    
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 To label cells migrating from the lateral ventricle to the peri-infarct area after 
stroke, stereotaxic surgery was performed immediately after dMCAO surgery. 
Stereotaxic surgery was used to deliver 50 µmol/L DiI (CellTracker CM-DiI; Invitrogen) 
in 5 µL of phosphate-buffered saline into the lateral ventricle (lateral ventricle 
coordinates: anteroposterior, −0.3 mm, mediolateral ±1.0 mm, and dorsal/ventral −3.0 
mm). The solution was delivered at a rate of 1 µL/min. Three days later, mice were 
euthanized. 
 
Isolation of Reactive astrocyte-derived NSCs (Rad-NSCs) and typical NSCs 
For isolation of Rad-NSCs, brains were removed 3 days after dMCAO, placed into a 
polyacrylic brain block (Acrylic Matrices, RBMA-200C, World Precision Instruments, 
Sarasota, FL) and cut coronally in 1 mm sections. The sections were transferred into 
alpha minimum essential medium (Invitrogen, Carlsbad, CA) in 6-well plates. The 
cortical peri-infarct area was dissected under a light microscope. Tissues from the 
anterior lateral ventricle, posterior lateral ventricle, hippocampal arch, dentate gyrus, 
white matter, and third ventricle were carefully excluded. The tissues containing the peri-
infarct area were harvested, diced into 1 mm3 pieces, and digested in enzyme digestion 
solution (200 units papain [Worthington, Lakewood, NJ], 20 µg /ml DNase 
[Worthington], 1.5 mM EDTA [Fisher Scientific, Fair Lawn, NJ], 1.5 mM CaCl2 
[Sigma], 2 mg L-Cysteine [Sigma], DMEM/F12 media [Invitrogen, Carsbad, CA]) at 37 
C° for 15 min. Following enzymatic digestion, the tissues were triturated 2 times in 
trituration solution in (10 mls of DMEM/F12 medium containing 15 mg trypsin inhibitor 
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[Invitrogen] and 15 mg BSA [Fisher Scientific]). Cells were resuspended in DMEM/F12 
medium containing 0.9 M sucrose and centrifuged to remove myelin (111 x g for 10 
minutes). Cells were grown at a low density (10,000 cells/ml) in NSC growth medium 
(10 ng/ml EGF [BD Biosciences, Bedford, MA], 20 ng/ml bFGF [recombinant human 
bFGF produced in our laboratory], 1 x B27 supplement [Invitrogen], 2 mM L-Glutamaine 
[Mediatech], and 100 units/ml Penicillin/100 µg/ml Streptomycin, in Neurobasal A 
[Invitrogen]) in a 100 mm2 dishes (Nunc, Thermo Fisher Scientific, Rochester, NY). Two 
weeks after plating, the number of neural spheres was counted under microscopy. To 
generate clonally-derived spheres, individual small spheres (10-100 cells) were pipetted 
under microscopy into separate 24-well plates a week after plating. The clonally-isolated 
neurospheres were expanded and passaged in NSC growth medium for further studies. 
For sphere formation assays, clonally-isolated primary spheres were dissociated, and 
plated again into NSC growth medium (24-well plates, 20 cells/µl density, 500 µl per 
well). Seven days after plating, the number of neural spheres was counted under 
microscopy. 
Post-natal day 4 neural stem cells (PD4-NSCs) and adult NSCs from the SVZ (adult-
NSCs) were isolated as neurospheres from whole brains or lateral ventricle of C57BL/6J 
mice, GFP mice, or mT/mG mice (Neural Stem Cell Isolation Kit; StemCell 
Technologies, Inc., Vancouver, BC, Canada). To isolate typical adult NSCs, 1 mm 
coronal brain sections from adult mice (4-8 weeks of age) were dissected to obtain tissues 
from the lateral ventricle and hippocampus under microscopy. To isolate NSCs from the 
lateral ventricle, tissues were obtained from the dorsal and lateral sides of the lateral 
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ventricle. To isolate NSCs from the hippocampus, tissues were obtained from the 
hippocampus that excluded the posterior lateral ventricle.   
Cell transplantation 
Rad-NSCs were dissociated, diluted to 25,000 cells/µl in Neurobasal A media, and 5 µl of 
cell suspension was transplanted into the lateral ventricle (A/P, -0.3mm, M/L ±1.0 mm, 
and D/V -3.0mm), hippocampus (A/P, -2.3 mm, M/L ±1.3 mm, and D/V -2.0mm) or 
RMS (A/P, -2.5mm, M/L ±0.8 mm, and D/V -3.0mm) in adult C57BL/6J mice. Two µl of 
the NSC cell suspension was transplanted into the brains of day 0-4 C57BL/6J mice. For 
neonatal transplants, neonates were anaesthetized with cold vapor from dry ice (carbon 
dioxide). The length between the posterior part of the left and right eyes was measured 
and divided into 3 equi-distant sections. Rad-NSCs were injected at both edges of the 
middle section, 1/3 of the distance inward from the posterior part of left and the right 
eyes, and about 1 mm below the skin using 30 gauge needle (7803-07, Hamilton, Reno, 
Nevada) and 10 µl Hamilton syringe (1701, Hamilton). To examine retention of 
transplanted cells and their location, some mice were injected with DiI (50 µmol/L, 
CellTracker CM-DiI; Invitrogen) or NSCs and the location of DiI or cells injection was 
analyzed. Neonatal mice were returned to their mothers after the cell injections. They 
were euthanized 28 days after injection. For embryonic transplants, 1 µl of the Rad-NSC 
cell suspension was transplanted into the brains of embryonic day 15 C57BL/6J mice in 
utero. Rad-NSCs were injected at both edges of the middle section of the skull, 1/3 of the 
distance inward from the dorsal part of left and the right eyes, and about 1 mm below the 
skin using 30 gauge needle (7803-07, Hamilton, Reno, Nevada) and 10 µl Hamilton 
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syringe (1701, Hamilton). The mother was returned to the cage, and pups were 
euthanized at embryonic day 20 for further analysis.     
BrDU (5-Bromo-2’-deoxyuridine) administration 
Mice received 50 mg/kg of BrDU (5-Bromo-2’-deoxyuridine, Sigma) by intraperitoneal 
injection for 5 consecutive days from day 0 immediately after dMCAO or cell transplant. 
Mice were euthanized on day 28 after dMCAO or on day 28 or day 90 after cell 
transplant.  
TTC (2, 3, 5-Triphenyltetrazolium chloride) staining 
Three days following dMCAO, mice were euthanized. Brains were removed and coronal 
sections were cut to 1 mm thickness with a polyacrylic brain block. The sections were 
incubated in 10% TTC (Sigma) solution (diluted in distilled water) for 15 minutes at 37 
°C.  After staining, the sections were photographed with a digital camera.   
Treatment of cultured cells 
Twenty-four well dishes (Nunc) were coated with 5 µg/ml laminin/poly-D-lysine (both 
from BD Biosciences]) for 1 hour or overnight. Cells (5,000 cells/cm2) were plated into 
NSC growth medium in 24-well plates. One day after plating, the cells were incubated in 
various treatments.  For the gamma-secretase inhibitor study, cells were treated with 
L685-485 (Calbiochem) or DMSO (vehicle) for 2 days. For the 4-OH-Tamoxifen (4-OH-
TM) study, cells were treated with 0.5 µM 4-OH-TM (Sigma) or ethanol (vehicle) for 2 
days.   
CyQUANT assay 
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Cells (5,000 cells/cm2) were grown in NSC medium in 24-well plates. Two days after 
plating, the cells were washed with PBS and plates were frozen at −80 °C (n=4 for each 
time point). Cell numbers were quantified by dye labeling of nucleic acids (CyQUANT; 
Invitrogen) using a fluorescence plate reader (Biotek Synergy HT; BioTek Instruments, 
Winooski, VT). 
MTS assay 
Cells (5,000 cells/cm2) were grown in NSC medium in 24-well plates. Cell number was 
assayed 2 days after plating (CellTiter 96 AQueous One Solution Cell Proliferation 
Assay, Promega, Madison, WI). Relative intensity was quantified using a fluorescence 
plate reader. 
Neural stem/progenitor cell differentiation 
Twelve mm2 round cover glasses (Electron Microscopy Sciences, Hatfield, PA) were 
coated with 5 µg/ml laminin/poly-D-lysine in 24-well plates for 1 hour. Clonally-isolated 
single dissociated cells (5,000 cells/cm2/500 µl passage 3-5) were plated into 24-well 
plates, and cultured in NSC growth medium for 1 day. For differentiation, single 
dissociated cells were cultured in differentiation medium (1 % FBS, 100 units/ml 
Penicillin/100 µg/ml Streptomycin, B27 supplement, 2 mM L-Glutamine in Neurobasal 
A) for 7 days. The number of cells that differentiated into neurons, astrocytes, and 
oligodendrocytes was determined after immunocytochemistry. To examine the 
multipotency of clonal spheres, clonal spheres were plated into 24-well plates, and 
cultured in NSC growth medium for 1 day. For differentiation, the spheres were cultured 




Total RNA was prepared from Rad-NSCs and PD4-NSCs with a commercially available 
kit, according to the manufacturer’s protocol (PureLink RNA Mini Kit, Invitrogen). 
DNAse I (Turbo DNase, Invitrogen) was used to remove genomic DNA from RNA 
samples. cDNA was synthesized from 1 µg of total RNA with SuperScript III RT 
(Invitrogen) and an oligo-dT primer.  As a negative control, no-RT samples were made 
by omitting SuperScript III from duplicate RT reactions. The cDNA was used for PCR 
with the following primers: Sox2, 5’-GGCAGCTACAGCATGATGCAGGAGC-3’ and 
5’-CTGGTCATGGAGTTGTACTGCAGG-3’;Pax6, 5’-
AGTTCTTCGCAACCTGGCTA-3’ and 5’-TGAAGCTGCTGCTGCTGATAGGA-3’; 
Mash1, 5’-CGTCCTCTCCGGAACTGA-3’ and 5’-TCCTGCTTCCAAAGTCCATT-3’; 
Olig2, 5’-TCATCTTCCTCCAGCACCTC-3’ and 5’-CCGTAGATCTCGCTCACCAG-
3’; and GAPDH, 5’-CGGAGTCAACGGATTTGGTCGTAT-3’ and 5’-
AGCCTTCTCCATGGTGGTGAAGAC-3’.        
qRT-PCR 
Real-time quantitative PCR was performed using SYBR Green I detection Taq 
ReadyMixTM (S4438, Sigma, St. Louis, MO, USA) containing 5 mM MgCl2 and 400 nM 
of each primer in a final 24 ul reaction volume. We ran reactions with an Applied 
Biosystems 7500 Fast real-time PCR system (Applied Biosystems, Foster City, CA, 




TGAAGGATTCCAAAAATAAAATTCTCTGGG-3’ and 5’- 
CGCCTCTTCTCCATGATAGGCTTTGATGAC-3’; Deltex1, 5’- 
TGAGGATGTGGTTCGGAGGT-3’ and 5’-CCCTCATAGCCAGATGCTGTG-3’; and 
RBPJ, 5’- TGGCACTGTTCAATCGCCTT-3’ and 5’- 
AATCTTGGGAGTGCCATGCCA-3’. 
Flow cytometry analysis 
Cells (500,000 cells/ml) were suspended in 0.5 ml alpha MEM and analyzed by closed 
stream flow cytometry (Epics XL; Beckman Coulter; LSR II; Becton Dickinson, Franklin 
Lakes, NJ). 
Magnetic-Activated Cell Sorting (MACS) 
To isolate GLAST-positive cells from whole brains, we performed magnetic-activated 
cell sorting using GLAST antibody (130-095-822, Miltenyi Biotec, Auburn, CA) 
according to the manufacturer’s instructions. 
Immunoblotting 
Total proteins were extracted from the sorted cells using a cell lysis buffer (0.1 % SDS, 
1x complete protein inhibitor cocktail [Roche, Basel, Switzerland] in PBS). Protein 
concentrations were determined with a Bio-Rad DC Protein Assay (Bio-rad, Hercules, 
CA). Protein preparations were separated by SDS-PAGE and transferred to an 
immobilon-P membrane (PVDF, Millipore, Boston, MA). The membrane was blocked 
with 5 % BSA (BP1605, Fisher) and then incubated with a primary antibody. After 
washing, the membrane was incubated with an HRP-conjugated secondary antibody for 1 
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hour at room temperature. The blot was visualized with Western Lightning Plus-ECL 
(NEL103001EA, Pierce, Waltham, MA), and exposed to Kodak X-ray film. Equivalence 
of protein loading was verified by probing for GAPDH or β-actin. The antibodies used 
were against GFAP (Z0334, DAKO, Glostrup, Denmark), NICD1 (Notch 1 Intracellular 
Domain, ab8925, Abcam), Presenilin 1 (MA1-752, Thermo Scientific) GAPDH 
(MAB374, Millipore) and β-Actin (A5441, Sigma). 
Immunohistochemistry 
Frozen sections were dried for 30 minutes at 37 °C, and incubated in PBS for 15 minutes.  
Sections were then blocked in blocking buffer (10 % normal goat serum, 0.4 % Triton X 
in PBS) for 1 hour at room temperature. For BrDU staining, sections were treated with 2 
N HCl for 30 minutes at 37°C and washed before the incubation with blocking buffer.  
For Galactocerebroside (GalC) staining, sections were treated with proteinase K (20 
µg/ml, Invitrogen) for 5 minutes at 37°C. Sections were incubated in the following 
primary antibodies overnight at 4 °C: β-tubulin III (1:1000, PRB-435P, Tuj1; Covance), 
BrDU (1:500, A21300; Molecular Probes), Calbindin (1:1000, CB38; Swant, Marly, 
Switzerland), Calretinin (1:1000, AB149; Millipore), Doublecortin (1:1000, AB5910; 
Millipore), GalC (1:200, MAB342; Millipore), GFAP (1:1000, Z0334; DAKO), GFAP 
(1:500, G3893; Sigma),  GFP(1:1000, A11122; Invitrogen), GSTπ (1:1000, MSA-102E; 
Stressgen, Ann Arbor, MI), Hu C/D (1:1000, A21271; Invitrogen), NG2 (1:200, 
MAB5384; Millipore), NG2 (1:200, AB5320; Chemicon), Nestin (1:500, PRB-315C; 
Covance), Nestin (1:500, ab81755; Abcam), NeuN (1:1000, MAB377; Millipore), NICD 
1 (1:500, ab8925; Abcam), RC2 (1:40, University of Iowa Hybridoma Bank), RFP 
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(1:250, 632496; Clontech), Sox2 (1:1000, AB5603; Millipore), S100B (1:500; S2532; 
Sigma), and Tyrosine Hydroxylase (TH, 1:1000, TYH; Aves labs inc). Antibodies against 
RFP (1:250, 5F8; Chromotek) and Ki67 (1:500, ab1667; Abcam) were incubated 
overnight at room temperature. After 3 PBS washes, sections were incubated in 
secondary antisera (Alexa Fluor 488 or Alexa Fluor 594, 1:500; Molecular Probes) for 1 
hour at room temperature. Cell nuclei were stained with DAPI (Vector Laboratories, 
Burlingame, CA). Isotype controls: Rabbit IgG (2 µg/ml), Mouse IgG (2 µg/ml), and 
Mouse IgM (2 µg /ml) were used as negative controls for immunohistochemical stains as 
in Shimada et al. (2010). Photomicrographs were obtained using an epifluorescence 
deconvolution microscope with an automated x,y,z stage (Leica DM6000B, Leica, 
Wetzlar, Germany) and Leica FW4000 software. For deconvolution, images were 
obtained every 0.1 µm under 100 X magnification, and de-convolved using Leica Deblur 
software. For some photomicrographs, images were obtained using a confocal 
microscope (Zeiss LSM 510 META, Zeiss Microimaging, Thornwood, NY). 
Immunocytochemistry 
Cells were fixed with 4 % paraformaldehyde for 15 min at room temperature and washed 
3 times with PBS. Some cells were treated with methanol at 4 °C for longer than 1 hour 
to eliminate endogenous GFP or tdRFP expression. Cells were blocked as above, and 
incubated with primary antisera overnight at 4 °C: Nestin (1:1000, Covance), RC2 (1:40, 
University of Iowa Hybridoma Bank), Sox2 (1:1000, Chemicon), β-tubulin III (1:1000, 
PRB-435P, TUJ1; Covance), and GFAP (1:500, Sigma). Non-fixed, live cells were 
stained for O4 (1:50, O7139; Sigma) and then post-fixed for analysis. After 3 PBS 
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washes, cells were incubated in secondary antisera for 1 hour at room temperature. The 
coverglasses were mounted onto slides with DAPI or Citifluor (100496-532, VWR 
International).   
Cell quantification and statistics 
The infarct area was defined by tissue autofluorescence, whereas the peri-infarct area was 
defined by the presence of GFAP-positive reactive astrocytes. One out of every ten 
sections was quantified. Cell counts were performed by observers blinded to slide 
(sample) identity.  Cell numbers were determined with Optical Fractionator of Stereo 
Investigator in the cortical peri-infarct area (MBF Biosciences, Williston, VT). Stereo 
Investigator was used in conjunction with a Nikon Optiphot 2 microscope, a Hitachi 
HVC20 camera, a Heidenhahn focus encoder, and a motorized, computer-driven X–Z 
stage (all microscope attachments provided by MBF Biosciences). Under low 
magnification, the area of interest was identified and boundary contours were drawn 
using the software-pointing device. Spacing between sampling sites (grid size) was set 
such that 6-12 sampling sites were counted per section. For GFAP, RC2, Nestin or 
S100B-positive cell quantification, cell identity was ascertained by DAPI localization. 
We defined the inner peri-infarct area as cortical tissue that covered 200 µm radially 
outside the edge of the infarct core where proliferative reactive astrocytes were typically 
located (Shimada et al., 2010). All data were expressed as means and standard error 
means. Comparisons made between any two groups were performed by 2-tailed Student’s 





GFAP-positive reactive astrocytes express NSC-related proteins after cortical 
stroke. 
To study reactive astrocytes following stroke, we induced cortical infarcts by distal 
permanent middle cerebral artery occlusion (dMCAO) (Shimada et al., 2011). Three days 
following stroke, mice were euthanized and brains were prepared for analysis. TTC 
staining revealed that the infarct caused by dMCAO occurred exclusively in the cortex, 
but not in the striatum (Figure 1A).  Immunohistochemical studies identified numerous 
GFAP-positive reactive astrocytes on the ipsilateral side of the cortical infarct area, but 
not on the contralateral side of the cortex (Figure 1B, B’). GFAP-positive reactive 
astrocytes adjacent to the infarct core expressed the cell proliferation marker, Ki67, and 
several NSC-associated proteins such as Nestin, RC2 and Sox2 (Figure 1C-E) (Shimada 
et al., 2010). We did not observe Nestin or RC2 expression on the contralateral side of 
the brain after stroke. In agreement with recent studies, we observed that GFAP-positive 
reactive astrocytes did not express the oligodendrocyte progenitor cell marker, NG2 
(Dimou et al., 2008; Barnabe-Heider et al., 2010; Zawadzka et al., 2010). As reported, the 
NSC-associated protein, Sox2, was expressed by many reactive astrocytes and astrocytes 
in the cortex (Komitova and Eriksson, 2004). After stroke, we observed that GFAP-
positive reactive astrocytes and Nestin-positive reactive astrocytes expressed Sox2 in the 
peri-infarct area (Figure 1F,G). To examine whether stroke induced a greater number of 
cells that expressed NSC-associated proteins, we examined the number of Sox2-positive 
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cells after stroke. We observed a significantly increased number of Sox2-positive cells on 
the ipsilateral side of the brain compared with the contralateral side of the brain (n=3, p < 
0.01; Figure 1H).   
 
Heterogeneous populations of reactive astrocytes are observed in the peri-infarct 
area of GFAP-CreERTM;tdRFP mice after stroke. 
To examine GFAP-positive reactive astrocytes, we generated GFAP-CreERTM;tdRFP 
mice. In GFAP-CreERTM;tdRFP mice, tdRFP was induced permanently in GFAP-
positive cells after tamoxifen (TM) administration  (Luche et al., 2007; Chow et al., 
2008). Focal cortical stroke was induced by the dMCAO surgery on GFAP-
CreERTM;tdRFP mice. Mice received 0.1 mg/g of TM by intraperitoneal injection for 3 
consecutive days starting immediately after stroke.  Three days after dMCAO, mice were 
euthanized and brains were prepared for analysis.  tdRFP-positive cells were observed in 
the peri-infarct area (Figure 2A). By immunohistochemistry, 58.7% of GFAP-positive 
cells were positive for tdRFP, and 74.5% of tdRFP-positive cells expressed GFAP in the 
peri-infarct area of the cortex (n=3 mice; Figure 2A). To analyze further the 
characteristics of tdRFP-positive cells in the peri-infarct area, we stained for the presence 
of other proteins expressed by reactive astrocytes. Nestin is a marker of NSCs and neural 
progenitor cells, and its expression is observed in a subpopulation of reactive astrocytes 
after stroke (Shimada et al., 2010; White et al., 2010). Three days after stroke, 63.3% of 
Nestin-positive cells were positive for tdRFP, and 78.9% of tdRFP-positive cells 
expressed Nestin in the peri-infarct area of the cortex (n=3 mice; Figure 2B).  RC2 is a 
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commonly used marker of radial glial cells during development and is expressed by a 
subpopulation of reactive astrocytes after stroke that reside directly adjacent to the infarct 
core (Shimada et al., 2010). We observed that 41.5% of RC2-positive cells were positive 
for tdRFP, and 24.2% of tdRFP-positive cells expressed RC2 in the peri-infarct area of 
the cortex (n=3 mice; Figure 2C). S100B is a commonly used marker of astrocytes and 
reactive astrocytes (Sellers et al., 2009). We observed that 31.1% of S100B-positive cells 
were positive for tdRFP, and 28.4% of tdRFP-positive cells expressed S100B in the peri-
infarct area of the cortex (n=3; Figure 2D).  
 
Isolation of tdRFP-positive spheres from the cortical peri-infarct area after stroke. 
Previously, we reported the isolation of locally-derived NSC-like cells from the peri-
infarct area 3 days after stroke (Shimada et al., 2010). In that work, we observed neural 
sphere formation from peri-infarct tissues after stroke, but the cellular origin of the neural 
sphere-forming cells from the cortical peri-infarct area was not determined. To study the 
origin of locally-derived neural spheres after stroke, we isolated cells from the peri-
infarct area of GFAP-CreERTM;tdRFP mice 3 days following the dMCAO surgery 
(Figure 3A). To prevent contamination of typical NSCs residing in neurogenic niches, 
tissues from the anterior lateral ventricle, posterior lateral ventricle, hippocampal arch, 
dentate gyrus, white matter, and third ventricle were carefully excluded from the 
dissected peri-infarct tissues. We cultured cells in NSC growth medium with EGF and 
bFGF. After 2 weeks in culture, we observed tdRFP-negative spheres and tdRFP-positive 
spheres (n=3; Figure 3B,C). As a negative control, cortical tissues from the contralateral 
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side of the brain were harvested. From the contralateral side of cortical tissues, we did not 
observe sphere formation (n=3; Figure 3D).   
  
Lack of neuroblast migration from the SVZ to the cortex after stroke. 
To determine whether the cells that generated tdRFP-positive neural spheres had 
migrated from the SVZ after stroke, migrating neuroblasts were analyzed by 
immunohistochemistry.  Doublecortin-positive migrating neuroblasts did not migrate into 
the peri-infarct area from the SVZ 3 days following stroke (Figure 3E, F). Moreover, the 
staining pattern for doublecortin in the SVZ on the ipsilateral and contralateral sides of 
the brain was similar. Since there could be doublecortin-negative neuroblasts migrating 
from the SVZ to the peri-infarct area, we also stained to localize PSA-NCAM-positive 
immature neuroblasts. However, we did not observe PSA-NCAM-positive cells in the 
peri-infarct area 3 days following stroke (data not shown). To examine whether any cells 
from the lateral ventricle migrated into the peri-infarct area, DiI was injected into the 
lateral ventricle to label cells in the SVZ immediately after the dMCAO surgery.  As a 
positive control for DiI labeling, we examined whether DiI-positive cells migrated in the 
rostral migratory stream (RMS) from the SVZ. We observed the migration of DiI-
positive cells from the lateral ventricle to the RMS, demonstrating that our DiI injection 
was successful (data not shown). However, we found that DiI-positive cells did not 
migrate into the peri-infarct area 3 days after stroke (Figure 3G, H). These data indicated 
that cells from the lateral ventricle niche did not migrate into the cortical peri-infarct area 
within 3 days after MCA ligation in the dMCAO stroke model.   
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 We also examined tdRFP-positive cells in the SVZ. Similar to a report that used 
the same GFAP-promoter strain (Chow et al., 2008), we found that most GFAP-positive 
cells on the striatal side of the lateral ventricle did not express tdRFP in GFAP-
CreERTM;tdRFP mice (Figure 3I,J). We then isolated cells from the dorsal and lateral 
(striatal) sides of the lateral ventricle 3 days after dMCAO, and cultured them in NSC 
growth medium. After 1 to 2 weeks of culture, numerous lateral ventricle-derived neural 
spheres were observed (Figure 3K,L).  However, most spheres did not express tdRFP 
(n=3). Therefore, the lack of tdRFP-labeled neural spheres from the lateral ventricle 
appeared to relate to mosaicism in the transgenic mouse model.  As a positive control, 
cells from the hippocampus were also cultured. Many tdRFP-positive cells were observed 
in the SGZ of the hippocampus (data not shown). We then isolated cells from the 
hippocampus and cultured them in NSC growth medium. As expected, hippocampus-
derived neural spheres expressed tdRFP (data not shown). In agreement with previous 
reports, we failed to passage the hippocampus-derived neural spheres in culture (Seaberg 
and van der Kooy, 2002; Clarke and van der Kooy, 2011). Altogether, these data 
indicated that the tdRFP-positive neural spheres isolated from the cortical peri-infarct 
area after stroke had originated from tdRFP-positive reactive astrocytes of the peri-infarct 
area, and not from cells that had migrated from the SVZ. Hereafter, we call the injury-
induced tdRFP-positive neural sphere-forming cells “Reactive astrocyte-derived NSCs” 
or Rad-NSCs.        
 
Rad-NSCs self-renew and are multipotent in culture. 
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To examine the self-renewal and multipotential capacities of Rad-NSCs in culture, clonal 
Rad-NSC spheres were derived. To obtain clonal spheres, individual spheres from low 
density cultures were pipetted under microscopy into separate 24-well dishes. To confirm 
whether the isolated clonal sphere population was homogenous in terms of tdRFP 
expression, we analyzed the passaged clonal spheres by flow cytometry. As a negative 
control, we used postnatal day 4-derived NSCs (PD4-NSCs) that were negative for 
tdRFP. We confirmed that the clonal tdRFP-positive sphere population was homogenous 
for tdRFP expression (n=2; Figure 4A). To examine the self-renewal capacity of Rad-
NSCs ex vivo, sphere formation assays were performed with the clones. As a positive 
control, we used PD4-NSCs. As expected, PD4-NSCs formed secondary and tertiary 
spheres in culture. Clonal Rad-NSC spheres were also able to form secondary and tertiary 
spheres in culture. The number of Rad-NSC spheres was significantly less than that of 
cultures from PD4-NSCs, and the Rad-NSC spheres were smaller in size (number of 
spheres: secondary; p < 0.01, tertiary; p < 0.01, size of spheres: secondary; p <  0.01, 
tertiary; p <  0.01, n=3; Figure 4B,C). We observed that Rad-NSCs grew slower than 
PD4-NSCs (day 2; p < 0.01, day 4; p < 0.01, day 6; p < 0.01, n=4; Figure 4D). Rad-NSCs 
expressed several mRNAs commonly expressed by NSCs such as Sox2, Pax6, Mash1 and 
Olig2 (Figure 4E). To determine whether Rad-NSCs also expressed NSC-associated 
proteins, we performed immunocytochemistry. Immunocytochemical analysis 
demonstrated that tdRFP-positive Rad-NSCs expressed several stem cell-associated 
proteins, such as Sox2, Nestin, RC2 and GFAP in culture (Figure 4F-J).   
 248 
 To examine the multipotency of Rad-NSCs, dissociated Rad-NSCs were 
differentiated for 7 days. Immunocytochemistry demonstrated that cultured Rad-NSCs 
differentiated into neurons, astrocytes, and oligodendrocytes (Figure 4K-N). About 89% 
of Rad-NSCs differentiated into astrocytes. Since dissociated cell analysis does not fully 
examine the multipotency of spheres, we also used a more stringent test to examine 
multipotency. To examine the multipotency of Rad-NSC spheres and PD4-NSC spheres, 
clonal spheres were plated into 24-well dishes and differentiated for 7 days and then 
examined by triple immunocytochemistry (Figure 4O-Q). Following 
immunocytochemistry, the number of unipotent (astrocytes), bipotent (astrocytes and 
neurons, or astrocytes and oligodendrocytes) and tripotent (astrocytes, neurons and 
oligodendrocytes) spheres was quantified. Interestingly, Rad-NSC cultures contained 
significantly more tripotent spheres than did PD4-NSC cultures (unipotent, p= 0.32; 
bipotent, astrocytes and neurons, p=0.10; astrocytes and oligodendrocytes p=0.17; 
tripotent, p < 0.05; Figure 4Q).     
 
Control of Rad-NSC self-renewal by Presenilin 1- and Notch 1-dependent signaling. 
The Notch signaling pathway has critical roles in development and NSC maintenance. 
Notch is cleaved by gamma-secretase, and the intracellular domain is transported to the 
nucleus and interacts with DNA via DNA-binding proteins. Notch signaling maintains 
the undifferentiated state of NSCs, and also enhances gliogenesis from NSCs (Borghese 
et al.; Furukawa et al., 2000; Satow et al., 2001; Ge et al., 2002; Hitoshi et al., 2002; Iso 
et al., 2003; Eiraku et al., 2005; Alexson et al., 2006; Androutsellis-Theotokis et al., 
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2006; Patten et al., 2006) . Therefore, we examined whether reactive astrocytes in cortical 
peri-infarct tissues expressed the cleavage product of the Notch 1 receptor after stroke. 
By immunohistochemistry, GFAP-positive reactive astrocytes expressed Notch1 
Intracellular Domain (NICD1) in the cortical peri-infarct area after stroke (Figure 5) 
(Shimada et al., 2011). tdRFP-positive Rad-NSCs also expressed NICD1 in culture 
(Figure 5A). Based on the requirement for Notch signaling to maintain NSCs, we 
hypothesized that this gamma-secretase-mediated pathway also regulates Rad-NSCs. 
First, to determine whether gamma-secretase-mediated cleavage was required for 
proliferation, cultured Rad-NSCs were plated and treated with a gamma-secretase 
inhibitor (GSI) for 2 days. The number of Rad-NSCs decreased significantly following 
GSI treatment compared with vehicle control (p<0.01; Figure 5B), suggesting that a 
gamma secretase-mediated pathway regulated the proliferation of Rad-NSCs.   
 Presenilin 1 is thought to act as the catalytic subunit for gamma secretase (Fortini, 
2002). To determine whether gamma secretase itself was important for self-renewal of 
Rad-NSCs, we generated GFAP-CreERTM;Presenilin 1 inducible conditional knock out 
(GP cKO) mice.  In GP cKO mice, Presenilin 1 is deleted after TM treatment in GFAP-
positive reactive astrocytes. To determine if Presenilin 1 expression levels were 
decreased in astrocytes in GP cKO mice following TM treatment, we isolated astrocytes 
by MACS using an antibody against GLAST, a cell surface protein commonly expressed 
by astrocytes (Mori et al., 2006). We confirmed that sorted GLAST-positive cells 
expressed GFAP by western blotting, indicating that GLAST-positive cells were enriched 
for astrocytes (Figure 5C). GLAST-positive astrocytes were isolated and used for further 
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analysis. We treated GP cKO mice with TM for 3 days and isolated astrocytes. By 
immunoblotting, we observed decreased Presenilin 1 expression levels in TM treated 
mice compared with vehicle treated mice 14 days after TM treatment but not 3 days after 
TM treatment, suggesting that residual Presenilin 1 was present in a proportion of 
GLAST-positive cells at 3 days after TM treatment (Figure 5D and data not shown). It is 
noteworthy that by analysis of GFAP-CreERTM;tdRFP mice, not all GFAP-positive cells 
expressed Cre enzyme (Figure 2A). Therefore, we did not expect to observe knockout of 
Presenilin 1 in all astrocytes of GP cKO mice. To determine whether reduction of 
Presenilin 1 affected neural sphere formation from reactive astrocytes after stroke, Rad-
NSCs were isolated from cortical peri-infarct tissues 3 days after stroke from GP cKO 
mice that were treated with TM for 3 consecutive days after MCA ligation. As negative 
controls, Rad-NSC spheres were isolated from the brains of GP cKO mice that were 
treated with corn oil, and also from littermate control mice (GFAP-CreERTM;Presenilin 1 
heterozygous mice or Presenilin 1-loxp mice) that were treated with TM. After 2 weeks 
in culture, the number of neural spheres generated decreased significantly for GP cKO 
mice treated with TM compared with both negative control groups (n=6-8 for each group; 
Figure 5E). To understand whether cell proliferation affected neural sphere formation 
from GP cKO-derived Rad-NSCs, we isolated clonal Rad-NSCs from GP cKO mice 3 
days after stroke. Clonal Rad-NSCs were treated with either ethanol (vehicle control) or 
4-OH-TM to flox Presenilin 1 in culture. Two days following treatment, the proliferation 
of Rad-NSCs was examined by CyQUANT assay and MTS assay. We observed that 
conditional knockout of Presenilin 1 significantly reduced the proliferation of cultured 
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Rad-NSCs (n=4 for each group; Figure 5F,G). Therefore, gamma-secretase mediated 
signaling controlled both the generation of Rad-NSCs from cortical reactive astrocytes 
after stroke injury as well as the proliferation of Rad-NSCs in culture. 
 To determine whether Notch1 signaling was important for self-renewal in Rad-
NSCs, inducible GFAP-CreERTM;Notch 1 conditional knockout (GN cKO) mice were 
generated.  In the GN cKO mice, Notch 1 is deleted after TM treatment in GFAP-positive 
reactive astrocytes. To examine Notch 1 expression levels in astrocytes, we performed 
western blotting using sorted GLAST-positive cells. We observed decreased Notch1 
expression levels in TM treated mice compared with oil treated mice (Figure 5H). Next, 
we examined expression of NICD1 in reactive astrocytes. By immunohistochemistry, we 
observed lack of NICD1 expression in reactive astrocytes in TM-treated mice, but not 
corn oil-treated mice 3 days after stroke (Figure 5I,J). To determine whether Notch 1 
reduction affected proliferation of reactive astrocytes, the number of proliferating 
reactive astrocytes was quantified in the peri-infarct area 3 days following dMCAO. 
Three days after stroke, the number of total GFAP-positive astrocytes or the overall 
number of Ki67-positive proliferating cells did not differ among treatment groups (data 
not shown). However, in agreement with our previous study, the number of proliferating 
reactive astrocytes was significantly decreased in TM-treated GN cKO mice compared 
with TM-treated GN heterozygous cKO mice and the corn oil-treated group (Shimada et 
al., 2011). The number of proliferating reactive astrocytes was also significantly 
decreased in TM-treated GN heterozygous cKO mice compared with corn oil-treated 
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mice of the same genotype (n=3-4; Figure 5K-N). These data indicate that Notch 1 
knockout affects reactive astrocyte proliferation in vivo.   
 To determine whether Notch 1 signaling affected neural sphere formation by 
reactive astrocytes after stroke, Rad-NSCs were isolated from cortical peri-infarct tissues 
of GN cKO mice that were treated with TM for 3 consecutive days after dMCAO. The 
number of neural spheres generated in culture decreased significantly for GN cKO mice 
treated with TM compared with corn oil-treated mice. Interestingly, the number of neural 
spheres was significantly decreased for GN heterozygous mice too (n = 4; Figure 5O). To 
understand whether cell proliferation affected neural sphere formation in GN cKO-
derived Rad-NSCs, we isolated clonal Rad-NSCs from GN cKO mice 3 days after stroke. 
Clonal Rad-NSCs were treated with either ethanol or 4-OH-TM to reduce Notch1 levels 
in cultured cells. Two days following treatment, the number of Rad-NSCs was examined. 
By CyQUANT assay and MTS assay, we observed that reduction of Notch1 significantly 
reduced the number of cultured Rad-NSCs (n = 4; Figure 5P, Q). Therefore, Notch 1 
signaling controlled both the generation of Rad-NSCs from reactive astrocytes as well as 
the proliferation of Rad-NSCs in culture. To examine whether downstream aspects of the 
Notch 1 signaling pathway was altered in TM-treated GN cKO-derived Rad-NSCs, Notch 
target gene mRNAs were examined by quantitative real time-PCR (qRT-PCR). First, we 
confirmed that Notch 1 was deleted in Rad-NSCs derived from TM-treated GN mice by 
RT-PCR. We did not observe Notch 1 expression in Rad-NSCs derived from TM treated 
GN mice (data not shown). qRT-PCR results also demonstrated that Hes1, Deltex and 
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Rbpj mRNA levels were all significantly decreased in Rad-NSCs derived from TM 
treated GN mice compared with corn oil treated GN mice (n=3-6; Figure 5R).  
 
Transplanted Rad-NSCs self-renew in vivo. 
To study the self-renewal capacity of Rad-NSCs in vivo, tdRFP-positive Rad-NSCs were 
transplanted into day 0-4 mouse brains (Figure 6A). First, to examine retention of 
transplanted cells and their location, we injected DiI into the day 0 mouse brains. Four 
hours after injection, we observed DiI-positive cells located in the lateral ventricle. DiI-
positive cells were also observed in the needle track (Figure 6B). Twenty eight days after 
transplantation, we observed tdRFP-positive cells residing in the lateral ventricle walls 
(Figure 6C-F). We then investigated whether transplanted tdRFP-positive cells might 
reside in the lateral ventricle as NSCs. By Immunohistochemistry, tdRFP-positive cells in 
the SVZ expressed GFAP and Sox2 (Figure 6C, D). However, we did not observe Rad-
NSCs that expressed Ki67, suggesting that tdRFP-positive cells were not actively 
dividing at the time of the assay (Figure 6E). To examine whether transplanted Rad-
NSCs proliferated in vivo, we injected BrDU to the mice for 5 consecutive days 
immediately after transplantation. We observed BrDU-positive Rad-NSCs in the SVZ 1 
month after transplantation, indicating that tdRFP-positive Rad-NSCs proliferated in the 
SVZ after transplantation (Figure 6F).   
 To examine whether Rad-NSCs maintained stem cell characteristics in the mouse 
brain after transplantation, we repeated transplantation of Rad-NSCs to day 0-4 mouse 
brains and dissected tissues from the lateral ventricle after 28 days (Figure 6G). From 
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these isolates, we observed neural sphere formation after 1 week of culture in NSC 
growth medium (Figure 6H,I). These data indicated that Rad-NSCs transplanted to the 
SVZ self-renewed and maintained their multipotency for differentiation. Notably, we 
observed both tdRFP-positive and tdRFP-negative neural spheres in culture, indicating 
that some neural spheres were obtained from host-derived NSCs of the SVZ, whereas 
some had derived from transplanted tdRFP-positive Rad-NSCs.   
To determine the self-renewal capacity and multipotency of secondary-transplanted 
tdRFP-positive Rad-NSCs (hereafter called 2nd Rad-NSCs), clonal tdRFP-positive 
spheres were isolated from mixed sphere cultures and analyzed. The purity of tdRFP cells 
in the clones was examined by flow cytometry. We found that clonally-isolated 2nd Rad-
NSCs were homogeneous in terms of tdRFP expression (n=6; Figure 6J). To confirm that 
2nd Rad-NSCs had self-renewal capacity and multipotency, sphere formation assays and 
differentiation assays were performed. Similar to primary Rad-NSCs, dissociated clonal 
2nd Rad-NSCs differentiated into neurons, astrocytes, and oligodendrocytes in culture 
(Figure 6K-N). To examine the multipotency of clonal 2nd Rad-NSC spheres, spheres 
were plated into 24-well dishes and differentiated for 7 days. Multipotency of clonal 2nd 
Rad-NSC spheres was examined by immunocytochemistry (Figure 6O). Following 
immunocytochemistry, the number of unipotent (astrocytes), bipotent (astrocytes and 
neurons, or astrocytes and oligodendrocytes) and tripotent (astrocytes, neurons, and 
oligodendrocytes) spheres were quantified (Figure 6P). We observed that 42% of spheres 
from clonal 2nd Rad-NSCs were tripotent. Clonal 2nd Rad-NSCs also formed secondary 
and tertiary spheres, suggesting that 2nd Rad-NSCs self-renewed ex vivo (Figure 6Q, R). 
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Therefore, the primary Rad-NSCs that were transplanted into neonatal brains maintained 
their ability to self-renew as NSCs in vivo for 28 days. 
 
Transplanted Rad-NSCs generate astrocytes and oligodendrocytes in vivo. 
To examine further the self-renewal and multipotency of tdRFP-positive Rad-NSCs in 
vivo, we first transplanted GFP-positive PD4-NSCs that were isolated from the lateral 
ventricles of healthy mice. For some transplants, the location of GFP-positive cells was 
examined 4 hours after transplantation. As expected, we observed many GFP-positive 
PD4-NSCs in the lateral ventricle and the needle track (Figure 7A). Other groups of 
transplanted mice were examined 28 days after transplantation. In these mice, many 
surviving GFP-positive cells were observed to remain in the SVZ after injection (Figure 
7B). Notably, however, we also observed GFP-positive cells in the olfactory bulb (Figure 
7C). To examine whether transplanted GFP-positive PD4-NSCs differentiated into 
neurons in vivo, confocal imaging was performed to visualize NeuN/GFP-positive cells in 
the olfactory bulb. We found that 66.6% of GFP-positive cells differentiated into NeuN-
positive neurons in the olfactory bulb (n=48 cells, n=4 mice; Figure 7D). We also 
observed 5% GFP-positive cells, derived from PD4-NSCs, that differentiated into GFAP-
positive astrocytes in the olfactory bulb (n=20 cells, n=2 mice; Figure 7E).   
 To examine whether adult NSCs were multipotent following transplantation, we 
isolated adult NSCs from the lateral ventricles of adult mice (4-8 weeks of age). We 
obtained adult NSCs from GFP mice and also from mT/mG mice. Cells derived from 
mT/mG mice express tdTomato without Cre recombination and provide a bright red 
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signal to track cell lineage. We transplanted GFP-positive or tdTomato-positive cells into 
the lateral ventricles of neonatal mice (Figure 7F). We observed migrating lineage-traced 
cells in the RMS 1 month after transplantation (Figure 7G).  Differentiated neurons and 
astrocytes derived from adult NSCs were also observed in the olfactory bulb. After 1 
month, we found that 16.2% of transplanted lineage-traced adult NSCs differentiated into 
NeuN-positive neurons once they reached the olfactory bulb (n=482 cells, 3 mice; Figure 
7H).  We also observed that 14.1% of adult NSCs differentiated into GFAP-positive 
astrocytes in the olfactory bulb (n=377 cells, 3 mice; Figure 7I). These data confirmed 
that the multipotency of cultured adult NSCs could be evaluated by in vivo 
transplantation back to mouse brains (Neumeister et al., 2009).   
 We then examined the multipotency of transplanted tdRFP-positive Rad-NSCs.  
tdRFP-positive Rad-NSCs were transplanted into the RMS, lateral ventricle (SVZ), and 
hippocampi (SGZ) of adult C57BL/6J mice. Twenty-eight days after transplantation, 
brains were examined by immunohistochemistry. tdRFP-positive cells localized primarily 
to the injection areas in the RMS, SVZ, and SGZ (n=3-13 mice; Figure 8A-C). In adults, 
transplanted tdRFP-positive cells did not migrate to the RMS from the SVZ, and we did 
not observe tdRFP-positive cells in the olfactory bulb 1 month after transplantation.  
Moreover, after 1 month, no tdRFP-positive cells expressed NeuN (mature neuronal 
marker) in the striatum, SVZ or SGZ, suggesting that the adult mouse brain did not 
provide a suitable environment for Rad-NSCs to differentiate into neurons.   
 To determine if the age of the host affected the differentiation output from Rad-
NSCs, tdRFP-Rad-NSCs were transplanted into postnatal day 0-4 mouse brains (n=15 
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mice).  Following tdRFP-positive Rad-NSC transplantation, tdRFP-positive cells 
localized to the SVZ, gray matter, and white matter (Figure 8D,E and data not shown). 
After 28 days, transplanted tdRFP-positive Rad-NSCs differentiated into GFAP-positive 
astrocytes and GST-π-positive oligodendrocytes in both gray and white matter (n=85-198 
cells; Figure 8D-G).  Although we observed tdRFP-positive cells in the SVZ, we did not 
observe any tdRFP-positive cells in the RMS or olfactory bulb. These data indicated that 
tdRFP-positive cells did not migrate into the olfactory bulb from the SVZ 1 month after 
transplantation into neonates. Additionally, tdRFP-positive cells were detected after 
direct transplantation to the hippocampus. However, analysis by confocal microscopy 
demonstrated that transplanted tdRFP-positive Rad-NSCs also did not differentiate into 
NeuN-positive mature neurons in the hippocampus (Figure 8F). Similarly, we did not 
observe tdRFP-positive cells expressing NeuN in gray or white matter 28 days after 
transplantation into brains of neonates (n=489 cells; Figure 8G). Since immature 
neuroblasts and some mature neurons do not express NeuN, we checked for other 
markers of neurogenesis. However, tdRFP-positive cells did not express other neuronal 
proteins, such as β-tubulin III, doublecortin, Hu C/D or PSA-NCAM (data not shown). 
Therefore, tdRFP-positive Rad-NSCs differentiated into GFAP-positive astrocytes and 
GSTπ -positive oligodendrocytes, but not neurons 1 month after transplantation into 
neonates.   
 Because tdRFP-positive Rad-NSCs might require a longer time to differentiate 
into neurons, we also examined transplanted cells 3 months after transplantation into 
neonates. Three months after transplantation, tdRFP-positive cells expressed Nestin and 
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Sox2 and also stained positive for BrDU in the SVZ, suggesting that self-renewing 
tdRFP-positive cells could reside in the SVZ for 3 months (n=4 mice; Figure 8H-J). 
Interestingly, at this time point, we observed that some tdRFP-positive cells had migrated 
to the olfactory bulb. However, immunohistochemistry showed that tdRFP-positive cells 
did not express NeuN in the olfactory bulb (n=117 cells; Figure 8K). Since not all 
neurons in the olfactory bulb express NeuN, we also performed immunohistochemistry 
using other neuronal markers, such as β-tubulin III, doublecortin, TH, Calretinin and 
Calbindin (Parrish-Aungst et al., 2007; Batista-Brito et al., 2008). tdRFP-positive cells 
did not express any of these additional neuronal markers (n=68-109 cells; Figure 8L and 
data not shown). In contrast, we observed that 21% of tdRFP-positive cells expressed 
GFAP. Thus, after 3 months, tdRFP-positive Rad-NSCs had migrated into the olfactory 
bulb and differentiated into astrocytes, but not neurons (n=123 cells; Figure 8M). To 
better understand the identify of the Rad-NSC-derived cells in the olfactory bulb, we 
performed double stains for RFP and GalC (a marker of oligodendrocytes), NG2 (a 
marker of oligodendrocyte progenitor cells and pericytes), and smooth muscle alpha actin 
(SMA, a marker of smooth muscle cells and myofibroblasts). Despite confirmation of 
positive staining for each marker throughout the brain, we did not observe any tdRFP-
positive cells that co-expressed GalC, NG2, or SMA (data not shown).  
 To determine if the embryonic brain environment was more suitable for neuronal 
differentiation of Rad-NSCs, we transplanted tdRFP-positive Rad-NSCs in utero into 
embryonic day 15 (E15) mouse brains. Mice were euthanized at E20 to examine neuronal 
differentiation. We observed many tdRFP-positive cells in both gray and white matter 
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(Figure 8N). Although many tdRFP-positive cells were observed throughout the brains, 
transplanted tdRFP-positive Rad-NSCs did not differentiate into NeuN-, Hu C/D-, or β-
tubulin III-positive neurons (n=837 cells, n=5 mice; Figure 8N,O and data not shown). 
We observed that 53% of tdRFP-positive cells expressed GFAP in gray and white matter 
(n=548 cells, n= 5 mice; Figure 8O). Therefore, despite their ability to generate neurons 
in culture, we did not observe transplanted Rad-NSCs that differentiated into neurons in 
vivo, regardless of host age.   
 
Native reactive astrocytes are unipotent in vivo following stroke. 
To determine whether endogenous reactive astrocytes are multipotent in the peri-infarct 
area following stroke, we analyzed the cell types that were generated in the peri-infarct 
area 1 month after stroke. We treated mice with BrDU immediately after stroke surgery 
for 5 consecutive days and analyzed the mice 1 month after stroke. In agreement with our 
previous study (Shimada et al., 2010), we did not observe BrDU-positive mature neurons 
in the cortical peri-infarct area 1 month after stroke (n=3; Figure 9A). We observed 
BrDU-positive newly-generated astrocytes and oligodendrocytes, (Figure 9B,C), but the 
origin of these cells was not clear.  To determine whether native reactive astrocytes were 
multipotent in the cortical peri-infarct area in vivo after stroke, we performed a lineage 
tracing study with GFAP-CreERTM;tdRFP reporter mice. Lineage tracing demonstrated 
that tdRFP-positive reactive astrocytes did not differentiate into NeuN-positive mature 
neurons or GSTπ-positive oligodendrocytes, but remained as GFAP-positive reactive 
astrocytes in the peri-infarct area 28 days following stroke (n=3; Figure 9D-F). Therefore, 
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endogenous tdRFP-positive reactive astrocytes were unipotent, and not multipotent in the 
cortical peri-infarct area following stroke.    
 
DISCUSSION     
Our data demonstrate that cortical GFAP-expressing reactive astrocytes isolated from the 
stroke injury environment can de-differentiate into Rad-NSCs that self-renew and are 
multipotent. Lineage tracing demonstrated that reactive astrocytes are a cell of origin for 
NSCs derived from in the cortical peri-infarct tissues after stroke. Our data also showed 
that Rad-NSCs did not originate from cells that had migrated from the SVZ after stroke. 
Previously, there were several possibilities regarding the cellular origin of cortical neural 
sphere-forming cells after stroke: (1) neuroblasts or progenitor cells that migrated from 
the SVZ to the cortex in the absence of stroke, (2) neuroblasts or progenitor cells that 
migrated from the SVZ to the cortex after stroke, (3) bona fide stem cells that resided in 
non-neurogenic niches, (4) oligodendrocyte progenitor cells, (5) pericytes, and (6) 
reactive astrocytes. However, several of the possibilities were unlikely candidates for the 
origin of Rad-NSCs. For example, in the brains of uninjured adult rodents, NSCs from 
the SVZ are not known to migrate to the cortex after the completion of development 
(Chen et al., 2009). In addition, NSCs or progenitors from the SVZ do not migrate to the 
damaged cortex following brain stab injury or focal cortical stroke (Buffo et al., 2008; 
Nakagomi et al., 2009; Shimada et al., 2010). Notably, we and others have not been able 
to generate neural spheres from healthy adult cortical tissue (e.g. contralateral, uninjured 
side of the cortex after stroke). In our hands, cells that reside in healthy cortex such as 
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NG2-expressing oligodendrocyte progenitor cells, or other adult stem/progenitor cells 
that potentially reside in non-neurogenic niches do not form neural spheres in NSC 
growth medium. Furthermore, Buffo et al. (2008) sorted NG2-positive cells from cortical 
tissue after stab injury and found that they did not give rise to neural spheres. In 
agreement with our GFAP lineage tracing studies after stroke, GLAST-positive reactive 
astrocytes were reported to form multipotential neural spheres in culture after brain stab 
injury (Buffo et al., 2008). Therefore, reactive astrocytes are the most plausible candidate 
for the cells that produce neural spheres from cortical tissue, regardless of type of injury. 
It is noteworthy that we also obtained tdRFP-negative spheres from the peri-infarct area. 
Although it is of interest to study the origin of these cells, we focused on GFAP-CreER-
positive cell populations. Because inducible lineage tracing mice do not tag all relevant 
cells (we found that Cre was not expressed by 100% of GFAP-positive cells), some of the 
tdRFP-negative neural spheres could have derived from GFAP-expressing reactive 
astrocytes that were not labeled. Since reactive astrocytes are phenotypically 
heterogeneous in the peri-infarct area, generating other types of transgenic mice to track 
subpopulations of reactive astrocytes would likely provide valuable tools to improve 
understanding of reactive astrogliosis and also possibly neurogenesis (Li and Chopp, 
1999; Ganat et al., 2006; Shimada et al., 2010; White et al., 2010; Bi et al., 2011).   
Hematopoietic stem cell self-renewal capacity is generally tested in vivo using 
transplantation studies (Kiel and Morrison, 2008; Nakada et al., 2011). Recently, the 
Taylor group reported transplantation assays in mice to examine NSC self-renewal 
capacity (Neumeister et al., 2009). They found that transplantation of typical mouse 
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NSCs into embryonic or neonatal brains could generate neurons (Neumeister et al., 
2009). With a similar transplantation model, we showed that cultured PD4-NSCs and 
adult NSCs that both were derived from the SVZ could migrate to the olfactory bulb in 1 
month and produce mature neurons (NeuN-positive). To test the self-renewal and 
multipotency of Rad-NSCs, we transplanted Rad-NSCs into the RMS, SVZ, or SGZ, in 
adult mice, and also into the brains of neonatal mice and embryonic mice. Following 
transplantation, Rad-NSCs in the SVZ expressed Sox2 and GFAP and BrDU 
incorporation assays showed that Rad-NSCs proliferated in the SVZ after neonatal 
transplantation. Transplanted Rad-NSCs could be re-isolated from the SVZ and grown as 
NSCs, even after remaining 28 days in vivo. These data suggest that some Rad-NSCs 
may maintain their capacity to self-renew as multipotent NSCs in the SVZ after 
transplantation.     
Despite their tri-potent capacity and ability to produce neurons in culture, Rad-NSCs 
differed from SVZ-derived PD4-NSCs and adult NSCs in their ability to migrate to the 
olfactory bulb and also in their ability to generate neurons once they reached the olfactory 
bulb. The restriction for Rad-NSCs to produce neurons in vivo did not appear to involve 
age-related changes in environmental (neurogenic) cues from the host; Rad-NSCs did not 
differentiate into neurons in the brains of adult, neonatal or embryonic hosts.  
Transplanted Rad-NSCs were at most, bipotent, producing astrocytes and 
oligodendrocytes, but not neurons. Based on the similarities between Rad-NSCs and 
bona fide NSCs from the SVZ in culture, and their differences following transplantation 
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in vivo, Rad-NSCs may provide a valuable system to identify epigenetic and/or other 
regulators of neurogenesis. 
We identified Presenilin1-based Notch 1 signaling as a mechanism that controlled the 
generation, proliferation, and self-renewal of Rad-NSC neural spheres. Consistent with 
our study, other groups have shown that Notch 1 plays a critical role in the proliferation 
and self-renewal of embryonic and adult NSCs (Borghese et al.; Hitoshi et al., 2002; 
Androutsellis-Theotokis et al., 2006; Breunig et al., 2007; Ables et al., 2010; 
Veeraraghavalu et al., 2010).  Therefore, both Rad-NSCs and typical NSCs utilize a 
common pathway that regulates stem cells.  
The mechanisms that control de-differentiation of reactive astrocytes into Rad-NSCs, will 
be interesting to study. Because we did not obtain any neural spheres from the 
contralateral side of the cortex after stroke, our data indicate that the cortical peri-infarct 
area contains signals that are permissive to the de-differentiation of reactive astrocytes. 
Importantly, however, de-differentiation did not appear to occur in vivo. Lineage tracing 
demonstrated that GFAP-positive reactive astrocytes were unipotent in the peri-infarct 
area 28 days after stroke. Therefore, the combination of signals from the injury 
environment after stroke, (e.g. hypoxia, reactive oxygen species, cytokines, growth 
factors, Notch ligands, etc.) and signals during culture in NSC growth medium (e.g. 
bFGF and/or EGF) are both important for the generation of Rad-NSCs.   
All reactive astrocytes may not have the capacity to de-differentiate after stroke injury. 
Reactive astrocytes are heterogeneous after injury, composed of subpopulations of cells 
that differentially express proteins associated with stem/progenitor cells (White et al., 
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2010). Some reactive astrocytes proliferate, but many do not (Robel et al., 2011). We 
recently identified RC2/Nestin/GFAP-positive reactive astrocytes in the cortical peri-
infarct after stroke (Shimada et al., 2010). The RC2-positive subpopulation of reactive 
astrocytes also expressed Sox2 and NICD1, proliferated, and was located immediately 
adjacent to the infarct core. We found that the RC2 antigen was undetectable in uninjured 
adult cortex, or in the contralateral cortex after stroke. RC2 is an antigen commonly used 
to label radial glial cells during development, and is not expressed by astrocytes in 
uninured adults (Misson et al., 1988; Hartfuss et al., 2001; Dromard et al., 2007). We 
found that cultured RAD-NSCs as well as typical NSCs express RC2. Based on their 
unique appearance in injured cortical tissue, their proliferation, and their protein 
expression, the subpopulation of RC2-positive reactive astrocytes may contain the cell of 
origin for Rad-NSCs. Because neuroblast migration from the SVZ is limited or absent in 
strokes that do not involve the striatum (Shimada et al., 2010), proliferating RC2-positive 
reactive astrocytes may provide a target cell population for in vivo reprogramming to 
enhance neurogenesis in cortical peri-infarct tissues after stroke.  
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Figure 1. Emergence of reactive astrocytes in the peri-infarct area after stroke.  (A) 
Representative TTC staining of an infarct in C57BL/6J mouse brain. The infarct region is 
white. (B, B’) GFAP-positive reactive astrocytes (green) were observed surrounding the 
infarct area on the ipsilateral side of the cortex, but not on the contralateral side of the 
cortex. (C-E) Some GFAP-positive reactive astrocytes (red) expressed Ki67 (C, green) 
and Nestin (D, green), but did not express NG2 (E, green) in the peri-infarct area. (F, G) 
GFAP- and Nestin-positive reactive astrocytes (red) expressed Sox2 (green). (H) The 
number of Sox2-positive cells was significantly greater on the ipsilateral side of the 
cortex compared with the contralateral side of the cortex after stroke. Arrows indicate 
colocalizations. Scale bars indicate 50 µm unless otherwise noted. Dotted lines indicate 















































Figure 2. Heterogeneous tdRFP-positive reactive astrocytes in GFAP-
CreERTM;tdRFP mice. 
(A-D) Three days after stroke and TM treatment, tdRFP-positive reactive astrocytes (red) 
expressed GFAP (A, green), Nestin (B, green), RC2 (C, green), and S100B (D, green) in 
the peri-infarct area in GFAP-CreERTM;tdRFP mice. The percentage of colocalization 
was quantified in the peri-infarct area. Arrows indicate colocalizations. Scale bars 



















































































Figure 3. tdRFP-positive reactive astrocyte-derived NSCs (Rad-NSCs) isolated from 
the cortical peri-infarct area. (A) Schematic illustration of cell isolation from the 
cortical peri-infarct area 3 days after stroke. Tissue was dissected from the area 
delineated by the black box. (B, C) Clonally-isolated cells formed neural spheres that 
expressed tdRFP (TRITC filter) in culture. (D) We were unable to generate neural 
spheres from tissues of the contralateral side of the cortex. (E, F) Neuroblasts 
(Doublecortin, DCX) did not migrate from the SVZ to the peri-infarct area in the cortex 3 
days after stroke. Note that the relative staining areas for contralateral (F) and ipsilateral 
(E) DCX-positive cells did not differ. (G) Schematic illustration of DiI injection 
immediately after stroke to label migrating cells derived from the lateral ventricle. (H) 
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DiI-labeled cells (red) did not reach the cortical peri-infarct area 3 days after stroke. (I, J) 
Most GFAP-positive cells (green) on the lateral side of the LV did not express tdRFP 
(red), but colocalization was observed in the medial side of the LV in GFAP-
CreERTM;tdRFP mice. (K, L) Most neural spheres isolated from the dorsal and lateral 
sides of the LV of GFAP-CreERTM;tdRFP mice did not express tdRFP. Cell nuclei are 
shown by DAPI staining (blue). Scale bars represent 200 µm where indicated, otherwise 
50 µm. LV indicates lateral ventricle.   
 
Figure 4. Cultured Rad-NSCs have characteristics of NSCs, self-renew, and are 
multipotent ex vivo. (A) Clonally-isolated Rad-NSCs were homogenous in terms of 
tdRFP expression (gray). Post-natal day 4 (PD4)-derived NSCs (blue) were used as a 
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negative control. (B, C) By sphere formation assays, Rad-NSCs formed fewer and 
smaller spheres compared with PD4-derived NSCs. (D) Rad-NSCs proliferated at a 
slower rate compared with PD4-NSCs. (E) By RT-PCR assays, Rad-NSCs expressed 
different transcription factor mRNAs associated with NSCs. (F-J) Stem cell-related 
proteins and the cell proliferation marker, Ki67 (green), were also expressed by Rad-
NSCs (tdRFP, red). (K-N) Cultured Rad-NSCs (red) were dissociated and differentiated 
into Tuj1-positive neurons (K, green), GFAP-positive astrocytes (L, green) and O4-
positive oligodendrocytes (M, green). Note that most Rad-NSCs differentiated into 
astrocytes. (O-Q) Multipotency of clonal Rad-NSC spheres and clonal PD4-NSC spheres. 
(O, P) Tuj1-positive neurons (red), O4-positive oligodendrocytes (green), and GFAP-
positive astrocytes (blue) were stained by immunocytochemistry. Side panels provide 
magnified view of neurons (red), oligodendrocytes (green) and astrocytes (blue) in 
separate channels. (Q) The number of unipotent (A, astrocytes only), bipotent (A+N, 
astrocytes and neurons; A+O, astrocytes and oligodendrocytes) and tripotent (A+N+O, 
astrocytes, neurons and oligodendrocytes) spheres was quantified.  Rad-NSCs produced 
more tripotent spheres than PD4-NSCs.  Side panels (F-M) show FITC and TRITC 
channels. Arrows indicate co-localizations. Cell nuclei are shown by DAPI staining 




Figure 5. Notch 1 signaling regulates self-renewal of Rad-NSCs. (A) NICD1 (green) 
was expressed in tdRFP-positive Rad-NSCs (red) in culture. (B) Gamma-secretase 
inhibitor (GSI) treatment reduced the number of Rad-NSCs compared with DMSO 
treatment. (C) GLAST-positive cells were sorted from mouse brains by MACS. GLAST-
positive cells were enriched with GFAP compared with GLAST-negative cells (as 
determined by immunoblotting).  β-Actin levels were used as an internal loading control. 
(D) Following TM treatment of GFAP-CreERTM;Presenilin 1 cKO mice (GP mice), 
Presenilin 1 expression levels decreased compared with levels in oil-treated GP mice. 
GAPDH was used as an internal loading control.  (E) TM treatment of GP mice 
significantly reduced the number of neural spheres formed in culture compared with 
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both significantly reduced following 4-OH-TM treatment compared with vehicle control. 
(H) Following TM treatment of GFAP-CreERTM;Notch 1 cKO mice (GN mice), NICD1 
expression levels in sorted GLAST-positive cells were decreased compared to levels in 
control oil-treated mice. (I, J) TM treatment of GN mice (I), but not oil treatment (J) 
removed NICD1 (green) expression in GFAP-positive reactive astrocytes (red). (K-M) 
The numbers of Ki67 (green)-positive proliferating reactive astrocytes (GFAP, red) were 
compared in oil- or TM- treated GN mice and TM-treated GN heterozygous mice. (N) 
TM treatment of GN mice and TM treatment of GN heterozygous mice significantly 
reduced the number of proliferating reactive astrocytes compared with oil treatment of 
GN mice. TM treatment of GN mice significantly reduced the number of proliferating 
reactive astrocytes compared with TM treatment of GN heterozygous mice. (O) TM 
treatment of GN mice and TM treatment of GN heterozygous mice significantly reduced 
the number of neural spheres formed in culture compared with oil treatment of GN mice. 
(P, Q) 4-OH-TM treatment significantly reduced the proliferation of Rad-NSCs from GN 
mice and GN heterozygous mice compared with vehicle control (EtOH). (P) CyQUANT 
assay. (Q) MTS assay. (R) mRNA levels for proteins expressed downstream of Notch 
signaling were decreased in Rad-NSC spheres derived from TM -treated GN mice 
compared with oil-treated GN mice. Cell nuclei are shown by DAPI staining (blue). TM: 
Tamoxifen.  Arrows indicate co-localizations. Scale bars represent 50 µm.  * p < 0.05. ** 
p < 0.01,  *** p < 0.001   
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Figure 6. Self-renewal capacity of transplanted Rad-NSCs in vivo. (A) Schematic 
illustration of tdRFP-positive Rad-NSC transplantation into post-natal day 0-4 C57BL/6J 
mouse brain. (B) DiI staining shown 4 hours after transplantation of labeled cells into 
post-natal day 0 mouse brain. DiI was observed in the lateral ventricle and the needle 
track. (C-F) tdRFP-positive Rad-NSCs (red) located in the SVZ 28 days after 
transplantation.  (C, D) tdRFP-positive cells expressed stem cell markers, GFAP (C) and 
Sox2 (D).  (E) tdRFP-positive cells did not express Ki67, suggesting that these cells were 
not actively dividing.  Side panels show type B cell-like shape of engrafted tdRFP-
positive cells. (F) tdRFP-positive cells expressed BrDU, suggesting that these cells self-
renewed in the SVZ after transplantation. Insets (C, D, F) show deconvolution for co-
localization (x,y,z planes). (G) Schematic illustration of cell isolation from lateral 
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Rad-NSC-derived, and typical C57BL/6J-derived neural spheres ex vivo.  Arrow: Rad-
NSC-derived neural sphere.  Arrowhead: host-derived neural sphere. (J) Clonal 
secondary-isolated Rad-NSCs (2nd Rad-NSCs) were homogenous in terms of tdRFP 
expression (gray). Post-natal day 4 (PD4)-derived NSCs (blue) were used as a negative 
control. (K) Most 2nd Rad-NSCs differentiated into astrocytes. (L-N) 2nd Rad-NSCs (red) 
differentiated into neurons (L), astrocytes (M) and oligodendrocytes (N) ex vivo. Arrows 
indicate co-localizations. Side panels show FITC and TRITC channels. (O, P) Tuj1-
positive neurons (red), O4-positive oligodendrocytes (green), and GFAP-positive 
astrocytes (blue) were stained by immunocytochemistry. Side panels show magnified 
views of neurons (red), oligodendrocytes (green) and astrocytes (blue) in separate 
channels. The numbers of unipotent (A, astrocytes only), bipotent (A+N, astrocytes and 
neurons; A+O, astrocytes and oligodendrocytes) and tripotent (A+N+O, astrocytes, 
neurons and oligodendrocytes) spheres were quantified. (Q, R) Clonally-isolated 2°Rad-
NSCs continued to form spheres ex vivo. Cell nuclei are shown by DAPI staining (blue).  
Scale bars represent 500 µm or 200 µm where indicated, otherwise 50 µm. 
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Figure 7. NSCs from the SVZ are multipotent and neurogenic in vivo after 
transplantation. (A) GFP-positive PD4-NSCs (green) 4 hours after transplantation into 
post-natal day 0 mouse brains. (B) GFP-positive cells (green) were observed in the lateral 
ventricle 1 month after transplantation. (C) GFP-positive cells (green) with neuronal 
morphology were observed in the olfactory bulb 1 month after transplantation. (D,E) 
Confocal imaging demonstrated that GFP-positive PD4-NSCs (green) differentiated into 
NeuN-positive neurons (D, red) and GFAP-positive astrocytes (E, red) in the olfactory 
bulb. (F) tdTomato-positive adult NSCs (red) derived from the SVZ were observed in the 
lateral ventricle 1 month after transplantation. (G) tdTomato-positive cells (red) with the 
morphology of migrating neuroblasts were observed in the RMS 1 month after 



























positive neurons (H, green) and GFAP-positive astrocytes (I, green) in the olfactory bulb 


































































Figure 8.  Rad-NSCs differentiate into astrocytes and oligodendrocytes in vivo after 
transplantation, but not neurons. (A-C) Transplanted Rad-NSCs (tdRFP, red) did not 
differentiate into NeuN-positive neurons in the striatum (A, NeuN, green) or 
hippocampus (B, NeuN, green) in adult brains. (C) Transplanted Rad-NSCs were 
observed in the lateral ventricle in adult brains, but did not migrate in the RMS. (D, E) 
Transplanted Rad-NSCs (tdRFP, red) differentiated into GFAP-positive astrocytes (D, 
green) and GSTπ-positive oligodendrocytes (E, green) in the both white and gray matter 
of neonatal mice after transplantation. (F) Transplanted Rad-NSCs (red) did not express 
NeuN (green) in the hippocampus. (G) Quantification of Rad-NSC differentiation 1 
month after neonatal transplantation into whole brain. (H, I) Three months after 
transplantation, tdRFP-positive Rad-NSCs (red) expressed Sox2 (H, green) or Nestin (I, 
green) in the SVZ. (J) Three months after transplantation, tdRFP-positive Rad-NSCs 
(red) stained for BrDU (green) in the SVZ. (K, L) tdRFP-positive Rad-NSCs (red) that 
migrated by the RMS did not express NeuN (K, green) or DCX (L, green) in the olfactory 
bulb 3 months after transplantation. (M) tdRFP-positive Rad-NSCs (red) differentiated 
into GFAP-positive astrocytes (green) in the olfactory bulb 3 months after 
transplantation. (N) Transplanted Rad-NSCs (red) were observed to engraft in embryonic 
day 20 brains. (O,P) Transplanted Rad-NSCs (tdRFP, red) did not differentiate into 
NeuN-positive (O, green) or Hu C/D-positive (P, green) neurons in embryonic day 20 
brains. (Q) Transplanted Rad-NSCs (red) expressed GFAP protein in embryonic day 20 
brains. Cell nuclei are shown by DAPI staining (blue). Insets are magnified 
deconvolution views of the white boxes. Scale bars represent 200 µm.   
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Figure 9. Native reactive astrocytes are unipotent in vivo after stroke. 
(A-C)  BrDU (green) tracing studies revealed newly-generated cells in the peri-infarct 
area 28 days after stroke. (A) No BrdU-positive neurons (NeuN, red) were observed in 
the peri-infarct area 28 days after stroke. (B, C) Newly-generated oligodendrocytes 
(GSTπ, red) and astrocytes (GFAP, red) were observed in the peri-infarct area 28 days 
after stroke. (D-F) Lineage tracing revealed that tdRFP-positive reactive astrocytes (red) 
did not differentiate into NeuN-positive mature neurons (D, green) or GSTπ-positive 
oligodendrocytes (E, green), but remained as GFAP-positive reactive astrocytes (F, 
green) in the peri-infarct area 1 month after stroke. Cell nuclei are shown by DAPI 
staining (blue). Insets show magnified deconvolution view of the white boxes. Scale bars 
represent 50 µm.  
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